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ABSTRACT 
 
Irina Mordukhovich: Vehicular Traffic Exposure to Polycyclic Aromatic Hydrocarbons and 
Breast Cancer Risk 
(Under the direction of Marilie D. Gammon) 
 
 
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants, 
known human lung carcinogens, and potent mammary carcinogens in animal models.  However, 
the association between PAHs and breast cancer in women is unclear.  Vehicular traffic is a 
major source of ambient PAH exposure.  This study evaluates the association between residential 
exposure to vehicular traffic-related PAHs and risk of breast cancer, overall and by tumor 
subtype, and within strata of nucleotide excision repair and base excision repair genotypes and 
fruit/vegetable intake.  For this population-based study, residential histories, dietary intake, and 
other factors were assessed in 1996-1997 for 1,508 newly diagnosed breast cancer cases and 
1,556 controls.  Residential traffic exposure estimates were reconstructed using a validated 
model for the years 1960 through 1995.  The following single nucleotide polymorphisms were 
genotyped: ERCC1 8092C/A, OGG1 Ser326Cys, XPA -4A/G, XPD Lys751Gln and Asp312Asn, 
XPF Arg415Gln, XPG Asp1104His, XRCC1 Arg194Trp and Arg399Gln.  Medical records and 
archived tumor tissue were used to determine case tumor subtype.   
In spline figures, which were used to inform quantile cutpoints for regression models, 
breast cancer risk was increased among women with the top 1% of traffic PAH exposures.  Odds 
ratios (and 95% confidence intervals) for breast cancer, estimated using unconditional logistic 
regression, were modestly elevated for the top 5% of long-term 1960-1990 traffic PAH exposure 
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estimates, compared with below the median (1.44 (0.78, 2.68)).  Associations between recent 
traffic exposure in 1995 (top 5% vs. below the median) and breast cancer were attenuated toward 
the null (1.14 (0.80, 1.64)), but were stronger among women with low fruit/vegetable intake 
(1.46 (0.89, 2.40)) and hormone-receptor negative tumors (1.67 (0.91, 3.05)).  Associations were 
approximately two- to three-fold stronger among women with variant alleles for XPD 
(Lys751Gln) and XRCC1 (Arg194Trp), and wild-type alleles for XRCC1 (Arg399Gln) and 
OGG1 (Ser326Cys), when comparing the upper and lower tertiles of traffic exposure during 
1995 or 1960-1990.  This study reports positive associations between traffic-related PAH 
exposure and breast cancer risk among women with comparatively high long-term traffic 
exposures or among those with certain DNA repair genotypes, low fruit/vegetable intake or 
hormone receptor negative tumors, although confidence intervals were wide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
   
 
 
 
 
            TABLE OF CONTENTS       
      
List of Tables………………………………………………………………………….......….....viii 
  
List of Figures……………………………………………………………………………….........x 
 
List of Abbreviations…………………………………………………………………………..…xi 
 
Chapter I: Background…………………………………………………………………………….1 
 
 Breast Cancer Biology and Epidemiology………………………………………….……..1 
 
 Environmental Exposures and Breast Cancer…………………………………….……….5 
  
 PAH Exposure Sources and Associations with Breast Cancer…………….…..……......…7 
 
 Traffic and Air Pollution…………………………………………………….…………...28 
  
 PAHs and Breast Cancer: Proposed Mechanisms………………………………………..46 
  
 DNA Repair Mechanisms: Biology and Epidemiology………………………………….61 
  
 Addressing Limitations of Previous Investigations……………………………………...76                                                                                             
 
 Summary and Conclusions……………………………………………….……………....79 
 
Chapter II: Research Methods…………………………………………………………………...81 
 
 Research Aims, Hypotheses, and Study Rationale……………………………....………81 
  
 Long Island Breast Cancer Study Project (LIBCSP)……………………………….……89 
 
 Results from the LIBCSP: PAH-Related Exposures and Breast Cancer………….……..93 
 
 PAH Exposure Assessment: A Historical Geographic Model…………………….……..96 
  
 Genotyping Assays…………………………………………………………….………..104 
 
 Covariate Assessment………………………………………………………….………..110 
 
 Statistical Approach…………………………………………………………….……….112 
vi 
 
 
 Strengths and Limitations………………………………………………………………120 
  
 Summary…………………………………………………………………......…………125 
 
Chapter III: Exposure to Traffic-Related Polycyclic Aromatic Hydrocarbons  
and Breast Cancer Risk…………………………………………………………………………127 
  
 Introduction……………………………………………………………………………..127 
  
 Materials and Methods………………………………………………………………….128 
 
 Results…………………………………………………………………………………..134 
 
 Discussion………………………………………………………...…………………….136 
 
 Conclusions……………………………………………………………………………..139  
 
 Supplemental Material……………………………………...…………………………..145 
 
Chapter IV: Polymorphisms in DNA Repair Genes, Traffic-Related Polycyclic Aromatic 
Hydrocarbon Exposure, and Breast Cancer Risk……………………………………………….148              
  
 Introduction……………………………………………………………………….…….148 
  
 Materials and Methods…………………………………………………………….……149 
 
 Results……………………………………………………………………………….….154 
 
 Discussion………………………………………………………………………………156 
 
 Conclusions……………………………………………………………………………..161 
 
Chapter V: Discussion…………………………………………………………………………..167 
  
 Summary of Study Aims and Rationale………………………………………………...167                   
  
 Summary of Results……………………………………………………………….……167     
 
 Comparison to Previous Studies …………………………………………………..…...168                            
  
 Biological Plausibility and Potential Underlying Mechanisms……………….…….….172 
 
 Study Limitations……………………………………………………………………….173 
 
 Study Strengths…………………………………………………………………………175 
vii 
 
 
 Future Directions, Public Health Implications and Conclusions……………………….177 
 
Appendix: Additional Tables and Figures……………………………………………....……....179                                                                                                
 
References………………………………………………………………………………………189
  
 
  
  
 
 
      
viii 
 
     LIST OF TABLES 
 
 
Table 3.1. Distributions of cumulative residential vehicular traffic PAH exposure estimates…140                                                                                                    
 
Table 3.2. Residential traffic polycyclic aromatic hydrocarbon exposure 
 estimates by case-control status…………………………………..…...………………..141                          
 
Table 3.3. Associations between varying time ranges of exposure to PAHs  
 from residential traffic and breast cancer risk………………………..…………………142 
 
Table 3.4. Associations between residential vehicular traffic exposure and  
 breast cancer risk, within strata of fruit/vegetable intake and menopausal status…...…143     
 
Table 3.5. Associations between residential vehicular traffic PAH exposure  
and the risk of breast cancer categorized by tumor hormone receptor status……...…...144                                                                                                  
 
Table 3.6. Correlations between selected residential vehicular traffic PAH  
exposure variables…………………………...………………………………………….147                                                                   
 
Table 4.1. Associations between traffic polycyclic aromatic hydrocarbon 
exposure in 1995 and breast cancer, stratified by DNA repair genotype………..……...162                                                                                                                                  
 
Table 4.2. Associations between traffic polycyclic aromatic hydrocarbon  
 exposure in 1960-1990 and breast cancer, stratified by DNA repair genotype…………164                                                                                                                           
 
Table 4.3. Associations between traffic PAH exposure and breast cancer, stratified  
 by combined DNA repair genotypes in XPD, XRCC1, and OGG1 ………...….……….…166                                                                                                                                   
 
Table A2.1 Previously reported participant characteristics by case-control status.…………….180          
 
Table A2.2. Associations between traffic exposure in the year 1995 and breast  
cancer, overall and among long-term residents………………………………………....182 
                                                                                       
Table A2.3.  Associations between selected residential traffic exposure variables 
 and breast cancer, removing participants with the highest exposure levels………….....183        
                                                                                            
Table A2.4.  Associations between traffic polycyclic aromatic hydrocarbon exposure  
 and breast cancer, varying the relative contribution of the pre-arrival surrogate…...….184   
                                                                                      
Table A2.5. Associations between traffic PAH exposure and breast cancer,  
 turning off the intersection component of exposure model………………………….…185         
 
Table A2.6. Associations between traffic PAH exposure and breast cancer, with  
 partial imputation conducted using imputation by census place………...………..….…186                                                
 
 
ix 
 
Table A2.7. Associations between selected residential traffic exposure variables  
 and breast cancer categorized by tumor characteristics……………………………..….187                                                                                                 
 
Table A2.8. Previously reported main effects of DNA repair polymorphisms on  
 breast cancer risk………………………..…………………………………...………….188                                                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
LIST OF FIGURES 
 
 
Figure A1.1 Metabolism of Polycyclic Aromatic Hydrocarbons in Relation to  
Breast Cancer Risk ………………………………………….……………………….…179                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF ABBREVIATIONS 
 
ACS: American Cancer Society 
Ah: Aryl hydrocarbon 
AP: Apurinic 
ATSDR: Agency for Toxic Substances and Disease Registry 
BER: Base excision repair 
BPDE: Benzo[a]pyrene diolepoxide 
CA EPA: California Environmental Protection Agency 
CARB: California Environmental Protection Agency Air Resources Board 
CCA: complete case analysis 
CI: Confidence interval 
CK5/6: Cytokeratin 5/6 
CO: Carbon monoxide 
CYP: Cytochrome P450 
EGFR: Epidermal growth factor receptor  
EHHI: Environment and Human Health, Inc. 
ELISA: Enzyme-linked immunosorbent assay 
ER: Estrogen receptor  
ERCC1: Excision repair cross-complementing group 1 
FEN1: Flap structure-specific endonuclease 1 
FFQ: Food frequency questionnaire 
FP: Fluorescence polarization 
GIS: Geographic information system 
xii 
 
GGR: Global genome repair 
GST: Glutathione S-transferase 
HER2: Human epidermal growth factor receptor 2 
HR: Homologous recombination 
HWE: Hardy-Weinberg equilibrium 
IARC: International Agency for Research on Cancer 
IQR: interquartile range 
LIBCSP: Long Island Breast Cancer Study Project 
LIG1: DNA ligase I 
MALDI-TOF: Matrix-assisted laser desorption/ionization time-of-flight 
MI: Multiple imputation 
MMR: Mismatch repair 
NCRP: National Council on Radiation Protection and Measurement 
NER: Nucleotide excision repair 
NHEJ: Non-homologous end-joining repair 
NTP: National Toxicology Program 
OGG1: 8-oxoguanine DNA glycosylase 1 
OR: Odds ratio 
OSHA: Occupational Health and Safety Administration 
PAH: Polycyclic aromatic hydrocarbons  
PBS: Phosphate-buffered saline 
PCNA: Proliferating cell nuclear antigen 
PCR: Polymerase chain reaction 
xiii 
 
PM: Particulate matter 
PR: Progesterone receptor         
 
ROS: Reactive oxygen species          
 
SD: Standard deviation           
 
SNP: Single nucleotide polymorphism       
 
TCR: Transcription-coupled repair          
 
TSP: Total suspended particulates         
  
US: United States 
USDOT: United States Department of Transportation 
US EPA: United States Environmental Protection Agency 
UV: Ultraviolet 
VOCs: Volatile organic compounds 
WHO: World Health Organization 
XP: Xeroderma pigmentosum 
XPA, XPD, XPF, XPG: xeroderma pigmentosum groups A, D, F or G 
XRCC1: X-ray repair cross complementing group 1 
 
 
 
1 
 
 
 
 
 
CHAPTER I: BACKGROUND 
This investigation aims to examine associations between historical residential traffic-
related polycyclic aromatic hydrocarbon (PAH) exposure and breast cancer, and to examine 
gene-environment interactions between traffic PAHs and DNA repair polymorphisms with 
respect to breast cancer risk.  Secondary aims include examining effect modification of the traffic 
PAH-breast cancer association by fruit and vegetable intake and menopausal status, and 
evaluating associations between traffic PAHs and breast cancer with cases categorized according 
to tumor hormone receptor status and p53 mutation status.   
 The following chapter provides a detailed review of the relevant literature.  Specifically, 
Chapter I presents information regarding breast cancer biology and epidemiology, PAH sources, 
including traffic and air pollution, and relevant metabolic pathways, including DNA repair 
processes and genetic polymorphisms.    
BREAST CANCER BIOLOGY AND EPIDEMIOLOGY 
Breast cancer is the most incident cancer, excluding non-melanoma skin cancers, and the 
second-leading cancer-related cause of death among women in the United States (US) (American 
Cancer Society [ACS] 2011).  The American Cancer Society estimates that, in 2011, US age-
adjusted breast cancer incidence and mortality were approximately 120.7 cases per 100,000 
women and 24.0 deaths per 100,000 women, respectively.  This translates to an estimated 
230,480 new cases and 39,520 deaths in 2011 (ACS 2011).  As of 2011, a US woman's lifetime 
risk for developing breast cancer was estimated to be 12.15% (ACS 2011).  In contrast, male 
breast cancer is an uncommon disease (Weiss et al. 2005).  This document focuses on female 
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breast cancer unless otherwise noted.      
 The human breast is primarily composed of lobules (glands which produce breast milk) 
and ducts for the release of milk (ACS 2009-2010).  The breast also contains lymphatic, 
connective, and fatty tissues (ACS 2009-2010).  Most diagnosed breast cancers are ductal or 
lobular adenocarcinomas (ACS 2009-2010, ACS 2011, Kelsey and Horn-Ross 1993), and are 
invasive (i.e. having spread out of one tissue type into another) rather than in situ (ACS 2009-
2010, ACS 2011).  Invasive ductal carcinoma is the most common form of the disease (ACS 
2011).          
 The risk factors and etiology of breast cancer, both genetic and lifestyle/environmental, 
are incompletely understood.  Confirmed genetic risk factors for breast cancer are divided into 
three categories: (1) rare, high-penetrance genetic mutations (e.g. in BRCA1 or BRCA2) that 
confer a large personal risk of breast cancer, (2) rare, intermediate-penetrance genetic mutations 
(e.g. in ATM or CHEK2), and (3) low-penetrance, common single nucleotide polymorphisms 
(SNPs) that confer a low personal risk of breast cancer but are so prevalent as to be significant on 
a public health/population level (e.g. SNPs found in FGFR2 or LSP1) (Turnbull and Rahman 
2008).   
 Family history of breast cancer, which represents shared genetic and 
lifestyle/environmental factors (Lichtenstein et al. 2000), is also an established risk factor for the 
disease (ACS 2009-2010), especially for women with more than one affected relative (ACS 
2009-2010).  However, most women diagnosed with breast cancer do not have a family history 
of this disease (Mayo Clinic 2011).   
 Established non-genetic risk factors for breast cancer (ACS 2009-2010, ACS 2010, 
Hankinson et al. 2004) include age, reproductive history (late age at first birth, nulliparity or low 
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parity, late menopause, early menarche, and little or no lactation), medical history (exposure to 
ionizing radiation, hormone replacement therapy use, recent oral contraceptive use, high breast 
density, personal history of certain types of benign breast disease, and personal history of breast 
and certain other cancers), body mass index, alcohol intake, and low physical activity levels.  
Breast cancer risk factor profiles differ by menopausal status (Barlow et al. 2006, Velentgas and 
Daling 1994).  For example, obesity is an established risk factor for postmenopausal breast 
cancer, but is negatively associated with premenopausal breast cancer risk (Rose and Vona-Davis 
2010, Velentgas and Daling 1994). 
 Many breast cancer risk factors are related to systemic circulating estrogen levels (Brody 
and Rudel 2003, Pike et al. 1993).  For example, in postmenopausal women, endogenous 
estrogen mainly originates in adipose tissue stores.  Therefore, increased body size is likely to be 
related to postmenopausal breast cancer risk through estrogenic pathways (Hankinson 2005-
2006).  Circulating estrogen levels are consistently associated with postmenopausal breast cancer 
risk in epidemiologic research (Hankinson et al. 2004, 2005-2006, Kaaks et al. 2005, Key et al. 
2002).  Clinical investigations report that estrogen receptor antagonists, such as the drug 
tamoxifen, can prevent breast cancer development (ACS 2009-2010, Visvanathan et al. 2009).   
 Breast cancer risk factor profiles, both genetic and lifestyle/environmental, differ with 
respect to tumor estrogen and progesterone receptor (ER/PR) status (Althuis et al. 2004, Chen 
and Colditz 2007, Colditz et al. 2004, Garcia-Closas and Chanock 2008).  Estrogen plays a role 
in the development of a subset of breast tumors: "ER+ tumors are those with the capacity to be 
stimulated by estrogen (Dickson and Stancel 2000) and among these, PR expression is 
considered indicative of an intact ER signaling pathway (Lapidus et al. 1998)" (Hankinson et al. 
2005-2006).   Inconsistent findings regarding potential risk factors in the breast cancer literature 
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could be attributable in part to differences in tumor hormone receptor status distribution between 
study populations (Chen and Colditz 2007).   
 Breast cancer risk factor patterns may also differ with respect to tumor subtypes defined 
by hormone receptor status in combination with other markers such as human epidermal growth 
factor receptor 2 (HER2/neu) or cytokeratin immunohistochemical expression status (Chen and 
Colditz 2007, Millikan et al. 2008, Susan G. Komen for the Cure 2010, Yang et al. 2011).  More 
specifically, breast tumors are generally classified into the following molecular subtypes: luminal 
A (ER+ or PR+, HER2-), luminal B (ER+ or PR+, HER2+), HER2 type (ER-, PR-, HER2+), and 
triple-negative (ER-, PR-, HER2-).  Using data on immunohistochemical expression of 
cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor (EGFR) proteins, triple-negative 
breast cancer can be further categorized into basal-like (ER-, PR-, HER2-, CK5/6+ or EGFR+) 
and unclassified (ER-, PR-, HER2-, CK5/6-, EGFR-) subtypes (Chen and Colditz 2007, 
McCullough L. et al, unpublished data, Millikan et al. 2008, Susan G. Komen for the Cure 2010, 
Yang et al. 2011).  Although it is too early to make definitive conclusions, research suggests that 
triple-negative breast cancer differs in etiology from hormonally responsive breast cancer, with 
studies reporting positive associations between triple-negative cancer, parity and premenopausal 
body mass (McCullough L et al, unpublished data, Millikan et al. 2008, Susan G. Komen for the 
Cure 2010, Yang et al. 2011).  Triple-negative breast cancer comprises approximately 10-25% of 
all breast cancers, and is overrepresented among premenopausal and African American women 
(Chen and Colditz 2007, Carey et al. 2006, 2010, McCullough L et al, unpublished data).  
Hormonally responsive, luminal tumors are the predominant breast cancer subtypes in the United 
States, particularly among White, postmenopausal women (Potter et al. 1995).   
 Breast cancer subtypes also differ in prognosis (Dunnwald et al. 2007, Fan et al. 2006, 
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Pharoah et al. 1999, Ross and Fletcher 1998, Susan G. Komen for the Cure 2010).  Triple-
negative and HER2 type cases generally have worse prognoses than luminal cases (Carey et al. 
2006, 2010, McCullough L et al, unpublished data, Susan G. Komen for the Cure 2010), and 
luminal A cases have the best prognosis of any subtype (Susan G. Komen for the Cure 2010).  
Cases with p53 mutation-positive tumors tend to have worse prognoses than p53 mutation-
negative cases (Pharoah et al. 1999); p53-mutation positive breast tumors are more likely to be 
hormone-receptor negative (Olivier et al. 2006).    
ENVIRONMENTAL EXPOSURES AND BREAST CANCER  
Studies of immigrant groups report that breast cancer rates gradually increase from the 
levels of immigrants' country of origin to the levels of their new country.  This process continues 
into subsequent generations (Buell 1973, Kelsey and Horn-Ross 1993, Kliewer and Smith 1995).  
These results suggest the importance of lifestyle or environmental factors to breast 
carcinogenesis (Kelsey and Horn-Ross 1993).  Also pointing to a lifestyle/environmental 
component to breast cancer development is the relatively low breast cancer concordance 
observed in studies of monozygotic twins (Brody and Rudel 2003, Lichtenstein et al. 2000, Mack 
et al. 2002).   
 Breast cancer rates vary greatly between countries and regions (Althuis et al. 2005, Hulka 
et al. 2008).  Rates are higher in more developed and urban regions, both geographically and 
historically (Althuis et al. 2005, Bray et al. 2004, Kelsey and Berkowitz 1988, Laden and Hunter 
1998, MacMahon 2006, Nasca et al. 1992, Reynolds et al. 2004, Sturgeon et al. 1995).  In the 
United States, breast cancer rates are highest in the Northeast, and elevated rates are also 
reported in the Midwest and West relative to the South (Kulldorff et al. 1997, Laden and Hunter 
1998, Sturgeon et al. 1995).  Varying rates are to some extent explained by regional differences 
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in known lifestyle, reproductive, and demographic breast cancer risk factors (Laden et al. 1997, 
Laden and Hunter 1998, Sturgeon et al. 1995, 2003).  However, differing environmental 
exposure profiles between regions may also play a role.   
 With the exception, to some extent, of accidents in which large amounts of radiation or 
environmental pollutants are released (Brody and Rudel 2003, Laden and Hunter 1998), 
investigations examining environmental exposures in relation to cancer outcomes are challenging 
to conduct given a number of methodological issues (Laden and Hunter 1998).  These include (1) 
difficulty finding a truly unexposed group given the ubiquity of many environmental 
contaminants, (2) difficulty measuring exposures and reconstructing individual exposure 
histories, and (3) small hypothesized relative risks, requiring very large studies for sufficient 
statistical power (Laden and Hunter 1998).   
 Certain environmental chemicals have been hypothesized to increase breast cancer risk 
due to their genotoxic or hormonally active properties (Brody and Rudel 2003, el-Bayoumy et al. 
1992, Laden and Hunter 1998, Morris and Seifter 1992, Nasca and Pastides 2008).  However, 
most of these environmental contaminants have not shown a consistent association with breast 
cancer risk in epidemiologic research.  For example, the potential relationship between 
organochlorines and breast cancer has been extensively studied (Nasca and Pastides 2008).  The 
majority of investigations report null associations (Nasca and Pastides 2008), including in three 
large prospective cohort studies (Engel et al. 2005, Hunter et al. 1997, Reynolds et al. 2004), the 
largest case-control study on this topic to date (Gammon et al. 2002a), and a meta-analysis of 22 
investigations (Lopez-Cervantes et al. 2004) (Nasca and Pastides 2008).  Similarly, despite 
engendering speculation in both scientific and lay communities, exposure to electromagnetic 
fields was not associated with female breast cancer risk in well-powered epidemiologic 
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investigations (Gammon et al. 1998, Hulka et al. 2008).  Studies may point to a weak association 
between electromagnetic fields and male breast cancer (Erren 2001, Weiss et al. 2005).   
 High-level ionizing radiation is an established environmental risk factor for breast cancer 
(Laden and Hunter 1998), as seen in studies of nuclear fallout and medical treatments (ACS 
2009-2010, Laden and Hunter 1998, Land et al. 2003).  Electric light at night, which affects 
circadian rhythm and melatonin production (Stevens 2009a), is also consistently related to breast 
cancer based on studies of sleep duration, blindness, non-day shift work, and light pollution 
(ACS 2009-2010, Kolstad et al. 2008, Stevens 2009a,b) (Straif et al. 2007).  Bulky PAH-related 
DNA adducts, a form of DNA damage induced by polycyclic aromatic hydrocarbons (PAHs), are 
the only other environmentally-related factor consistently associated with breast cancer risk in 
epidemiologic research (Gammon et al. 2004a, Gammon and Santella 2008, Li et al. 1996, 2002, 
Perera et al. 1995, Rundle et al. 2000a).   
PAH EXPOSURE SOURCES AND ASSOCIATIONS WITH BREAST CANCER 
PAHs are ubiquitous environmental contaminants which contain at least two conjoined 
aromatic rings (Bostrom et al. 2002, International Agency for Research on Cancer [IARC] 2010).  
These chemicals are formed as incomplete combustion by-products of organic matter (e.g. fossil 
fuels; Phillips 1999, Samanta et al. 2002).  Humans are exposed to PAHs via inhalation, 
ingestion, or absorption through the skin (Morris and Seifter 1992).  PAH exposure sources, such 
as traffic, cigarette smoke, and grilled or smoked foods, differ with respect to their PAH profiles 
(i.e. which specific PAHs are present) and contain varying combinations of known or suspected 
non-PAH carcinogens (Bostrom et al. 2002, IARC 2010, Naumova et al. 2002).  Individual PAHs 
differ in structure and therefore in reactivity and carcinogenicity (Cavalieri et al. 1991, Leavitt et 
al. 2008, Ramesh et al. 2004, Straif et al. 2005).   
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 PAHs are established mammary carcinogens in laboratory rodents (Hecht et al. 2002).  
Certain PAHs and PAH sources (e.g. vehicular exhaust, cigarette smoke) are classified as 
confirmed, probable, or possible human carcinogens by several health and environmental 
agencies, largely based on lung cancer studies (California Environmental Protection Agency [CA 
EPA] 1999, IARC 2010, Minnesota Department of Health 2004, National Toxicology Program 
[NTP] 2011, Straif et al. 2005, United States Environmental Protection Agency [US EPA] 2011).  
The association between PAHs and breast cancer in humans is not well researched and is 
therefore currently unclear (Gammon and Santella 2008).   
 Associations between PAHs and cancer risk are difficult to evaluate for several reasons.  
PAH sources are usually complex mixtures of various PAHs and non-PAH carcinogens.  Also, 
exposure to PAHs is ubiquitous, which complicates defining a referent group (Boffetta et al. 
1997).  Associations between PAHs and cancer risk are likely to be influenced by individual 
susceptibility factors as well as PAH exposure levels, which both differ between study 
populations (Bostrom et al. 2002) 
Occupational PAH Exposure 
Occupational exposure to PAHs occurs among firefighters (Caux et al. 2002), traffic 
policemen (Merlo et al. 1998), toll booth operators (Tsai et al. 2004a), professional drivers 
(Boffetta et al. 1997), heavy equipment and crane operators, and road, railroad, dock, coke-oven, 
aluminum, and iron and steel foundry workers (Boffetta et al. 1997, Gammon and Santella 2008, 
Mastrangelo et al. 1996).  Other occupational PAH sources include but are not limited to rubber 
production, shale oil extraction, wood impregnation, energy generation from coal, oil and other 
fuels (including coal gasification), carbon black, carbon electrode and calcium carbide 
production, coal tar distillation, roofing, chimney sweeping, and motor vehicle repair (Boffetta et 
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al. 1997, Bostrom et al. 2002, IARC 2010).  Certain workers are exposed to especially high 
levels of vehicular exhaust, a major PAH source.  Relevant occupations include “transportation 
and garage work, underground mining, vehicle maintenance and examination, traffic control, 
logging, firefighting and heavy equipment operation” (IARC 1989).   
 Ambient levels of benzo[a]pyrene, a commonly measured carcinogenic PAH, range 
widely across occupational settings (i.e. between approximately 0.1 and 100,000 ng/m3) 
(Angerer et al. 1997, Castaño-Vinyals et al. 2004, IARC 2010, Ovrebo et al. 1995).  
Occupational PAH exposure occurs mainly through inhalation of both gaseous and particulate 
PAHs and skin absorption (Boffetta et al. 1997, IARC 2010).  PAHs may be absorbed through 
the skin from contact with coal or petroleum-derived products such as tar, soot, or pitch 
(Bostrom et al. 2002, IARC 2010). 
 Few investigations examining associations between PAHs and breast cancer are 
conducted in occupational settings (Cantor et al. 1995, Labreche et al. 2010, Petralia et al. 1999, 
Weiderpass et al. 1999).  This is largely because of the paucity of women available for such 
research (Brody and Rudel 2003).  Two studies did not find elevated breast cancer rates among 
women with higher estimated occupational PAH exposures (Cantor et al. 1995, Weiderpass et al. 
1999).  Another study reported a positive association between employment in motor vehicle 
repair and breast cancer risk (Band et al. 2000).  One investigation reported increased 
premenopausal breast cancer among women exposed to PAHs based on occupational histories 
(OR = 1.82, 95% CI: 1.02, 3.16) (Petralia et al. 1999).  Upon stratification by tumor estrogen 
receptor status, this association was limited to ER-positive tumors (OR = 2.27, 95% CI: 1.14, 
4.54; Petralia et al. 1999).  However, the effects of PAH independent of benzene could not be 
evaluated due to insufficient sample size in the relevant subgroup (Petralia et al. 1999).  Finally, 
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a recent study reported associations between postmenopausal breast cancer and PAH exposure 
determined from occupational histories, especially from petroleum sources and for exposure 
prior to age 36 (Labreche et al. 2010).  Upon stratification by tumor hormone receptor status, 
associations with PAHs from petroleum sources were present only for ER and PR-positive breast 
tumors.  No significant or marginal findings were reported with respect to hormone receptor 
status when evaluating occupational PAH exposure from all sources (Labreche et al. 2010).   
General Population PAH Exposure: An Overview 
In the general population, major PAH exposure sources include cigarette smoke 
(Besaratinia et al. 2002), grilled, smoked or broiled foods (Phillips 1999), wood and coal-burning 
stoves, house dust (Lewis 1999), PAH-contaminated food crops (Bostrom et al. 2002, Morris and 
Seifter 2002, Phillips 1999), and air pollution from industrial emissions, traffic, and heating 
(Bostrom et al. 2002, IARC 2010, Lioy and Greenberg 1990, Narvaez et al. 2008).  Additional 
PAH sources include cooking, candles and incense (Wallace 2000), contaminated soil (IARC 
2010), certain pharmaceutical products (IARC 2010), space heaters, and wood, leaf and garbage 
burning (Bostrom et al. 2002, Friedman and Calabrese 1977, Mumtaz et al. 1996, Ramesh et al. 
2004).   
 In the US, wood smoke is the largest source of ambient PAHs overall (Bostrom et al. 
2002).  However, traffic pollution is an important source of both indoor and outdoor ambient 
PAHs.  This is especially true in or near urban areas, where traffic is often the largest ambient 
PAH source (Bostrom et al. 2002, Dubowsky et al. 1999, Dunbar et al. 2001).  PAHs emitted 
from wood burning show relatively little carcinogenic activity, in contrast to PAHs in vehicular 
traffic emissions (Boffetta et al. 1997, Lewtas 1993, Lewtas et al. 1992, Lewtas and Gallagher 
1990).  Wood burning is also more likely to occur away from areas of high population density 
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(Shen et al. 2011).       
 PAHs have been detected in water supplies, especially in urban areas (Bostrom et al. 
2002, Morris and Seifter 1992, IARC 2010).  This is due to traffic runoff (Ramesh et al. 2004), 
atmospheric deposition, and industrial pollution (IARC 2010, Ramesh et al. 2004).  However, 
drinking water PAH levels are generally low due to the relative insolubility of PAHs and 
effective water treatment procedures (IARC 2010).  Emissions from natural sources such as 
forest fires or volcanoes comprise a small fraction of PAHs relative to anthropogenic sources of 
these chemicals at ground level (Bostrom et al. 2002).  It is estimated that, on average, an 
individual's exposure to carcinogenic PAHs from all sources amounts to approximately 3 μg per 
day in the general population (Castaño-Vinyals et al. 2004).  Due to the ubiquity of PAH 
exposure, nearly all members of the general population have measurable concentrations of 
urinary PAH metabolites (Huang et al. 2004, IARC 2010).       
 Diet is the main source of PAH exposure among non-occupationally exposed non-
smokers (IARC 2010, Phillips 1999, Ramesh et al. 2004).  Average daily dietary PAH intake is 
estimated to range from several nanograms to several micrograms (IARC 2010).  PAHs are 
found in a wide variety of foods, most notably barbecued, broiled, grilled or smoked meat.  They 
are also found in other cooked foods, foods that are processed or preserved in certain ways (e.g. 
oils, cereals, breads), and in environmentally contaminated foods, including vegetables, dairy 
products, and seafood (IARC 2010, Larsson et al. 1983, Lijinsky 1991, Ramesh et al. 2004, Roth 
et al. 1998).  Atmospheric PAH deposition leads to contamination of foods via water, soil and air 
(Bostrom et al. 2002, IARC 2010, Ramesh et al. 2004, Shabad and Cohan 1972).  PAH 
deposition onto soil is proportional to ambient PAH concentrations, and crops grown near roads, 
industrial sites, or urban areas show higher levels of PAH dust than crops from less polluted 
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areas (Bostrom et al. 2002, Ramesh et al. 2004).  Crop deposition is an important source of PAH 
exposure in the general population (Bostrom et al. 2002).  
  PAH dose from inhalation has been estimated to be approximately 5-10% of dietary dose 
in the general population (Bostrom et al. 2002, Lioy et al. 1988).  One study reported that for 
male non-smokers between 19 and 50 years of age, the contributions of dietary and ambient 
sources to total PAH dose were 96.2% and 1.6%, respectively (IARC 2010, Menzie et al. 1992).  
However, environmental ambient PAHs can show stronger associations with PAH-DNA adducts 
than diet, smoking, or occupational exposures (Beyea et al. 2006, Eder 1999).  It is known that 
“the carcinogenic risk of PAH mixtures is highly dependent on the exposure pathway” (Ramesh 
et al. 2004).  The impact of different exposure routes on effective biological PAH dose is unclear 
(Bostrom et al. 2002).    
 Associations between PAH-related sources and breast cancer have been explored in 
general population settings.  Briefly, surrogates for PAH exposure that have been evaluated in 
relation to breast cancer risk include cigarette smoke, grilled or smoked meat intake, PAH-DNA 
adducts, and air pollution exposure (Bonner et al. 2005, Gammon et al. 2004a, Rundle et al. 
2000a, Steck et al. 2007, Terry and Rohan 2002).  The results of these efforts are described in 
more detail in later sections of this document.  In addition, one ecological study found a null 
association between very low-level PAH water contamination and breast cancer after adjustment 
for known breast cancer risk factors (Dean et al. 1988, Laden and Hunter 1998).  Another 
ecological investigation reported positive associations between breast cancer and creosote-
contaminated water (Dusich et al. 1980).  No other identified studies have evaluated associations 
between water PAHs and breast cancer risk.  Finally, one investigation reported null associations 
between urinary PAH markers (1-hydroxypyrene and 2-naphthol, but not benzo[a]pyrene 
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metabolites) and breast cancer risk (Lee et al. 2010).       
Tobacco Smoke 
PAH Content of Cigarette Smoke  
Tobacco smoke contains several PAHs, including benzo[a]pyrene and dibenzo[a,l]pyrene, 
which are both potent mammary carcinogens in laboratory animals (Cavalieri et al. 1991, el-
Bayoumy et al. 1995, Hecht et al. 2002).  Other PAHs, such as dibenz[a,h]anthracene and 
benz[a]anthracene, are also found in cigarette smoke (Smith et al. 2000).  Many non-PAH 
carcinogenic chemicals, including aromatic amines and N-nitrosamines, are found in tobacco 
smoke as well (Terry and Rohan 2002).   
 The concentration and carcinogenic activity of benzo[a]pyrene and other PAHs may be 
higher in sidestream than in mainstream smoke (IARC 2010, Jinot and Bayard 1996, Laden and 
Hunter 1998, Morris and Seifter 1992, Nasca and Pastides 2008, Nelson 2001).  For example, a 
study of smokers found that benzo[a]pyrene exposure per 100 cigarettes ranged from 0.5 to 7.8 
mg in mainstream smoke and from 2.5 to 19.9 mg in sidestream smoke (Castaño-Vinyals et al. 
2004, IARC 1983).       
Biological Relevance of PAHs in Cigarette Smoke to Breast Cancer Risk 
Active smokers have increased urinary levels of the PAH metabolite, 1-hydroxypyrene 
(IARC 2010, Terry and Rohan 2002).  Levels of this metabolite are also associated with second-
hand smoking (Gunier et al. 2006).  Nicotine and cotinine (a metabolite of nicotine) from 
cigarette smoke are found in breast fluid (Hecht et al. 2002, Petrakis et al. 1978), and smoking 
has been associated with PAH-DNA adduct levels in breast tissue (Hecht et al. 2002, Li et al. 
1996, Perera et al. 1995).  Therefore, it is known that metabolites and chemicals from cigarette 
smoke reach the breast (Hecht et al. 2002).  Both active and passive smoking induce DNA 
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damage according to in vivo and in vitro studies as well as epidemiological investigations 
(Husgafvel-Pursiainen 2004, Lodovici and Bigagli 2009).  
 It is also known that certain PAHs, including those found in cigarette smoke (Hecht 
2002), are highly carcinogenic to the mammary gland in laboratory animals (el-Bayoumy et al. 
1995, Huggins and Yang 1962, Ranadive and Karande 1963, Santodonato 1997).  
Benzo[a]pyrene from cigarette smoke likewise induces neoplastic transformation of human 
breast epithelial cells in vitro (Russo et al. 2002).   
 Smoking can impact ovarian function, leading to earlier menopause onset (Kaufman et al. 
1980, Tanko and Christiansen 2004).  Cigarette smoke may also exhibit antiestrogenic properties, 
independent of effects on the ovaries (Band et al. 2002, Tanko and Christiansen 2004).  For 
example, studies report that smoking induces hydroxylation of estrogens (specifically, via the 2-
hydroxylation pathway); the metabolic products, 2-hydroxyestrogens, show little estrogenic 
activity and are rapidly cleared from the bloodstream (Meek and Finch 1999, Michnovicz et al. 
1986, Tanko and Christiansen 2004).  Similarly, an in vitro investigation using breast cancer cells 
reported that PAHs, a component of tobacco smoke, “inhibited estradiol-induced cell 
proliferation” (Santodonato 1997) (Chaloupka et al. 1992).  The postulated effects of cigarette 
smoke or its constituents on ovarian function and estrogenic activity are supported by in vitro 
and in vivo experimental studies (Santodonato 1997, Tanko and Christiansen 2004), and by 
epidemiologic associations between active smoking and, for example, osteoporosis (Lane 2006) 
and decreased serum and urinary estrogen levels among premenopausal women (Tanko and 
Christiansen 2004).  The resulting reduction in estrogen exposure could counteract the genotoxic 
effects of smoking, as circulating estrogen levels are consistently associated with breast cancer 
risk in epidemiological studies (Hankinson et al. 2004, 2005-2006).  It should be noted that 
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PAHs also exhibit weak estrogenic activity (Santodonato 1997), and cigarette smoke has been 
reported to induce transcription via the estrogen receptor (Meek and Finch 1999).   
 The literature regarding passive smoking and endpoints related to ovarian function or 
estrogenic activity is relatively sparse.  A recent investigation among young women reported that 
passive smokers had higher serum estrogen levels (for estrone, estradiol, estriol, and 16-
hydroxyestrone) than active smokers, when smoking status was classified according to serum 
cotinine levels (Soldin et al. 2011).  Serum estradiol and estriol levels were higher among passive 
smokers relative to both active smokers and non-smokers in this study, whether classified by 
serum cotinine levels or by self-report (Soldin et al. 2011).  Another investigation, which did not 
include active smokers, reported negative associations between passive smoke exposure and 
urinary estrone conjugate levels among premenopausal women (Chen et al. 2005).  Active 
smoking, but not passive smoking, has been associated with decreased antimullerian hormone 
levels, a marker of ovarian function (Plante et al. 2010).  In another study, follicle-stimulating 
hormone levels, also a marker of ovarian function, were higher among active smokers (66% 
higher) and passive smokers (39% higher) relative to women with no active or passive smoking 
exposure (Cooper et al. 1995).  Several investigations report negative associations between age 
at menopause and active smoking, but not passive smoking (Cooper et al. 1999, Cramer et al. 
1995, Mikkelsen et al. 2007), though one earlier study did report a negative association between 
age at menopause and passive smoking (Everson et al. 1986).  Active smoking, but not passive 
smoking, was associated with reduced mammographic density in a 2010 investigation (Butler et 
al. 2010). 
Assessment of Smoking Patterns in Epidemiological Investigations 
In epidemiological studies, information on smoking habits is ascertained through self-
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report and classified in a variety of ways (Terry and Rohan 2002).  The most crude smoking 
exposure categorizations are ever/never smoking or current/former/never smoking.  Some 
studies, especially those conducted more recently, have collected more comprehensive 
information on smoking patterns, including estimates of frequency, intensity, duration and 
recency of smoking (Terry and Rohan 2002).   
 Reporting of smoking patterns is subject to recall bias and social desirability bias 
(Brigham et al. 2010).  Self-reported smoking exposure has been validated against measured 
cotinine levels (Nasca and Pastides 2008, Patrick et al. 1994).  However, cotinine reflects only 
recent smoking, and cannot differentiate between levels of tobacco smoke exposure (Nasca and 
Pastides 2008, Patrick et al. 1994).  Research has demonstrated long-term consistency of 
smoking reports that were collected at different time points across the life course, though 
concordance is not absolute (Brigham et al. 2010).   
Associations with Breast Cancer 
An association between cigarette smoke and breast cancer is biologically plausible based 
on knowledge of relevant mechanisms and pathways, cigarette smoke components, and 
toxicokinetics (Hecht et al. 2002).  Furthermore, smoking is a risk factor for cancers in other 
organs which are not directly exposed to tobacco smoke, such as the bladder and pancreas 
(Brennan et al. 2000, Lynch et al. 2009, Terry and Rohan 2002).  The association between 
smoking and breast cancer has been widely studied (Terry and Rohan 2002).  However, results 
are inconsistent across investigations (positive, null, and negative) (Palmer and Rosenberg 1993, 
Terry and Rohan 2002).  A review by Terry and Rohan (2002) concluded that a true negative 
association between smoking and breast cancer is extremely unlikely.   
 More consistently positive associations are found among women with certain genetic 
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polymorphisms, such as NAT2 slow acetylators (Ambrosone et al. 2008, Terry and Goodman 
2006, Terry and Rohan 2002), for smoking before first birth, and for long-term passive or active 
smoking (Khuder and Simon 2000, Morabia 2002, Terry and Rohan 2002).  For example, the 
literature examining associations between long-term residential passive smoke exposure and 
breast cancer consistently reports positive associations (Gammon et al. 2004b, Hirayama 1984, 
Laden and Hunter 1998, Morabia et al. 1996, Smith et al. 1994, Wells 1991).   
 Women may be more susceptible to initiating breast carcinogens prior to pregnancy 
because breast epithelial cells have not undergone terminal differentiation and are at "a peak of 
cell replication" (Nasca and Pastides 2008, Russo and Russo 2004).  Differing results for passive 
versus active smoking may be due to (1) a potential antiestrogenic effect of smoking that could 
be present upon active but not passive exposure levels, as described above (Band et al. 2002), (2) 
differences in duration or timing of exposure to passive versus active smoke, as women were 
historically more likely to be exposed earlier in life to passive than to active smoke, (3) the 
failure of many studies of active smoking to remove passive smokers from the referent group, 
which could attenuate results (Morabia et al. 1996, Terry and Rohan 2002), and (4) competing 
causes of death potentially resulting from active but not passive smoking exposure levels (Dr. 
Marilie Gammon, personal communication 2010).  It should be noted that "the California 
Environmental Protection Agency has concluded that regular exposure to secondhand smoke is 
causally related to breast cancer diagnosed in younger, primarily premenopausal women" (ACS 
2009-2010) (Miller et al. 2007).   
Cigarette smoking was associated with the presence of breast tumor p53 mutations in one 
study (Conway et al. 2002), but this result was not confirmed in a larger investigation 
(Mordukhovich et al. 2009).  A 2004 literature review concluded that cigarette smoking is not 
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differentially associated with breast tumor hormone receptor status subtypes (Althuis et al. 
2004), although individual investigations have reported evidence of differential associations (e.g. 
Britton et al. 2002, Gammon et al. 2004b).  
Grilled and Smoked Meat 
PAH Content of Grilled and Smoked Meat 
PAHs are found on or near the surface of grilled, barbecued and smoked meat (Morris 
and Seifter 1992 Steck et al. 2007).  Smoke is formed during the incomplete combustion of 
hydrogen and carbon in fat dripping onto a heat source; the smoke rises and deposits PAHs on 
meat (IARC 2010, Kazerouni et al. 2001, Lijinsky 1991, Steck et al. 2007).  In addition, PAHs 
are deposited on meat during preservation by smoke curing (IARC 2010).  PAHs are formed 
directly on charred meat (Jagerstad and Skog 2005).  Cooked meat also contains non-PAH 
carcinogens, such as heterocyclic amines (Taylor et al. 2009).     
 PAH levels in cooked meat depend on several factors, including cooking method, 
temperature and duration, doneness level, distance from the heat source, the amount of fat on the 
meat, and whether or how much fat dripped onto the heat source (IARC 2010, Kazerouni et al. 
2001, Lijinsky 1991, Lijinsky and Shubik 1965, Morris and Seifter 1992, Ramesh et al. 2004).  
PAH levels in smoked meat depend on the specific smoking technique used (Gomaa et al. 1993, 
IARC 2010).  It is estimated that, on average, an individual's dietary intake of PAHs in the US is 
less than 2 μg per kg of food (Agency for Toxic Substances and Disease Registry [ATSDR] 
1995).  The highest levels of dietary PAHs are found in charred meat (up to 10-20 μg per kg of 
food) (Castaño-Vinyals et al. 2004, Phillips 1999).   
Assessment of Grilled and Smoked Meat Intake in Epidemiological Studies   
In epidemiological studies, dietary habits are generally assessed through food frequency 
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questionnaires or other dietary questionnaires.  To a more limited extent, nutritional 
epidemiology studies may use biomarkers of exposure including DNA adducts and urinary 
metabolites to evaluate certain types of short-term dietary intake (IARC 2010, Ramesh et al. 
2004, Roth et al. 2001, Strickland et al. 2002).   
 Study questionnaires can be used to reconstruct dietary PAH exposures through questions 
on intake patterns and cooking methods.  Researchers can evaluate associations between health 
outcomes and specific PAH-containing foods (such as grilled and smoked meat), or can use a 
combination of questionnaire responses and databases of measured PAH concentrations in foods 
to construct a dietary PAH exposure index (Kazerouni et al. 2001, Sinha et al. 2005, Steck et al. 
2007).   
Regarding the latter approach, while PAH content in foods can be physically measured by 
assessing concentrations of several PAHs (Guillen 1994, Phillips 1999), this is difficult in 
practice given that PAH profiles differ between foods and not all PAHs are easily measured 
(IARC 2010).  Another option is to assess benzo[a]pyrene as a surrogate for all dietary PAHs 
(Kazerouni et al. 2001) (IARC 2010).  Benzo[a]pyrene is both a strong carcinogen and a 
reasonable surrogate for overall dietary PAHs because of its presence in many food items (IARC 
2010).  A 2001 investigation reported a correlation of r = 0.87 (p = 0.0001) between dietary 
benzo[a]pyrene concentrations and the combined levels of 14 other PAHs in a variety of foods.  
The correlation was even greater (r = 0.98; p = 0.0001) for PAHs that are carcinogenic in animals 
(Kazerouni et al. 2001) (IARC 2010).  Most studies of meat and breast cancer have evaluated 
associations with foods rather than an exposure index for specific chemicals.  The Long Island 
Breast Cancer Study Project evaluated associations with lifetime intake of grilled and smoked 
meat and also constructed a benzo[a]pyrene dietary index (Steck et al. 2007).   
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 Dietary questionnaires are hampered by a number of methodological limitations, 
including recall bias (Byers et al. 1983).  Recall bias may be especially problematic when 
assessing dietary intake in the distant past.  A number of studies have attempted to validate long-
term dietary recall and reported correlation coefficients ranging from 0.13 to 0.59 (Bakkum et al. 
1988, Byers et al. 1983, Jensen et al. 1984, Lindsted  and Kuzma 1989, Maruti et al. 2005, Sobell 
et al. 1989, Wu et al. 1988) (Steck et al. 2007).  The resultant misclassification can bias results 
towards or away from the null for a multi-level dietary variable (Steck et al. 2007).  Previous 
research suggests that recall bias for dietary intake is generally not differential by cancer case-
control status (Byers et al.1983, Freidenreich et al. 1992, Holmberg et al. 1996, Jensen et al. 
1984, Steck et al. 2007).  However, one breast cancer study found that recall bias patterns for 
reporting of meat intake differed by case-control status, though not in a consistent direction with 
respect to different meat variables (Holmberg et al. 1996).   
 In most epidemiological studies of meat consumption and breast cancer risk, 
questionnaires focused only on recent meat intake, most commonly in the past year (Steck et al. 
2007).  Longer-term exposure may be more relevant to breast carcinogenesis (Clark et al. 1997).  
In addition, many dietary questionnaires do not (or do not adequately) evaluate cooking methods 
(Steck et al. 2007), which does not allow differentiation between overall meat intake and intake 
of grilled, smoked or barbecued meat specifically (Steck et al. 2007).  Studies that do evaluate 
cooking techniques or doneness preferences differ in the method of assessing this information 
(Sinha et al. 2000, Steck et al. 2007, Zheng et al. 1998).  Resulting variation in reporting dietary 
habits may impact effect estimates.   
Associations with Breast Cancer 
Studies evaluating associations between meat consumption and breast cancer report 
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inconsistent results (Hermann et al. 2002, Missmer et al. 2002).  All three meta-analyses 
published on this topic show elevated effect estimates for total or red meat intake (Boyd et al. 
1993, 2003, Taylor et al. 2009).  In contrast, a pooled analysis of 8 prospective cohort studies 
found null associations between breast cancer and total, red, or white meat intake (Missmer et al. 
2002).  Studies consistently report null or negative associations between breast cancer and white 
meat intake (Ambrosone et al. 1998, Delfino et al. 2000, Goodman et al. 1992, Missmer et al. 
2002, Steck et al. 2007, van der Hel et al. 2004).   
Most (Dai et al. 2002, Deitz et al. 2000, Krajinovic et al. 2001, Zheng et al. 1998, 1999, 
2001, 2002), but not all (Delfino et al. 2000, Gertig et al. 1999), epidemiological studies do 
report positive associations between breast cancer and intake of well-done red meat both in 
general and among women with certain genetic variants.  The two studies reporting null results 
for well-done red meat consumption also found null or negative associations between breast 
cancer and grilled, barbecued, or charred red meat intake over the course of one year (Delfino et 
al. 2000, Gertig et al. 1999).  Few women reported eating red meat in the study by Delfino and 
colleagues (2000).  Another investigation found null results for total (red and white) well-done or 
charred meat consumption (Holmes et al. 2003).  A recent study from the Long Island Breast 
Cancer Study Project evaluating lifetime intake of grilled and smoked meat found positive 
associations with postmenopausal breast cancer, which were strongest among women with low 
fruit and vegetable intake (Steck et al. 2007).  Elevated effect estimates were reported for intake 
of red, but not white, grilled and smoked meat (Steck et al. 2007). 
PAH-DNA Adducts 
Biomarkers of PAH Exposure 
Biomarkers of exposure or dose are measurements of chemicals or their metabolites in 
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the body (e.g. in tissues, blood, or urine) (Godschalk et al. 2003).  PAH biomarkers include 
blood-protein adducts (most commonly assessed in albumin or hemoglobin), urinary PAH 
metabolites (primarily 1-hydroxypyrene), and DNA adducts in blood or tissues (Bostrom et al. 
2002, Castaño-Vinyals et al. 2004).   
 A 2003 review by Godschalk and colleagues concluded that, for PAHs, "the most 
promising biomarker seems to be the measurement of DNA adducts, since it takes into account 
individual differences in exposure, absorption and distribution of the chemical, its metabolism 
into DNA reactive forms, detoxification [of] reactive intermediates, as well as cell turnover and 
repair of DNA damage" (Godschalk et al. 2003).  Since PAH-DNA adducts reflect DNA damage 
levels, they may be considered an indicator of effective biological PAH dose, rather than purely 
of exposure (Beyea et al. 2006, Binkova et al. 1995, Nesnow et al. 1993).  PAH-DNA adducts 
have been found in human breast tissue and human breast milk (Bostrom et al. 2002, Gammon 
and Santella 2008, Moore et al. 1987, Ramesh et al. 2004, Rundle et al. 2000a, Santella 1999, 
Straif et al. 2005, Terry and Rohan 2002). 
 Due to high cell turnover rates (usually a few months to a few years), PAH-DNA adducts 
generally represent recent exposures in both target and surrogate (e.g. blood) cells (Gammon et 
al. 2002c, Shields et al. 1992).  PAHs are lipophilic and can thus also "accumulate in adipose 
tissue to be released over time” (Rundle et al. 2000a).  Hence, PAH adducts may potentially 
reflect exposures from the more distant past (Obana et al. 1981, Rundle et al. 2000a).  
Nevertheless, no known biomarkers represent long-term, historical PAH exposure or dose 
(Gammon et al. 2002c).   
PAH Sources as Predictors of Adduct Levels 
Many studies report associations between PAH-related DNA adducts and ambient 
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environmental PAHs, smoking, clinical or occupational PAH exposures, and intake of 
charbroiled food (Beyea et al. 2006, Binkova et al. 1995, Castaño-Vinyals et al. 2004, Dor et al. 
1999, Eder 1999, Hemminki et al. 1988, 1990, Kang et al. 1995, Lodovici et al. 1998, Mumford 
et al. 1993, Paleologo et al. 1992, Pavanello et al. 1999, Perera et al. 1988, 1992, Rojas et al. 
1995, Rothman et al. 1990, 1993, Santella 1999, Santella et al. 1992, 1993, Tuominen et al. 2002, 
van Maanen et al. 1994). 
 Ambient environmental PAHs can affect PAH-DNA adduct levels more strongly than 
dietary sources, active smoking, or occupational exposures (Beyea et al. 2006, Eder 1999), 
despite the fact that the average person’s exposure to PAHs from air pollution is lower than from 
these other sources (Castaño-Vinyals et al. 2004).  It is unclear why this is the case.  However, 
this fact does illustrate that exposure level is not the only consideration with respect to biological 
relevance.  Other factors including exposure route, actual internal dose, differences in 
metabolism or DNA repair, and other components of the PAH mixture may be of vital 
importance with respect to disease causation and other biologic effects (Bostrom et al. 2002).   
 Not all studies have found associations between PAH sources and adduct levels 
(Gammon et al. 2004a, Georgiadis et al. 2001, Perera et al. 1995, Scherer et al. 2000, 
Shantakumar et al. 2005).  This may be due to differing biological relevance of various PAH 
exposure sources, differences in PAH exposure levels between investigations, methodological 
limitations, small sample sizes, differing study population characteristics relevant to PAH 
metabolism or DNA repair, or the influence of unmeasured PAH exposures (Bostrom et al. 2002, 
Eder 1999, Shantakumar et al. 2005).  It has been hypothesized that inconsistent associations 
between PAHs and adducts may be an indication that adduct formation is more a function of 
individual susceptibility than exposure level (Gammon et al. 2004a).  Despite correlations 
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between PAH-related exposures and PAH-DNA adducts in many studies, individuals' adduct 
levels are known to vary significantly at similar exposure levels.  This “suggests that individuals 
respond differently as a result of genetic susceptibility related to activation or detoxification of 
carcinogens, DNA repair capacity, and other lifestyle or dietary factors” (Santella 1999).   
 A 2004 review that pooled results from twelve studies found a statistically significant 
correlation between ambient environmental benzo[a]pyrene levels and mean PAH-DNA adduct 
levels in blood cells (Castaño-Vinyals et al. 2004).  This review concluded that "PAH-DNA 
adducts can be usefully applied to assess environmental exposure to PAHs at a group level" 
(Castaño-Vinyals et al. 2004), and that biomarker measurement can discriminate between small 
differences (as low as 5 ng/m3) of monitored personal exposure to ambient benzo[a]pyrene 
(Castaño-Vinyals et al. 2004).  In this pooled analysis, the correlation coefficient varied with 
respect to adduct measurement strategy.  Specifically, the correlation between ambient 
environmental benzo[a]pyrene and PAH-DNA adducts was stronger when using enzyme-linked 
immunosorbent assay (ELISA) (r = 0.99; P = 0.02) than when using 32P-postlabeling (r = 0.406; 
P = 0.21, overall combined correlation: r = 0.60; P = 0.04) (Castaño-Vinyals et al. 2004).  It 
should be noted that ambient benzo[a]pyrene levels happened to be higher in studies using 
ELISA than in studies using 32P-postlabeling (Castaño-Vinyals et al. 2004).    
Laboratory Assessment of PAH-DNA Adducts 
PAH-DNA adducts can be detected in circulating blood cells and in biopsied healthy or 
malignant target tissue, including breast tissue (Bostrom et al. 2002).  PAH-DNA adducts are 
usually assessed in the blood, which is representative of "the systemic concentration of the parent 
compound and/or reactive metabolites" (Bostrom et al. 2002).  This may potentially attenuate 
associations between adduct levels and cancer risk relative to measurement in the target tissue 
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(Perera and Rundle 2003).  Researchers report correlations between PAH-DNA adduct levels in 
the blood and at least one group of target tissues - the lung and larynx (Bostrom et al. 2002, 
Szyfter et al. 1994, Wiencke et al. 1995).  Other studies of correlations between blood and tissue 
adducts in the lung and skin have shown null or mixed results (Godschalk et al. 1998a,b, Poirier 
et al. 2000, Santella et al. 1999, Spivack et al. 1997, van Schooten et al. 1997).  This association 
has not been evaluated for breast tissue.   
 A number of laboratory methods are available to assess PAH-DNA adduct levels, 
including 32P postlabeling of modified nucleotides, mass spectrometry, fluorescence 
spectroscopy, immunohistochemistry, and competitive ELISA (Bostrom et al. 2002, Gammon et 
al. 2000c, Poirier et al. 2000).  Several other methods of adduct detection exist, but are used 
rarely (never for breast cancer research) (Santella et al. 1999).  These methods are not discussed 
further in this document.   
 ELISA measures specific PAH-DNA adducts by using targeted antibodies (Bostrom et al. 
2002) including against "benzo[a]pyrene and structurally related PAH diol epoxide-DNA 
adducts" (Gammon et al. 2002c).  Like ELISA, fluorescence spectroscopy and mass 
spectrometry also identify and quantify structurally specific DNA adducts (Bostrom et al. 2002, 
Casale et al. 2001, Rojas et al. 1994, 1998).  In contrast, 32P-postlabeling measures general bulky 
aromatic or hydrophobic DNA adducts (Castaño-Vinyals et al. 2004, Phillips and Arlt 2007).  
Thus, this method is not specific to PAH-DNA adducts.  For example, it also measures adducts 
from heterocyclic amines (Castaño-Vinyals et al. 2004, Poirier and Weston 1996).  However, 
postlabeling is a more sensitive method than ELISA, fluorescence spectroscopy, or mass 
spectrometry (Bostrom et al. 2002, IARC 2010).      
 Immunohistochemistry is another option, allowing for the detection of adducts in target 
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tissue, such as breast tissue.   Immunohistochemical assays are inexpensive and have good 
sensitivity and specificity for PAH-DNA adducts (IARC 2010, Romano et al. 1999, Rundle et al. 
2000a, Santella 1999).  Both ELISA and immunohistochemistry require “the production of 
antibodies, prior knowledge of the adduct being measured and relatively large amounts of DNA 
for sensitivity” (IARC 2010) (Santella et al. 1999).  ELISA is generally more sensitive than 
immunohistochemistry (Santella et al. 1999).  Of all available methods, ELISA may be “most 
suited to large-scale epidemiology studies or clinical evaluations because it is a rapid and low-
cost procedure not requiring radiolabeled compounds” (Casale et al. 2001).   
 PAH-DNA adduct assays do not measure all forms of PAH-induced DNA damage (Casale 
et al. 2001).  For example, the Long Island Breast Cancer Study Project measured PAH-DNA 
adducts using an antibody against PAH diol epoxide adducts forming at the N2 position of 
guanine (Gammon et al. 2002c, Mordukhovich et al. 2009).  This assay does not recognize PAH 
quinone-DNA adducts, abasic sites left by depurinating adducts, oxidative lesions, or diol 
epoxide adducts at other positions.  Assays which detect all bulky adducts will still fail to detect 
abasic sites and oxidative lesions.   
 Population-based studies of PAH-DNA adducts and breast cancer assessed adducts in 
circulating mononuclear cells using ELISA (Gammon et al. 2002c, 2004a) or in leukocytes using 
32P-postlabeling (Saieva et al. 2011).  The Long Island Breast Cancer Study Project chose to use 
ELISA because of its specificity to PAH-DNA adducts and the speed and convenience of the 
assay, all assets for a large investigation (Gammon et al. 2002c).  All other studies of PAH-
related DNA adducts and breast cancer were hospital-based and measured adducts directly in 
breast tissue (tumor and/or adjacent tissue for cases), using control participants who underwent 
either reduction mammoplasties (Li et al. 1996, 2002, Perera et al. 1995) or surgery for certain 
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types of benign breast disease (Rundle et al. 2000a).  These hospital-based studies detected 
adducts using 32P-postlabeling (Li et al. 1996, 2002, Perera et al. 1995) or an 
immunohistochemical assay (Rundle et al. 2000a). 
Associations with Breast Cancer 
PAH-related DNA adducts are consistently related to breast cancer both in small hospital-
based case-control investigations (Li et al. 1996, 2002, Perera et al. 1995, Rundle et al. 2000a) 
and in larger population-based case-control studies (Gammon et al. 2002c, 2004a).  For example, 
Rundle and colleagues (2000) found that breast tumor tissue was more than twice as likely to 
contain elevated PAH-DNA adduct levels as breast tissue from women with benign breast 
disease (odds ratio [OR] = 2.56; 95% confidence interval [CI]: 1.05-6.24).  Results were of 
borderline significance for adducts in adjacent, non-tumor tissue (OR = 1.97, 95% CI: 0.94 - 
4.17) (Rundle et al. 2000a).  Similar or greater effects were observed in the other hospital-based 
studies (Li et al. 1996, 2002, Perera et al. 1995).   
 A population-based case-control study (the Long Island Breast Cancer Study Project) 
reported more modest positive associations between breast cancer and PAH-DNA adducts in 
circulating mononuclear cells (OR = 1.41, 95% CI: 1.07, 1.86 for the highest vs. lowest quantile, 
OR = 1.29, 95% CI: 1.05, 1.58 for detectable vs. nondetectable adduct levels) (Gammon et al. 
2004a).  This reduction in effect estimates relative to hospital-based investigations is likely 
related to increased sample size and therefore improved stability of results (Gammon et al. 
2004a).  The fact that the hospital-based studies assessed DNA adducts directly in breast tissue 
rather than in blood cells may also be relevant (Perera and Rundle 2003).  No dose-response 
relationship was observed when evaluating quantiles of PAH-DNA adduct levels in relation to 
breast cancer risk (Gammon et al. 2004a).  This may be due to (1) a threshold effect of PAH-
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DNA adducts on breast cancer risk, (2) greater importance of individual susceptibility to PAHs 
than of PAH exposure level, or (3) a potentially non-linear dose-response relationship between 
adducts and breast cancer (Dr. Jan Beyea, personal communication 2009, Gammon et al. 2004a).  
A recent Italian nested case-control study (292 cases, 292 controls) failed to find an association 
between bulky adducts in leukocytes and breast cancer risk (Saieva et al. 2011).    
TRAFFIC AND AIR POLLUTION 
Sources of Exposure to Ambient Environmental PAH 
Ambient PAHs, both indoor and outdoor, are emitted from anthropogenic sources 
including vehicular traffic, industrial processes, power generation, heating, incinerators, wood 
and coal stoves, cooking, candles, incense, tobacco smoke, space heaters, and leaf and garbage 
burning (Besaratinia et al. 2002, Boffetta 1997, Bostrom et al. 2002, Friedman and Calabrese 
1977, IARC 2010, Lioy and Greenberg 1990, Mumtaz et al. 1996, Narvaez et al. 2008, Ramesh 
et al. 2004, Wallace 2000).  In addition to trucks and cars, mobile sources of PAH emissions 
include "aircraft, shipping, railways...off-road vehicles, and machinery" (Ravindra et al. 2008).  
Natural PAH sources such as forest fires and volcanoes make a small contribution to ambient 
PAH levels at ground level, which is heavily outweighed by anthropogenic emissions (Bostrom 
et al. 2002). Because of the importance of anthropogenic PAH emissions relative to PAHs from 
natural sources, PAH levels in water sediments are strongly correlated with the historical onset of 
fossil fuel use (Bostrom et al. 2002).    
 Measured PAH air concentrations (Gigliotti et al. 2005, Morris and Seifter 1992) and 
urinary PAH metabolite levels (Adonis et al. 2003, Kanoh et al. 1993, Kuo et al. 2004) are higher 
in urban  areas than in more rural locations.  Vehicular traffic emissions are often the primary 
source of ambient PAH in urban and suburban areas (Bostrom et al. 2002, Dubowsky et al. 1999, 
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Dunbar et al. 2001, IARC 1989), though wood smoke is the largest source of ambient PAHs in 
the US overall (Bostrom et al. 2002).  PAHs emitted from wood burning show relatively little 
carcinogenic activity, however, in contrast to PAHs in vehicular traffic emissions (Boffetta et al. 
1997, Lewtas 1993, Lewtas et al. 1992, Lewtas and Gallagher 1990).  Wood burning is also more 
likely to occur away from areas of high population density (Shen et al. 2011).  PAHs, primarily 
bound to course particles (> 10 μm in diameter) (Bostrom et al. 2002), are also found in road 
dust originating from brake linings, tires, and asphalt (Bostrom et al. 2002, Ravindra et al. 2008). 
 Outdoor air pollution infiltrates indoors effectively (Sioutas et al. 2005).  Studies report 
that outdoor air pollution is the major source of indoor residential PAHs (Beyea et al. 2006, 
Dubowsky et al. 1999, Long et al. 2001, Naumova et al. 2002, Ohura et al. 2004).   
Ambient PAH Levels and Properties 
Ambient PAH levels vary significantly across regions (IARC 2010).  Concentrations tend 
to be high in large cities (IARC 2010).  Measured ambient benzo[a]pyrene levels range from 
0.01 to 100 ng/m3, and measured overall ambient PAH levels range from less than 5 ng/m3 to 
hundreds of ng/m3 (Castaño-Vinyals et al. 2004, Georgiadis and Kyrtopoulos 1999; IARC 2010, 
Vyskocil et al. 1997).  A 2010 review reports typical levels of a few ng/m3 for ambient 
benzo[a]pyrene and a typical range of 1 to 30 ng/m3 for total ambient PAHs, excluding 
naphthalene (IARC 2010).  PAH air concentrations are substantially higher in urban than in more 
rural areas (Gigliotti et al. 2005, Morris and Seifter 1992).   
 Most studies report that ambient PAH levels are highest in the winter (Flessel et al. 1991, 
Harrison et al. 2009, Moller et al. 1996, Srogi 2007, Topinka et al. 2000).  This is likely due to 
lower temperatures and solar radiation levels, leading to reduced PAH degradation.  Other 
potential contributing factors vary by location and include summer rainfall facilitating PAH 
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clearance from the atmosphere, less atmospheric mixing in the winter, and seasonal differences 
in heating emissions (Beyea et al. 2008, Bostrom et al. 2002, Castaño-Vinyals et al. 2004, 
Greenberg et al. 1985, Han and Naeher 2006, Moller et al. 1996, Srogi 2007, Topinka et al. 
2000).  
 Ambient PAH levels have decreased significantly over the past several decades due to the 
widespread introduction of catalytic converters in gasoline vehicles (Bostrom et al. 2002).  The 
lowered PAH emissions per vehicle were in part counteracted by increased vehicle use during the 
same time period (Beyea et al. 2008).  For example, a 2008 report described an approximately 
"15-fold decline in benzo[a]pyrene and other PAH cruise emission factors for the US vehicle 
fleet following introduction of automotive pollution controls," whereas "overall vehicle miles 
traveled in the US increased by about a factor of 2.7 between 1970 and 2005" (Beyea et al. 2008) 
(Davis and Diegel 2007).  Despite the historical decline in US traffic PAH emissions, it is 
important to evaluate associations between traffic PAHs and breast cancer for the following 
reasons: (1) many US women are still exposed to high levels of traffic PAHs, such as women 
living near highways, bus depots, and busy intersections, and (2) overall vehicular PAH emission 
levels remain high in other countries.      
 PAHs can be found in both gaseous and particulate phases, and are therefore considered 
semivolatile organic compounds (Zielinska et al. 2004).  Larger PAH molecules, such as 
benzo[a]pyrene, are usually particle-associated rather than in the gas phase and are generally 
much more carcinogenic than lighter-weight PAHs (Beyea et al. 2006, Bostrom et al. 2002, 
IARC 2010, Zielinska et al. 2004).  Airborne PAHs from gasoline vehicle emissions are 
primarily bound to particles (Bostrom et al. 2002, Westerholm and Egebäck 1994).  The relative 
proportion of particle and gas-phase PAHs is affected by meteorologic conditions (i.e. relative 
31 
 
humidity and temperature), the properties of specific PAHs in ambient mixtures, and the 
chemical composition of aerosols (Bostrom et al. 2002, Goss and Schwarzenbach 1998).  
Ambient gas-phase PAHs “generally have durations of less than a day, whereas particle-
associated PAHs may persist for weeks and undergo long-range atmospheric transport” (IARC 
2010) (Arey and Atkinson 2003). 
 It is reported that 90-95% of particle-associated PAHs are bound to particles less than 3.3 
μm in diameter (Bonner et al. 2005, Ravindra et al. 2001).  A 1998 study reported that almost all 
PAHs from gasoline vehicle emissions are bound to ultrafine particles (< 0.12 μm in diameter) 
(Bostrom et al. 2002, Miguel et al. 1998).  Relative to larger particles, small particles are able to 
penetrate more deeply into the respiratory tract, are absorbed into the circulation more quickly, 
and induce systemic oxidative stress and inflammation more efficiently (Li et al. 2003, Miller 
1973). 
Atmospheric Fate of Ambient PAH 
Airborne PAHs are oxidized and degraded in the atmosphere through photochemical and 
chemical transformation (i.e. due to interactions with radiation and other air pollutants), and are 
removed from the atmosphere via dry and wet deposition (Bostrom et al. 2002).  Deposition 
processes are influenced by particle size and relative concentrations of particle-associated and 
gaseous PAHs (Bostrom et al. 2002).  The efficiency of chemical transformation depends on the 
concentrations of other air pollutants, the relative proportion of particulate and gas-phase PAHs, 
and on meteorological conditions (Bostrom et al. 2002).  Photochemical transformation tends to 
decrease in the winter relative to other seasons because of lower temperatures and solar radiation 
levels (Bostrom et al. 2002).   
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Ambient PAH Measurement, Monitoring and Exposure Assessment 
Measurement of ambient benzo[a]pyrene and other PAHs in both environmental and 
occupational settings involves collection on specialized filters, extraction with organic solvents, 
and analysis through either gas chromotography/mass spectrometry or high performance liquid 
chromatography (Castaño-Vinyals et al. 2004, IARC 2010, Lewtas et al. 1997, Mumford et al. 
1993, Peluso et al. 1998, Poirier et al. 1998).  Since the 1970s, occupational studies have 
generally used personal rather than stationary PAH monitors (IARC 2010).   
 Environmental monitoring and measurement methods are not well developed for PAHs 
(Bostrom et al. 2002).  Monitoring of specific PAHs “often requires extensive separation 
schemes because of their lack of distinct functional groups, the existence of numerous structural 
isomers and the need to analyze PAHs in diverse environmental matrices” (IARC 2010).  Unlike 
US EPA criteria pollutants such as carbon monoxide or ozone, environmental ambient PAHs are 
monitored relatively infrequently and ambient PAH levels are thus not well quantified (Bostrom 
et al. 2002).   
 In epidemiologic research, ambient PAH exposure assessment methods include the use of 
personal monitors, measurement of PAH biomarkers of exposure or dose, and ascertainment of 
PAH-related exposures, such as traffic exposure variables for research in the general population, 
or coal-tar pitch volatiles in occupational studies, which may be used as surrogates of ambient 
PAH exposure level (Gunier et al. 2006, IARC 2010).  However, personal monitors are 
expensive and present other logistical difficulties, PAH biomarkers integrate non-ambient PAH 
sources and are likely to be influenced by individual-level factors and characteristics in addition 
to exposure levels (Shantakumar et al. 2005; see Chapter I), and surrogates of ambient PAH 
concentrations, such as distance to the nearest major road, are often crude. 
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 More than 100 PAHs have been isolated from air.  Studies that measure ambient PAHs 
directly usually report concentrations for a small number of PAHs, thereby potentially excluding 
PAHs relevant to health effects of interest (Bostrom et al. 2002, Castaño-Vinyals et al. 2004, 
IARC 2010).  Furthermore, the collection of measured PAHs differs across investigations 
(Bostrom et al. 2002, Castaño-Vinyals et al. 2004).  This is in large part due to the difficulty of 
finding an index PAH, since PAH profile varies with respect to both the specific exposure source 
and the temperature of combustion (Bostrom et al. 2002, Castaño-Vinyals et al. 2004, IARC 
2010).   
 Most often, only benzo[a]pyrene is measured as a surrogate for all ambient PAHs 
(Bostrom et al. 2002, Castaño-Vinyals et al. 2004).  On the one hand, "the presence in the 
environment of other PAHs, some of which are carcinogenic, does not allow an accurate 
estimation of the risk linked to a PAH mixture on the basis of [benzo[a]pyrene] concentration 
alone" (Castaño-Vinyals et al. 2004).  Similarly, in a real-life setting, “most if not all 
exposures...to PAHs involve complex organic mixtures” and “metabolism and bioactivation of 
individual PAH compounds are influenced by the presence of other PAHs” (Ramesh et al. 2004) 
(Goldstein 2001, Warshawsky 1999).  Traffic emissions include significant concentrations of 
benzo[g,h,i]perylene, pyrene, fluoranthene, phenanthrene and other PAHs (Bostrom et al. 2002).  
Monitoring only benzo[a]pyrene inevitably leads to some exposure misclassification (Bostrom et 
al. 2002, Castaño-Vinyals et al. 2004).    
 Nevertheless, benzo[a]pyrene is one of the most carcinogenic PAHs and is common to all 
ambient PAH sources (Bostrom et al. 2002, Castaño-Vinyals et al. 2004).  Benzo[a]pyrene is 
representative of ambient PAH exposure from vehicular exhaust (Beyea et al. 2008, Bostrom et 
al. 2002, Fertmann et al. 2002), and is a good surrogate for PAH carcinogenicity (Bostrom et al. 
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2002).  Furthermore, the Long Island Breast Cancer Study Project reports that soil 
benzo[a]pyrene levels are strongly correlated with other high molecular weight soil PAHs, which 
are generally more carcinogenic than lower weight PAH molecules (Beyea et al. 2006, Bostrom 
et al. 2002).  For example, Pearson correlation coefficients were greater than 0.9 for 
benzo[b]fluoranthene, benzo[ghi]perylene, benzo[k]flouranthene, dibenz[a,h]anthracene and 
indeno[1,2,3-cd]pyrene, and were greater than 0.8 for acenaphthylene, anthracene, 
benz[a]anthracene, chrysene and fluorine (Beyea et al. 2006).  With respect to historical 
reconstruction of traffic emissions exposure, benzo[a]pyrene is the only PAH for which historical 
data is consistently available (Beyea et al. 2008).  A 2008 report indicated that the pattern of 
historical decline of ambient PAH levels was similar between benzo[a]pyrene and other traffic-
related PAHs, including benzo[e]pyrene, benzo[ghi]perylene, chrysene, coronene, and perylene 
(Beyea et al. 2008).  
Cancer Risk Assessment for Ambient PAH 
Cancer risk assessment with respect to ambient PAH exposure is difficult given the fact 
that PAHs are rarely monitored, are almost always components of complex mixtures including 
varied carcinogenic PAHs and non-PAH carcinogens, and are mainly bound to particles, which 
can exert carcinogenic effects independent of PAH content (Bostrom et al. 2002, Valavanidis et 
al. 2008).  Risk assessment for PAHs with respect to various disease endpoints is largely based 
on animal studies in which one surrogate PAH is examined individually on a short-term basis, 
and from studies of high levels of complex occupational exposures, such as coal-tar pitch 
volatiles (ATSDR 1995). 
 Several research groups and organizations, including the World Health Organization 
(WHO) and the California EPA, have calculated lifetime risk estimates for an increase in lung 
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cancer risk in relation to a rise in ambient benzo[a]pyrene levels (Bostrom et al. 2002, CA EPA 
Air Resources Board [CARB 1994], WHO 2000).  For example, the WHO estimates "the lung 
cancer risk from a lifetime exposure to PAHs in ambient air at 8.7 x 10-5 per ng/m3 
benzo[a]pyrene" (Bostrom et al. 2002) (WHO 2000). Similar risk slopes have not been estimated 
for breast or other cancers. 
Regulations for Ambient PAH and Related Pollutants 
The US EPA does not regulate ambient environmental PAH levels, though it does set 
standards for several PAHs in drinking water (US EPA 2009).  The US Occupational Health and 
Safety Administration (OSHA) limits occupational exposure to coal tar pitch volatiles, a PAH-
heavy mixture (Han and Naeher 2006).  Some other countries also limit occupational exposures 
to coal-tar pitch volatiles or particulate PAHs, but none limit ambient environmental PAH levels 
(IARC 2010).   
 The US EPA regulates levels of ambient particulate matter (PM; US EPA 2011b), which 
often contains adsorbed PAH molecules (conversely, ambient heavy mass PAHs are mostly 
physically associated with particles) (Bostrom et al. 2002).  The EPA also regulates ambient 
levels of the traffic-associated pollutants carbon monoxide, ozone, nitrogen oxides and sulfur 
dioxide (US EPA 2011b), as well as tailpipe exhaust emissions of PM, carbon monoxide, 
nitrogen oxides, non-methane organic gases, and volatile organic compounds (VOCs) 
(Environment and Human Health, Inc. [EHHI] 2006, US EPA 1994a).  It should be noted that, in 
practice, ambient pollutant concentrations often exceed regulatory standards (EHHI 2006).  Also, 
air quality standards may need to be updated given evidence of health effects of traffic-related air 
pollutants even at levels that fall below federal standards (EHHI 2006).     
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Vehicular Traffic Composition and Concentrations 
Traffic exhaust is a highly heterogeneous mixture of gases and particles (IARC 1989).  In 
addition to carbon dioxide and water, vehicles emit many by-products including carbon 
monoxide, nitrogen oxides, sulfur dioxide, PM, and volatile organic compounds, including non-
methane hydrocarbons (Boothe and Shendell 2008, IARC 1989, Zielinska et al, 2001).  
Components and derivatives of some of the latter pollutants include benzene, 1,3-butadiene, 
formaldehyde, ozone, acetaldehyde, polycyclic organic matter and benzo[a]pyrene (Boothe and 
Shendell 2008, Han and Naeher 2006, IARC 1989, Nielsen et al. 1983, Sax et al. 2006, Wu et al. 
2006).  Particles in vehicular exhaust often contain elemental carbon, metals, and adsorbed 
organic materials including “polycyclic aromatic hydrocarbons, heterocyclic compounds, 
phenols, nitroarenes, and other oxygen- and nitrogen-containing derivatives” (IARC 1989) 
(Boothe and Shendell 2008, Oberdorster 2001).  A 2008 study evaluating US road tunnel data 
found that vehicular emissions of PAHs, VOCs, carbon monoxide, and particulate organic carbon 
have declined markedly over the past several decades (Beyea et al. 2008).    
 Traffic exposure is widespread (Han and Naeher 2006) and is usually the main source of 
air pollution in urban areas (Maitre et al. 2002).  Traffic emissions vary in persistence, "physical 
and chemical properties, composition, and toxicity of fuel mixtures" across geographic and 
demographic regions (Boothe and Shendell 2008) (Verma and des Tombe 2002).  This is due to a 
number of factors including average vehicle age, type, and maintenance status, fuel composition, 
presence of emissions control technologies such as catalytic converters, traffic and driving 
patterns, governmental regulations, and roadway conditions, "designs, grades, and distributions" 
(Boothe and Shendell 2008) (IARC 1989).     
 Particles from gasoline and diesel vehicle emissions differ with respect to size and 
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surface properties (IARC 1989).  Organic compound emissions from gasoline or diesel sources 
differ mainly in quantity.  For example, diesel engines emit greater levels of PM and nitroarenes 
relative to gasoline vehicles with catalytic converters, given comparable power output (2-40 
times and 20-30 times higher, respectively) (IARC 1989).  For PAHs in particular, emission 
levels are similar between diesel vehicles and gasoline vehicles without catalytic converters 
given similar power output, but are greatly reduced (by more than 10 times) in gasoline vehicles 
with catalytic converters (IARC 1989). 
 Measured ambient vehicular exhaust levels are highest near roads, with concentrations 
dropping to background levels within approximately 150-300 meters (Boothe and Shendell 
2008) (Gilbert et al. 2005, Zhu et al. 2002, 2006).  This decline is due to "evaporation of volatile 
constituents, atmospheric dispersion, and coagulation" (Boothe and Shendell 2008) (Zhu et al. 
2002). 
Influences on Traffic PAH Emissions 
Traffic PAH emission levels differ based on driving conditions and traffic patterns 
(Boothe and Shendell 2008, IARC 1989).  Vehicular PAH emissions are related to driving speed, 
with greater emissions at low and high speeds (Begeman and Colucci 1970, Kotin et al. 1954, 
Westerholm et al. 1992), and are higher during transient rather than steady-state driving cycles 
(Kado et al. 2005) (Shen et al. 2011).  Emissions are elevated at traffic intersections due to 
increased acceleration and deceleration at these sites (Beyea et al. 2006, 2008, Sculley 1989, 
Sheu et al. 1996a,b), and are also greater under cold-engine rather than warm-engine conditions, 
discussed in more detail below (Beyea et al. 2006, 2008, Bostrom et al. 2002, Ravindra et al. 
2008, Shen et al. 2011).    
 Emission levels also differ based on fuel characteristics and vehicle properties.  PAH 
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emissions differ with respect to fuel type (diesel versus gasoline, as described below) (Bostrom 
et al. 2002, Shen et al. 2011).  Also, both diesel and gasoline vehicle PAH emission levels are 
positively associated with increased concentrations of PAHs in the respective fuels (Bostrom et 
al. 2002, Shen et al. 2011, Ravindra et al. 2008).  Vehicular PAH emission levels are decreased 
greatly by the presence of a catalytic converter (Beyea et al. 2006, 2008, Bostrom et al. 2002, 
Shen et al. 2011).  Emissions are associated with engine condition and maintenance as well 
increased mileage (Ravindra et al. 2008).  PAH emission levels also vary with respect to "vehicle 
age and load, lubricant oil (Ravindra et al. 2008)" (Shen et al. 2011) and outdoor ambient 
temperatures (Bostrom et al. 2002, Shen et al. 2011).  Information regarding variation in PAH 
emission levels is derived from tunnel studies, road-side measurements, and dynamometer test 
beds (Beyea et al. 2008, Ravindra et al. 2008, Shen et al. 2011).     
 Both gaseous and particulate PAHs are found in vehicle exhaust, but particulate PAHs are 
much more prevalent in gasoline vehicle emissions (Bostrom et al. 2002, Han and Naeher 2006, 
Miguel and Friedlander 1978, Morris and Seifter 1992).  Gasoline-powered cars tend to emit 
higher molecular weight PAHs relative to heavy-duty diesel vehicles (e.g. coronene and 
benzo[a]pyrene vs. fluoranthene and pyrene, respectively) (Bostrom et al. 2002).  Heavy-duty 
diesel vehicles generally emit greater amounts of PAH per vehicle for the same distance traveled 
relative to gasoline vehicles without catalytic converters (Boffetta et al. 1997, Han and Naeher 
2006), though gasoline-fueled passenger vehicles “without catalytic converters and diesel 
engines of similar power output produce similar quantities of polycyclic aromatic hydrocarbons 
per kilometer" (IARC 1989).  Gasoline cars with catalytic converters emit fewer PAHs than any 
other vehicle type (Boffetta et al. 1997, IARC 1989), since catalytic converters reduce vehicular 
PAH emissions by greater than 10 times (IARC 1989).  Currently, it is likely that diesel vehicles 
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and older gasoline vehicles without catalytic converters emit the majority of traffic-related PAHs 
(Bostrom et al. 2002).  Studies indicate that diesel engine PAH emissions are mainly comprised 
of less carcinogenic lighter weight PAHs, and that gasoline engines have historically been the 
major vehicular source of heavy mass PAHs such as benzo[a]pyrene in the US (Begeman and 
Colucci 1970, Beyea et al. 2008, Bostrom et al. 2002, Miguel et al. 1998).   
 Although cold-engine emissions occur for only a short time and distance after starting a 
vehicle, they may nevertheless account for more than 50% of PAH emissions from gasoline cars 
(Bostrom et al. 2002).  Relative contributions from cold-engine emissions differ with respect to 
time and location (Beyea et al. 2006).  For example, the contribution of cold-engine emissions is 
higher in residential areas relative to highways, and at times when people are most likely to be 
starting their cars, such as prior to their morning commute (Beyea et al. 2006).  The distribution 
of gas and particle-phase PAHs does not appear to differ based on engine temperature conditions 
(Ravindra et al. 2008).   
Traffic and Air Pollution Exposure Assessment 
Most epidemiological studies assess air pollution exposure through either sparse pollutant 
monitoring data or through indirect measures such as distance to a pollution source (Beyea 1999, 
Boothe and Shendell 2008, Heinrich et al. 2005, Savitz and Feingold 1989).  Environmental 
ambient PAH concentrations are not commonly monitored.  Thus, studies evaluating associations 
between measured ambient PAH levels and health outcomes are infrequent (Farmer et al. 2003, 
Taioli et al. 2007).  No epidemiological investigations have used environmental PAH monitoring 
data in conjunction with a geographic information system.  Some epidemiologic studies have 
used personal monitoring of PAH exposures (e.g. Perera et al. 2009).  PM and some other traffic-
related pollutants are commonly monitored and may be considered surrogates of ambient PAH or 
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traffic exposure (Bonner et al. 2005, US EPA 2011b).   
 For traffic exposure in particular, previous epidemiological investigations have generally 
employed relatively crude measures such as distance to major roads or traffic density (Nie et al. 
2007, Savitz and Feingold 1989).  These measures are often based on self-reported data on 
"street type, traffic intensity, frequencies of traffic jams at the home address, or proximity of the 
home to major roads," "air pollution annoyance scores," or "traffic annoyance scores" (Heinrich 
et al. 2005) (Boothe and Shendell 2008).  Other investigations have evaluated less subjective 
traffic exposure surrogates, such as "traffic counts on major roads, air pollution data from 
municipal monitoring sites, files on traffic counts at home address, geographic information 
system (GIS) based assessment of distance from subject's home to a major road, spatial air 
pollution measurements, interpolated concentrations derived from monitoring network 
data...dispersion models...and finally complex regression models using measured air pollution 
data and GIS data on traffic count, distance to major roads, and population density" (Heinrich et 
al. 2005) (Boothe and Shendell 2008).   
 One previous study has taken excess traffic exhaust emissions at intersections and during 
engine warm-up into account (Nie et al. 2007).  Otherwise, none of these methods account for 
elevated emissions at intersections or shortly following engine start-up (Beyea et al. 2006, Carr 
et al. 2002, Nie et al. 2007).  Many studies do not validate their exposure estimates.  Research 
indicates that modeled traffic exposure estimates predict pollutant concentrations more 
effectively than cruder traffic exposure proxies such as "surrogate variables or...ambient 
monitoring data" (Brauer et al. 2003) (Heinrich et al. 2005). 
 Several studies have evaluated associations between traffic or air pollution exposure and 
breast cancer (Bonner et al. 2005, Crouse et al. 2010, Lewis-Michl et al. 1996, Nie et al. 2007, 
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Raaschou-Nielsen et al. 2011).  One of these investigations calculated residential traffic and 
chemical facility density using a geographic information system divided into 5 km2 grids and 1 
km2 grids, respectively (Lewis-Michl et al. 1996).  Four other population-based case-control 
studies examined relations between more individualized air pollution exposure estimates and 
breast cancer risk (Bonner et al. 2005, Crouse et al. 2010, Nie et al. 2007, Raaschou-Nielsen et 
al. 2011).  One investigation utilized a residential total suspended particulates (TSP) exposure 
estimate calculated from environmental monitor readings and subsequent "inverse distance 
squared weighed interpolation" (Bonner et al. 2005).  Another study used a version of the 
historical residential traffic emissions exposure model originally developed for the Long Island 
Breast Cancer Study Project (Beyea et al. 2006, Nie et al. 2007).  A recent hospital-based case-
control investigation estimated ambient residential nitrogen dioxide concentrations as a marker 
for traffic pollution using a combination of pollutant monitoring data and land-use regression 
models (Crouse et al. 2009a,b, 2010).  A cohort study evaluated associations between modeled 
long-term exposure to traffic-related nitrogen oxides and breast cancer risk (Raaschou-Nielsen et 
al. 2011).  Nitrogen oxides are gaseous pollutants, and therefore do not reflect depletion and 
long-term transport phenomena relevant to carcinogenic particulate traffic air pollution (Beyea et 
al. 2006, IARC 2010).  Finally, an ecological analysis reports associations between traffic-related 
pollutants and breast cancer incidence in the US (Wei et al. 2012).   
Vehicular Traffic and Overall Health Effects 
Numerous investigations report associations between a range of adverse health outcomes 
and (1) traffic-related pollutants such as benzene, particulate matter and carbon monoxide, (2) 
motor vehicle exhaust, and (3) traffic exposure surrogates such as residential proximity to major 
roads (Boothe and Shendell 2008).  These health-related outcomes include adult and perinatal 
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mortality (Chen et al. 2008, de Medeiros et al. 2009, Pope et al. 2002), cardiovascular (Dockery 
2001, Pope et al. 2002), respiratory (Braback and Forsberg 2009) and birth outcomes (Ritz et al. 
2000, 2002, Wilhelm and Ritz 2003), cancer-related subclinical changes such as chromosomal 
damage (Burgaz et al. 2002, Sree Devi et al. 2009), as well as lung cancer (Raaschou-Nielsen et 
al. 2010, 2011) and childhood cancers, including leukemia (Boothe and Shendell 2008, 
Feychting et al. 1998, Pearson et al. 2000, Raaschou-Nielsen et al. 2001).   
 Several studies have evaluated associations between traffic-related variables and female 
breast cancer, and all found some evidence of a positive association (Bonner et al. 2005, Crouse 
et al. 2010, Lewis-Michl et al. 1996, Nie et al. 2007, Raaschou-Nielsen et al. 2011). 
Occupational exposure to vehicular emissions has been linked to male breast cancer (Hansen 
2000).       
 IARC classifies diesel exhaust as probably carcinogenic to humans and gasoline vehicle 
exhaust as possibly carcinogenic to humans (IARC 1989).  In addition to PAHs (IARC 2010), 
confirmed human carcinogens in vehicle emissions include benzene (IARC 1987), formaldehyde 
(IARC 2006), and 1,3-butadiene (IARC 2008).  All three carcinogens cause mammary tumors in 
laboratory animals following ingestion or inhalation (Hecht 2002, Huff et al. 1989, IARC 2006, 
2008, Maltoni et al. 1988, 1989, Rudel et al. 2007).  Benzene and formaldehyde have also been 
linked with breast cancer in occupational research (Cantor et al. 1995, IARC 2008, Petralia et al. 
1999).  In addition, the US EPA classifies the traffic-related pollutant acetaldehyde as a probable 
human carcinogen (US EPA 1994b) and IARC classifies this pollutant as a possible human 
carcinogen (IARC 1985a).  A recent review noted that "because of their potency and high 
concentrations, most of the cancer risk [from traffic] has been attributed to benzene, 1,3-
butadiene, and particle-bound PAHs” (Boothe and Shendell 2008).    
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 Vehicular exhaust contains many highly correlated chemicals (Bostrom et al. 2002).  
Thus, it is not possible to definitively assess the contributions of individual traffic-related 
pollutants to health effects based on observational studies (Bostrom et al. 2002).  Furthermore, 
the specific components of the traffic mixture can influence the health effects of any given 
chemical in that mixture.  For example, "metabolism and bioactivation of individual PAH 
compounds are influenced by other PAHs" and transition metals found in particulate matter "can 
enhance the mutagenicity and carcinogenecity of other carcinogens such as PAHs" (Mehta et al. 
2008).  However, despite being correlated, traffic-related pollutants do not have identical 
distributions.  For example, in the Long Island Breast Cancer Study Project (LIBCSP), 
residential traffic PAH exposure estimates were modeled using PAH-specific vehicle emissions 
data and PAH-specific dispersion parameters, and were validated and calibrated against 
residential soil PAH levels (Beyea et al. 2006).  As an illustrative example, the benzo[a]pyrene 
geographic model used in the LIBCSP needed to be altered in order to predict carbon monoxide 
(CO) levels for a validation exercise.  Specifically, the carbon monoxide model excluded "all 
depletion phenomena, because deposition, washout, and photo decay are negligible in the case of 
CO" (Beyea et al. 2006).  Due to their "potency and high concentrations" in vehicular exhaust, 
particulate-phase PAHs are considered among the most carcinogenic traffic-related chemicals 
(Boothe and Shendell 2008).  Benzo[a]pyrene is one of the most carcinogenic PAHs and is 
representative of PAH exposure from vehicle exhaust (Beyea et al. 2008, Bostrom et al. 2002, 
Fertmann et al. 2002). 
Associations of Traffic and Air Pollution with Breast Cancer 
Studies examining relations between air pollution and breast cancer are sparse.  A case-
control study conducted on Long Island (Nassau and Suffolk counties) reported a positive, but 
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not statistically significant, association between high residential traffic density in 5 km2 grids and 
breast cancer (Lewis-Michl et al. 1996).  This association was limited to participants residing in 
Nassau County.  The study also reported elevated and statistically significant breast cancer odds 
among women living near chemical facilities, using a geographic information system divided 
into1 km2 grids (Lewis-Michl et al. 1996).  Participants had resided on Long Island for at least 
20 years.   
 Another population-based case-control study reported a positive relation between 
residential exposure to TSP at birth and postmenopausal breast cancer (OR = 2.42; 95% CI: 0.97, 
6.09 for the highest vs. the lowest quartile, p for trend = 0.01; Bonner et al. 2005).  This result 
was supported when evaluating TSP exposure at birth as a continuous variable (OR = 1.20; 95% 
CI: 1.04, 1.38 for every 30 μg/m3 increase in TSP), and by spline regression analysis (Bonner et 
al. 2005).  Cumulative TSP exposure was estimated using data on residential TSP concentrations 
at birth, menarche, first birth, and 10 and 20 years prior to the case-control interview.  This 
measure was also positively associated with postmenopausal breast cancer (OR = 3.5; 95% CI: 
1.4, 8.9 for the highest quartile, p for trend = 0.03; Bonner et al. 2005).  TSP was considered a 
surrogate for ambient PAH exposure in this investigation.  TSP levels correlated well with 
ambient benzo[a]pyrene measurements during the one year in which both pollutants were 
monitored simultaneously in the study region (r = 0.90; Bonner et al. 2005).   
 The third relevant investigation, another population-based case-control study, reported 
positive associations between modeled residential exposure to traffic emissions (specifically, the 
model was adapted from the LIBCSP and estimated exposure to traffic benzo[a]pyrene) at the 
age of menarche and premenopausal breast cancer (OR = 2.07; 95% CI: 0.91 – 4.72 for the 
highest quartile; p for trend = 0.03), and between residential exposure to traffic emissions at the 
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age of first birth and postmenopausal breast cancer (OR = 2.58; 95% CI: 1.15, 5.83 for the 
highest quartile, p for trend = 0.19) (Nie et al. 2007).  Upon stratifying by smoking history 
(ever/never), both associations were observed only among non-smokers.  P-values for interaction 
were 0.01 and 0.06, respectively (Nie et al. 2007).  Results did not differ with respect to tumor 
hormone receptor (ER/PR) status (Nie et al. 2007).  Further research suggested that these 
associations may be limited to women with the GSTM1 null genotype (OR for the association 
between traffic exposure at menarche and premenopausal breast cancer = 4.64, 95% CI: 0.98, 
21.94 for the highest vs. the lowest quartile, p for trend = 0.01; OR for the association between 
exposure at first birth and postmenopausal breast cancer = 3.27, 95% CI: 0.99-10.84, p for trend 
= 0.02) (Nie et al. 2005).  Risk was reported as not elevated among women with the GSTM1 
wild-type genotype, and variation in GSTM1 was not independently associated with breast 
cancer (though relevant effect estimates and confidence intervals were not reported) (Nie et al. 
2005).  No other variants were evaluated.  GSTM1 is an important detoxification and 
antioxidative defense enzyme (Reszka et al. 2006).  
 A recent hospital-based case-control study found associations between the traffic-related 
pollutant nitrogen dioxide and postmenopausal breast cancer (OR = 1.31; 95% CI: 1.00-1.71 for 
each 5 ppb pollutant increase in the year 1996) (Crouse et al. 2010).  The study evaluated 7 
different regression models (for the year 2006, and 2 models each utilizing estimates from 
somewhat different exposure assessment methods for the years 1985, 1996, and for the mean of 
1985 and 1996) (Crouse et al. 2010).  No other effect estimates reached statistical significance.  
However, all effect estimates were fairly consistent in that they ranged between OR = 1.17 and 
OR = 1.36 (Crouse et al. 2010).   
 A large cohort study examined the association between modeled residential exposure to 
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nitrogen dioxide concentrations as a marker of traffic exposure and breast cancer incidence 
(Raaschou-Nielsen et al. 2011). Age-adjusted models showed a positive association between 
nitrogen oxides and breast cancer (incidence rate ratio [IRR] = 1.39, 95% CI: 1.09, 1.77 per 100 
μg/m3 NOx), which was attenuated to some extent after adjustment for other covariates (IRR = 
1.16, 95% CI: 0.89, 1.51). 
 Finally, a recent ecological analysis reported associations between traffic-related 
pollutants and breast cancer incidence in the US (Wei et al. 2012). 
PAH AND BREAST CANCER: PROPOSED MECHANISMS 
PAHs as Animal Mammary Carcinogens 
Several PAHs, including benzo[a]pyrene, reliably induce mammary tumors in laboratory 
rodents (el-Bayoumy 1992, IARC 2010).  This is demonstrated by experimental studies in which 
PAHs (for example, benzo[a]pyrene, dibenzo[a,h]pyrene, dibenzo[a,i]pyrene, 
dibenzo[a,l]pyrene) were administered orally (el-Bayoumy et al. 1995, Huggins and Yang 1962), 
by direct injection to the mammary gland (Cavalieri et al. 1989, 1991, Hecht et al. 2002), 
through skin painting (Ranadive and Karande 1963), and through intracolonic instillation 
(Anderson 1983, IARC 2010).  Two PAH compounds are in fact used as model mammary 
carcinogens for experimental studies in Sprague-Dawley rats (Santodonato 1997).  No 
experimental studies examining associations between inhaled PAHs or PAH sources and 
malignant mammary tumors were identified in the literature.  One investigation evaluated and 
reported positive associations between inhaled diesel exhaust and mammary adenomas and 
fibromas (i.e. benign growths) among rats (Iwai et al. 1986).    
PAHs as Human Carcinogens 
Benzo[a]pyrene, several PAH-related occupational exposures (aluminum production, 
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roofing, paving, chimney sweeping, coal-tar distillation, coke production, coal gasification), and 
tobacco smoke are classified as known human carcinogens by IARC (IARC 1984, 1985b, 2004, 
2010, Straif et al. 2005).  Benzo[a]pyrene was classified as a human carcinogen “based on 
sufficient evidence in animals and strong evidence that the mechanisms of carcinogenesis in 
animals also operate in exposed human beings” (Straif et al. 2005).  PAH-containing 
occupational mixtures were classified as carcinogenic to humans based on results of both 
occupational studies and animal research (Straif et al. 2005).   
 Other individual PAHs (for example, benz[a]anthracene, indeno[1,2,3-cd]pyrene, 
benzo[b]fluoranthene, dibenz[a,h]anthracene, benzo[k]fluoranthene, chrysene) and PAH-
containing mixtures, including diesel engine exhaust and gasoline engine exhaust, are classified 
as probable or possible human carcinogens by health and environmental agencies based on 
animal research, epidemiologic/occupational studies, or mechanistic data (Bostrom et al. 2002, 
CA EPA 1999, IARC 1989, 2010, Minesotta Department of Health, NTP 2011, US EPA 2011a).  
It should be noted that (1) some PAH-containing mixtures, such as vehicular exhaust and 
cigarette smoke, contain confirmed, probable or possible human carcinogens other than PAHs 
(Bostrom et al. 2002), and (2) the above classifications are primarily based on tumorigenesis in 
tissues and organs other than the breast (i.e. primarily lung and skin cancers) (IARC 2010).  
There has been a paucity of research on associations between PAHs or PAH exposure sources 
and breast cancer risk.   
Initiation, Promotion, Progression, and Dose-Response 
Carcinogenesis for epithelial cancers such as breast cancer is conceptually divided into 
three broad stages: initiation, promotion, and progression (Bostrom et al. 2002, Pitot and Dragan 
1996).  Initiation involves carcinogen or metabolism-mediated mutations in tumor suppressor 
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genes or proto-oncogenes (Bostrom et al. 2002, Kinzler and Vogelstein 1998).  Promotion 
involves proliferation of initiated cells (Bostrom et al. 2002).  Progression is an irreversible 
process by which a cell gains further mutations and genetic instability and completes the process 
of attaining "malignancy and autonomous cell growth" (Bostrom et al. 2002).  In order for cancer 
to occur, a tumor must also evade host defenses, such as immunologic and DNA repair processes 
(Morris and Seifter 1992, Nasca and Pastides 2008).   
 Based on in vivo and in vitro experimental investigations, several PAHs including 
benzo[a]pyrene are known to be complete carcinogens that can act as initiators, promoters, and 
progressors through a combination of genotoxic and estrogenic mechanisms (Bostrom et al. 
2002, Cerutti et al. 1977, Morris and Seifter 1992).  PAHs may also interact with other inherited 
or lifestyle/environmental factors in exerting a carcinogenic effect (Bostrom et al. 2002).  
Individual PAHs differ in metabolic and mutagenic/carcinogenic properties (IARC 2010).  More 
structurally complex PAHs tend to have higher mutagenic and carcinogenic capacity (Bostrom et 
al. 2002).   
 Compounds acting via initiator or promoter mechanisms tend to have different dose-
response relationships with tumor formation.  Pure promoters generally show an 
approximately S-shaped dose-response curve, whereas purely genotoxic chemicals tend to 
show a more linear dose-response relationship (Bostrom et al. 2002).  Most animal studies 
yield non-linear dose-response relationships between PAHs and carcinogenesis "with an 
upward rise at high doses" (Bostrom et al. 2002), which can be linearized upon simultaneous 
administration of another promoter (Bostrom et al. 2002, Burns et a. 1983).   Animal research 
usually employs very high PAH doses, however, whereas humans are generally 
environmentally exposed to relatively low PAH levels (Bostrom et al. 2002).  A review noted 
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that "at the present state of knowledge, risk estimation for PAHs at low exposure levels 
should be based on the assumption of linear dose-response relationships despite the nonlinear 
responses often seen for high doses in animal tests" (Bostrom et al. 2002).  
PAH Properties Relevant to Breast Carcinogenesis 
PAHs are lipophilic, meaning that they are stored and can accumulate in adipose tissue, 
including in the breast (Morris and Seifter 1992, Obana et al. 1981, Terry and Rohan 2002).  
PAHs exhibit estrogenic and anti-estrogenic (Santodonato 1997), inflammatory (Jeng et al. 2010, 
Schober et al. 2007), pro-oxidant (Farmer et al. 2003, Jeng et al. 2010) and genotoxic (Farmer et 
al. 2003) properties that may be relevant to breast carcinogenesis (Gammon and Santella 2008). 
 Estrogens are endogenous steroid hormones that regulate breast growth and 
differentiation during adolescence and pregnancy and stimulate cell division in healthy or 
malignant estrogen receptor-positive breast tissue (Nasca and Pastides 2008).  PAHs are similar 
to estrogens with respect to structure, metabolism and transport (Morris and Seifter 1992).  
Estrogenic effects of PAHs may be especially relevant when a woman's endogenous estrogen 
levels are low, such as after menopause (Brody and Rudel 2003).  Exposure to environmental 
estrogens may contribute to breast carcinogenesis through (1) increased likelihood of 
spontaneous DNA replication errors due to higher levels of cell proliferation, (2) increased 
likelihood of DNA damage going uncorrected by DNA repair mechanisms due to higher levels of 
cell proliferation, and (3) promoting the growth of existing small tumors or initiated cells (Brody 
and Rudel 2003, Nasca and Pastides 2008).  Benzo[a]pyrene increases proliferation of both 
untransformed human mammary epithelial cells and human breast carcinoma cells in in vitro 
experimental research (IARC 2010, Tannheimer et al. 1997, 1998, Tsai et al. 2004b).   
 PAHs may also influence cancer risk through immunotoxic or inflammatory mechanisms 
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(Bostrom et al. 2002, IARC 2010, Jeng et al. 2010, Schober et al. 2007, Straif et al. 2005).  Since 
a well-functioning immune system can help protect against tumor formation, reduced immune 
function could adversely affect cancer risk (IARC 2010).  High-level PAH exposure has been 
linked to immunotoxic endpoints in animal studies within many species, in human cell lines, and 
in mechanistic studies (Davila et al. 1995, IARC 2010, Ramesh et al. 2004).  There is also 
epidemiological and clinical evidence that environmental exposure to PAHs may affect immune 
function in humans, but research is as yet too sparse to draw a definitive conclusion (IARC 
2010).  Similarly, chronic inflammation is linked to carcinogenesis (Fitzpatrick 2001), and PAHs 
are associated with induction of inflammatory activity in experimental research (Jeng et al. 2010, 
Schober et al. 2007).  It should be noted that because PAHs are often bound to particles, “there is 
considerable potential for covariance with an inflammatory response that is induced by the 
carrier particles alone” (IARC 2010).   
 Some PAHs have a high affinity to the cytosolic aryl hydrocarbon (Ah) receptor, which is 
distributed throughout the body, including in breast tissue (IARC 2010, Safe 2001).  Activation 
of this receptor leads to upregulation of genes relevant to cancer promotion, such as those 
involved in growth and differentiation (Bostrom et al. 2002).  In animal studies, Ah receptor 
activation by aromatic hydrocarbons induces endocrine disruptor effects, cell proliferation and 
tumor promotion (Bostrom et al. 2002).  The Ah receptor is also involved in the induction of 
enzymes which metabolize PAHs to electrophilic genotoxic intermediates (specifically, 
cytochrome P450s) (Bostrom et al. 2002, IARC 2010, Santodonato 1997).  In summary, “several 
of the biological effects of PAHs, such as enzyme induction of xenobiotic metabolizing enzymes, 
immunosuppression, teratogenicity and carcinogenicity, are thought to be mediated by activation 
of the aryl hydrocarbon receptor” (IARC 2010).   
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 Finally, PAHs may contribute to breast carcinogenesis through induction of DNA 
damage, both by direct interaction with DNA and via oxidative stress-related mechanisms 
(Harvey et al. 1996).  This is discussed in much more detail below. 
PAH Exposure, Absorption and Metabolism 
PAHs are rapidly absorbed into the human body following inhalation, ingestion, or skin 
contact (IARC 2010), and are released into the general circulation following all three exposure 
routes (IARC 2010, Modica et al. 1983, Rees et al. 1971, Withey et al. 1993a,b).  Because this 
document focuses primarily on the carcinogenic effects of ambient PAH pollution, the following 
review mainly concentrates on absorption and metabolism of PAHs following inhalation 
exposure.   
 It should be noted that gastrointestinal absorption may also occur following inhalation 
exposure, due to mucocilliary clearance and release of PAH metabolites following hepatobiliary 
processing (IARC 2010, Sun et al. 1982).  Ingested PAHs are absorbed by diffusion through the 
gastrointestinal tract epithelium (IARC 2010, O'Neill et al. 1991).  Gastrointestinal absorption 
and metabolism of PAHs is influenced by PAH size, other dietary factors (i.e. drugs, foods or 
nutrients, and environmental contaminants), gastric hormones, and bile salts (IARC 2010, 
Ramesh et al. 2004).   
 Ambient PAHs are absorbed through the airway epithelium upon inhalation, and then 
distributed to the circulation and to other tissues, where PAHs are metabolized through activation 
and detoxification pathways (Bostrom et al. 2002, Castaño-Vinyals et al. 2004, Gammon and 
Santella 2008).  Metabolism of PAHs can occur at the site of entry as well, though in practice the 
lung shows limited metabolic activity (Bostrom et al. 2002).  Absorption of inhaled PAHs is 
influenced by (1) the degree of lipophilicity, such that more lipophilic compounds diffuse at 
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lower rates (Bostrom et al. 2002), (2) whether the PAH has adhered to a particle, with slower 
clearance of particle-associated PAHs (Brzeznicki et al. 1997, Castaño-Vinyals et al. 2004, 
Creasia et al. 1976, Sun et al. 1982), (3) the location of PAH deposition on the airway epithelium 
(PAHs diffuse more quickly from the alveolar epithelium than from the epithelia of conducting 
and bronchial airways) (Bostrom et al. 2002, Gerde and Scott 2001, IARC 2010), (4) the size of 
the PAH molecule, as PAHs with fewer rings are absorbed more quickly and efficiently (IARC 
2010), and (5) if particle associated, the size of the particle to which a PAH is bound and the rate 
at which the PAH dissociates from the particle (IARC 2010).   
 Inhaled PAHs are released into the general circulation following absorption and diffusion 
through the airway epithelium, basement membrane, and finally the endothelium (Bostrom et al. 
2002).  This process can occur relatively quickly (IARC 2010).  For example, an experimental 
study in rats was able to measure radiolabelled benzo[a]pyrene and its metabolites in the blood 
within 95 minutes of inhalation exposure (IARC 2010, Withey et al. 1993b).  Upon entering the 
general circulation, PAHs are “widely distributed to most organs and tissues...with some 
preferential distribution to or retention in fatty tissues” (IARC 2010).  The breast contains a high 
proportion of adipose tissue (Yaffe et al. 2009).  PAHs are lipophilic and "can accumulate in 
adipose tissue to be released over time and redistributed to the breast epithelial cells” (Rundle et 
al. 2000a) (Obana et al. 1981).     
 The majority of PAH metabolism occurs in the liver, regardless of the route of exposure 
and entry (Bostrom et al. 2002, IARC 2010, Ramesh et al. 2004).  Resulting metabolites 
(including DNA-reactive metabolites) can be excreted via the biliary or renal systems or can be 
released into the general circulation and distributed to extra-hepatic tissues (Bostrom et al. 2002, 
Ramesh et al. 2004).  PAHs are metabolized and activated to reactive carcinogenic intermediates 
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by extra-hepatic tissues as well (Bostrom et al. 2002, Ramesh et al. 2004).  Experimental studies 
report that PAHs are metabolized by human mammary epithelial cells in vitro (Bartley et al. 
1982, Bostrom et al. 2002, Calaf and Russo 1993, Eldridge et al. 1992, Mane et al. 1990, Morris 
and Seifter 1992, Terry and Rohan 2002) and in the rat mammary gland in vivo (Cavalieri et al. 
1989, 2005, Todorovic et al. 2005).   
 PAHs are generally carcinogenic and chemically reactive only upon metabolic activation 
to charged electrophilic intermediates via Phase I pathways (Cavalieri and Rogan 1985, Gammon 
and Santella 2008, Hecht 1999, IARC 2010, Morris and Seifter 1992).  Many PAH metabolites, 
including DNA-reactive metabolites (IARC 2010), are produced during the course of Phase I 
metabolism (IARC 2010, Shimada 2006).  However, PAHs are ultimately mainly activated to the 
following DNA-reactive/carcinogenic metabolites: diolepoxides, radical cations, and PAH 
orthoquinones (Bostrom et al. 2002, IARC 2010, Jerina et al. 1991, Ramesh et al. 2004, Straif et 
al. 2005).  Metabolism of PAHs in relation to breast cancer risk is illustrated in Figure A1.1.  
Experimental "in vitro studies show that human breast epithelial tissue has the ability to 
metabolize PAH to their ultimate mutagenic/carcinogenic moieties (Calaf and Russo 1993, 
Eldridge et al. 1992, Mane et al. 1990)" (Rundle et al. 2000a) (MacNicoll et al. 1980, Terry and 
Rohan 2002).  
  PAH activation is usually initiated by cytochrome P450 enzymes, specifically CYP1A1, 
CYP1A2, CYP1B1, and to a smaller extent other enzymes in the CYP family such as CYP2C9 
and CYP3A4 (Bostrom et al. 2002, IARC 2010, Ramesh et al. 2004, Terry and Rohan 2002, Xue 
and Warshawsky 2005).  CYP enzymes are important to the generation of diol epoxides, radical 
cations, and orthoquinones (Bostrom et al. 2002, Cavalieri et al. 1990, Cavalieri and Rogan 
1995, Devanesan et al. 1987, Harvey et al. 1996, IARC 2010, Ramesh et al. 2004, Straif et al. 
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2005, Xue and Warshawsky 2005).  They are expressed in human breast tissue (Ding and 
Kaminsky 2003, IARC 2010, Shimada et al. 1996, 2006), along with other metabolic enzymes 
(e.g. Martinez et al. 2008).   
 Epoxide hydrolase can convert CYP-activated PAH intermediates into diols, which are 
further metabolized into diolepoxides - extremely DNA-reactive metabolites (Bostrom et al. 
2002, Harvey et al. 1996, IARC 2010, Ramesh et al. 2004, Xue and Warshawsky 2005).  
Peroxidases and aldo-keto reductases play important roles in the activation of radical cations 
(Cavalieri et al. 1990, Devanesan et al. 1987, Harvey et al. 1996, IARC 2010, Xue and 
Warshawsky 2005) and PAH orthoquinones (Cavalieri and Rogan 1995, Harvey et al. 1996, 
IARC 2010, Straif et al. 2005, Xue and Warshawsky 2005), respectively. Other enzymes (for 
example, prostaglandin H synthase, myeloperoxidase, lipoxygenase, and cyclooxygenase-2) can 
also contribute to PAH activation (Hughes et al. 1989, Mallet et al. 1991, Marnett et al. 1978, 
Ramesh et al. 2004, Wiese et al. 2001).     
 Reactive PAH metabolites from Phase I metabolism are detoxified to more polar and 
hydrophilic compounds through Phase II metabolic pathways (Shimada 2006).  For example, 
glutathione S-transferases such as GSTM1, GSTP1 and GSTT1 detoxify activated PAH 
metabolites through conjugation with glutathione (Bostrom et al. 2002, Ramesh et al. 2004, 
Straif et al. 2005, Terry and Rohan 2002).  Other detoxifying enzymes include UDP-
glucuronosyltransferases and sulfotransferases (Bostrom et al. 2002, IARC 2010, Straif et al. 
2005, Terry and Rohan 2002).  PAHs are thus commonly detoxified to metabolites including 
sulfate conjugates, glutathione conjugates, and glucuronides (Bostrom et al. 2002, Castaño-
Vinyals et al. 2004).  The products of Phase II metabolism are excreted, sometimes following 
further metabolic processing (Bostrom et al. 2002); this process "is relatively efficient 
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because of the wide distribution of enzymes that transform PAHs into polar metabolites" 
(ATSDR 2009).     
 PAHs can induce PAH-activating cytochrome P450 enzymes via the aryl hydrocarbon 
receptor (IARC 2010, Ramesh et al. 2004; Shimada 2006).  Similarly, PAHs and PAH 
metabolites can induce prostaglandin H synthase (Kelley et al. 1997).  In contrast, PAHs can 
also inhibit cytochrome P450 activity (Shimada 2006) and induce glutathione S-transferases 
(Pushparajah et al. 2008).  Thus, PAH exposure levels and conditions can “influence the 
balance of Phase I and Phase II enzymes, which can determine whether or not a toxic cellular 
response occurs” (IARC 2010).      
 Genetic variation in Phase I and Phase II pathway genes, which could influence the 
expression of the corresponding enzymes, is hypothesized to partially underlie differential 
cancer susceptibility upon PAH exposure (IARC 2010).  However, relevant epidemiological 
studies have been inconsistent (e.g. McCarty et al. 2009, Rundle et al. 2000b).  This may be 
due to insufficient power in some investigations or differences in participant characteristics 
such as genotype combinations, race, "age, sex, pathological and physiological conditions, 
and exposure to environmental pollutants" (Shimada 2006) across study populations (IARC 
2010, Shimada 2006).   
PAHs and DNA Adducts 
Given sufficiently high levels of PAH exposure or inadequate host detoxification, DNA-
reactive PAH metabolites bind to DNA and form adducts (Dipple et al. 1984, Gammon and 
Santella 2008, Harvey et al. 1991, 1996).  PAH metabolites preferentially bind to guanine 
residues (Braithwaite et al. 1998), and will almost always bind to either guanine or adenine 
(IARC 2010).  PAH-DNA adducts are found in human breast tissue and human breast milk 
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(Bostrom et al. 2002, Gammon and Santella 2008, Moore et al. 1987, Ramesh et al. 2004, 
Rundle et al. 2000a, Terry and Rohan 2002, Santella 1999, Straif et al. 2005), and are 
consistently linked with breast cancer in epidemiologic studies (Gammon et al. 2002c, 2004a, 
Gammon and Santella 2008, Li et al. 1996, 2002, Perera et al. 1995, Rundle et al. 2000a).   
 PAH-DNA adducts reflect both PAH exposure levels and host response (Gammon and 
Santella 2008, Santella 1999).  As demonstrated by in vitro and in vivo experimentation, bulky 
DNA adducts are generally repaired through nucleotide excision repair (NER) pathways 
(Braithwaite et al. 1998, Chakravarti et al. 2008, Wei et al. 1995), though base excision repair 
(BER) pathways may also contribute to bulky adduct repair (Braithwaite et al. 1998).  Apurinic 
sites left by depurinating DNA adducts are generally repaired via BER pathways (Braithwaite et 
al. 1998, Chakravarti et al. 2008).  DNA repair processes may be inadequate to fully correct the 
damage (Braithwaite et al. 1998), in which case PAH-induced adducts could ultimately lead to 
somatic mutations in cancer-related genes (Gammon and Santella 2008, Harvey et al. 1996).  
NER is a slower pathway than BER, so repair may be less efficient for stable than for 
depurinating adducts (Braithwaite et al. 1998, Leavitt et al. 2008).    
 Diol epoxide-derived adducts tend to be stable, whereas radical cations form unstable 
adducts “which spontaneously depurinate, leaving potentially promutagenic apurinic (AP) sites” 
(Braithwaite et al. 1998, Cavalieri and Rogan 1995, 1998, Devanesan et al. 1996, Drinkwater et 
al. 1980, IARC 2010, Leavitt et al. 2008, Ochi et al. 1986).  Ortho-quinones commonly lead to 
both depurinating and stable adducts (Burczynski and Penning 2000, McCoull et al. 1999).  AP 
sites from depurinating adducts are routinely formed as a result of normal cellular metabolism 
and are repaired quickly and efficiently (Leavitt et la. 2008).  DNA damage is more likely to go 
unrepaired at higher levels of AP site generation (Leavitt et al. 2008).  It is unclear whether stable 
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or depurinating adducts contribute more strongly to carcinogenesis (Shimada 2006).   
 In addition to individual differences in DNA repair capacity and adduct stability, adduct 
removal may be influenced by the surrounding bases (Bostrom et al. 2002, Hess et al. 1997) and 
by whether the adduct is found on a coding or non-coding DNA strand (Bostrom et al. 2002, 
Jernstrom and Graslund 1994, Mellon et al. 1987).  Adduct formation and persistence is also 
influenced by individual differences in cell cycle control, PAH exposure levels, PAH activation, 
detoxification and absorption, and lifestyle or environmental factors.  For example, enzymes 
relevant to PAH metabolism may be induced by medicines or environmental exposures, whereas 
other substances may act in a chemopreventive capacity (Eder 1999, Gammon and Santella 
2008, IARC 2010, Santella 1999).     
PAHs and Reactive Oxygen Species 
PAHs may also increase cancer risk through induction of reactive oxygen species (ROS) 
(Bolton et al. 2000, Flowers et al. 1997, IARC 2010, Singh et al. 2007, Yu et al. 2002).  PAHs 
influence ROS formation via (1) redox cycling of PAH quinone metabolites (Harvey et al. 1996, 
IARC 2010, Penning et al. 1999, Singh et al. 2007), (2) peroxidase reactions (e.g. involving 
myeloperoxidase; Gammon and Santella 2008, IARC 2010, Podrez et al. 2000, Singh et al. 
2007), and (3) inducing inflammation (Ferguson 2010, Jeng et al. 2010, Schober et al. 2007).  
Even “small amounts of quinone metabolites may result in generation of high ratios of reactive 
oxygen species,” such as hydroxyl radicals and superoxide anion (Flowers-Geary et al. 1993, 
Harvey et al. 1996, Penning et al. 1996).   
 Antioxidants can counteract PAH-induced ROS.  Superoxide dismutase and GST 
enzymes are examples of endogenous antioxidants (Gammon and Santella 2008, Scandalios 
2005).  Exogenous antioxidants include beta-carotene and vitamins C and E (Klaunig and 
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Kamendulis 2004).  Oxidative stress occurs when ROS are not balanced by antioxidants 
(Klaunig and Kamendulis 2004).    
 ROS damage DNA both directly and by forming DNA-damaging lipid peroxidation 
products (Farmer et al. 2003, Gammon and Santella 2008, IARC 2010).  Over 20 types of 
oxidative DNA damage have been identified (Cooke et al. 2003, Ferguson 2010).  The most 
common oxidative stress-induced DNA lesion is 8-oxodeoxyguanosine (Boiteux and Radicella 
1999, Piette 1991, Rossner et al. 2006), which causes somatic mutations, especially GC-TA 
transversions (Boiteux and Radicella 1999, Grollman and Moriya 1993).   
 Oxidative DNA damage is caused by both environmental exposures and normal cellular 
processes (Boiteux and Radicella 1999).  At background DNA damage levels, oxidized bases are 
efficiently and constitutively repaired (Leavitt et al. 2008).  However, uncorrected oxidative 
damage commonly occurs, especially at high environmental exposure and oxidative stress levels 
(Boiteux and Radicella 1999, Ferguson 2010).  When DNA repair pathways are inadequate to 
correct oxidative damage from PAHs, the resulting genetic damage persists (Boiteux and 
Radicella 1999, Grollman and Moriya 1993, Gammon and Santella 2008).  The extent of PAH-
induced oxidative damage may differ between individuals based on variations in PAH exposure 
level and frequency, activation and detoxification processes, DNA repair capacity and other 
defensive mechanisms, or antioxidant intake (IARC 2010, Singh et al. 2007).  Oxidative DNA 
damage is repaired mainly through the BER pathway (Goode et al. 2002), though NER can play 
a role as well (Gros et al. 2002).   
 Detoxification of PAH-induced ROS employs limited antioxidant resources, which may 
have otherwise protected against oxidative damage from other sources (Morris and Seifter 1992).  
ROS can also lead to “electrophilic and pro-oxidant signals that may affect cell growth” (IARC 
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2010).  Finally, recent research suggests that oxidative stress may lead to inhibition of NER 
activity, including repair of PAH-DNA adducts (Ferguson 2010, Mehta et al. 2008).  Oxidative 
stress is strongly linked to carcinogenesis in experimental research (Klaunig and Kamendulis 
2004).  Relevant studies are suggestive of an association between oxidative stress and breast 
cancer in humans (Li et al. 2001, Ray et al. 2000, Wang et al. 1996).  However, there is as yet 
insufficient evidence to conclusively confirm this relationship (Shen et al. 2009).    
DNA Damage, PAH-Induced Carcinogenesis and the Role of DNA Repair  
To summarize, several major mechanisms are proposed to underlie PAH-induced 
carcinogenesis (Harvey et al. 1996, IARC 2010), including metabolic formation of diol epoxides, 
quinones and radical cations, as well as induction of oxidative stress.  Metabolic formation of 
diol epoxides is the most widely accepted and likely most important proposed mechanism 
(Harvey et al. 1996).  Each of these processes may damage DNA and eventually lead to critical 
mutations in tumor suppressor genes or proto-oncogenes (Harvey et al. 1996, IARC 2010).  
These proposed “mechanisms are not mutually exclusive, and all may play a role in the induction 
of cancer” (Harvey et al. 1996) (IARC 2010). 
 In addition to detoxification of reactive metabolites, which may prevent DNA damage 
from occurring in the first place, the effects of existing DNA damage may be mitigated by a 
number of defensive mechanisms, including apoptosis, cell cycle arrest, and DNA repair (Goode 
et al. 2002, Harvey et al. 1996).  If these mechanisms fail or are insufficient, resulting 
uncorrected DNA damage can contribute to cancer risk through eventual formation of somatic 
mutations in tumor suppressor genes (such as p53) or proto-oncogenes (such as ras) during 
replication (Bigger et al. 1990, 1991, Braithwaite et al. 1998, Chakravarti et al. 2008, Glatt et al. 
1989, Harvey et al. 1996, Straif et al. 2005).  PAHs induce mutations in proto-oncogenes and 
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tumor suppressor genes in experimental research (Casale et al. 2001, Chakravarti et al. 1995, 
2008, Hollstein et al. 1991, IARC 2010, Prahalad et al. 1997, Ruggeri et al. 1993).  PAHs are 
reported to induce somatic base substitution mutations (both transversions and transitions) as 
well as frameshift mutations, insertions and deletions in laboratory studies (Adonis and Gil 2000, 
Leavitt et al. 2008, Lehman and Harris 1994, Mahadevan et al. 2003).  Both PAH-DNA adducts 
and PAH-induced oxidative DNA damage can cause insertions and deletions as well as base 
substitution mutations (Ferguson 2010, Greenblatt et al. 1994).   
 Because persistent mutations in critical genes can lead to genetic instability and 
carcinogenesis (Berwick and Vineis 2000, Neumann et al. 2005), polymorphic genes in DNA 
repair pathways are standard candidate cancer susceptibility genes (Gammon and Santella 2008).  
Certain DNA repair gene polymorphisms (for example, in OGG1 and XRCC1) are consistently 
associated with overall cancer risk in epidemiologic studies (Goode et al. 2002).  Reduced DNA 
repair (e.g. as measured by host-cell reactivation or benzo[a]pyrene diol-epoxide [BPDE] 
sensitivity assays) is consistently associated with risk of breast (Helzlsouer et al. 1996, Kennedy 
et al. 2005, Kosti et al. 2010, Motykiewicz et al. 2002, Parshad et al. 1996, Ramos et al. 2004, 
Shi et al. 2004, Xiong et al. 2001) and other cancers (Berwick and Vineis 2000, Lockett et al. 
2005).  Some confirmed breast cancer susceptibility genes are involved in DNA repair pathways 
(e.g. BRCA1, BRCA2; Kosti et al. 2010, Weber and Nathanson 2000).   
 Polymorphisms in DNA repair genes may modify effects of environmental exposures on 
carcinogenesis (Berwick and Vineis 2000, Gammon and Santella 2008), even without otherwise 
exhibiting a main effect on breast cancer risk.  It is hypothesized that associations between some 
DNA repair variants and cancer risk "may be apparent only in the presence of DNA-damaging 
agents such as tobacco smoke" (Goode et al. 2002).  Several investigations have been suggestive 
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of interactions between PAH-DNA adducts or cigarette smoking (a PAH source) and DNA repair 
polymorphisms or capacity with respect to breast cancer risk (Crew et al. 2007, Kosti et al. 2010, 
Mechanic et al. 2006, Metsola et al. 2005, Pachkowski et al. 2006, Shen et al. 2005a, Shore et al. 
2008, Terry et al. 2004).   
DNA REPAIR MECHANISMS: BIOLOGY AND EPIDEMIOLOGY 
Several classes of biochemical pathways can repair DNA damage: BER, NER, double-
strand break repair, and mismatch repair (MMR) (Christmann et al. 2003, Goode et al. 2002, 
Wood et al. 2005).   
 MMR corrects DNA polymerase-mediated replication errors (Goode et al. 2002).  This 
process operates through enzymes including MSH6, MLH1, MSH2, and PMS2 (Goode et al. 
2002).  Double-strand break repair, the only type of DNA repair in which no undamaged 
template is available, corrects DNA damage due to either replication errors or exogenous 
exposures such as ionizing radiation (Braithwaite et al. 1999, Goode et al. 2002).  Double-strand 
break repair can proceed through the homologous recombination (HR) pathway or the 
nonhomologous end-joining repair (NHEJ) pathway (Goode et al. 2002), and involves enzymes 
including BRCA1, BRCA2, and XRCC3 (Goode et al. 2002).  The HR pathway "is a process by 
which double-strand DNA breaks are repaired through the alignment of homologous sequences 
of DNA," whereas "the NHEJ repair pathway involves direct ligation of the two double strand 
break ends" (Kiyohara and Yoshimasu 2007).   
 NER and BER pathways remove damaged nucleotide bases and are therefore important to 
correcting PAH-induced DNA damage (Braithwaite et al. 1999).  These pathways are described 
in more detail below, in general and with respect to PAH damage and breast carcinogenesis.  In 
vitro and in vivo laboratory investigations demonstrate that PAH-DNA adducts are repaired by 
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NER (Braithwaite et al. 1998, Gunz et al. 1996, Koostra 1982, van Houten 1990, Venkatachalam 
et al. 1995).  BER repairs PAH-induced oxidative DNA damage (Braithwaite et al. 1998, Goode 
et al. 2002) and may also play a role in repairing PAH-DNA adducts (Blakey and Douglas 1990, 
Braithwaite et al. 1998, Day et al. 1978).  Many genes encoding DNA repair enzymes are 
polymorphic. These “polymorphisms can exist in the promoter regions, introns and exons of a 
given gene and therefore can affect transcription, mRNA processing, functional activity or 
enzyme stability, respectively” (IARC 2010).     
 The impact of DNA repair gene polymorphisms on DNA repair function is still largely 
unknown (Mechanic et al. 2006).  These functional effects are challenging to study because of 
(1) assay differences between studies, (2) variations in study population characteristics (for 
example, DNA repair capacity may be affected by factors such as age and smoking status), and 
(3) difficulty detecting "subtle difference in [DNA repair capacity] by studying only one or two 
SNPs in a very complex pathway" (Shen et al. 2006).   It is likely that “end-points of exposure to 
PAHs such as metabolic profile, DNA adducts...and tumor incidence may result from multigene 
interactions” (IARC 2010).    
 Similarly, studies of associations between DNA repair genes and cancer risk are often 
hampered by insufficient sample size, thereby increasing the likelihood of both false-negative 
and false-positive results (Rothman and Greenland 1998), and by other methodological issues 
including inappropriate genotypic groupings, confounder control strategies, or control group 
selection (Goode et al. 2002).  Few investigations have assessed haplotypes or gene-gene 
interactions with respect to breast or other cancer risk. Such investigations may yield important 
information given sufficient statistical power (Gammon and Santella 2008, Goode et al. 2002, 
Khoury et al. 1993, Kiyohara and Yoshimasu 2007).  
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 The following sections include a review of the literature regarding associations between 
selected BER and NER genes (XPA, XPD, XPF, XPG, ERCC1, XRCC1, and OGG1) and DNA 
repair capacity or DNA damage levels, with a special focus on PAH-related DNA damage.  
Benzo[a]pyrene exposure is associated with micronuclei, sister chromatid exchanges, cell 
transformation, chromosomal aberrations, somatic mutations and DNA strand breaks in 
experimental research (IARC 1983, IARC 2010).  Unless otherwise noted, the laboratory 
experiments described below examined in vitro human cells, rather than animal models.  The 
following text also gives an overview of the NER and BER pathways, and summarizes 
associations between selected DNA repair variants and breast cancer. 
Nucleotide Excision Repair (NER) 
Overview of the NER Pathway 
The NER pathway repairs DNA damage from bulky lesions that alter the shape of the 
DNA helix (Greenblatt et al. 1994), including thymine dimers, ultraviolet-induced lesions, cross-
links, some ROS-induced damage, and bulky adducts, including PAH-DNA adducts (Braithwaite 
et al. 1998, Gammon and Santella 2008, Goode et al. 2002, Manuguerra et al. 2006, Mechanic et 
al. 2006, Reardon et al. 1997).  This repair process is unique in repairing such a wide variety of 
DNA damage (Braithwaite et al. 1998, Friedberg et al. 1995).  The NER pathway is divided into 
two subpathways: transcription-coupled repair (TCR) and global genome repair (GGR) 
(Hanawalt 2002, Kiyohara and Yoshimasu 2007).  TCR "preferentially removes DNA damage 
that blocks ongoing transcription in the transcribed DNA strand of active genes," whereas GGR 
"removes lesions throughout the genome, including those from the nontranscribed strand in the 
active gene" (Hanawalt 2002, Kiyohara and Yoshimasu 2007).  These subpathways differ with 
respect to the DNA damage recognition process (Wang et al. 2010).       
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 NER is a complex multistep process involving at least 20 to 30 proteins (Braithwaite et 
al. 1998, Wood 1997), including from the xeroderma pigmentosum (e.g. XPA, XPC, XPD, XPF, 
XPG) and excision repair cross-complementing (e.g. ERCC1, ERCC6) groups (Sancar et al. 
2004).  The first step of the NER process is damage recognition and binding by a complex of 
proteins (Goode et al. 2002, Crew et al. 2007, Kiyohara and Yoshimasu 2007), which differs for 
the GGR (e.g. XPA, XPC) and TCR (e.g. ERCC6, ERCC8) subpathways (Lindahl and Wood 
1999, Wang et al. 2010).  Next, the TFIIH transcription factor complex of proteins, including the 
crucial adenosine triphosphate (ATP) dependent helicase XPD, unwinds DNA at the lesion site 
(de Boer and Hoijmakers 2000, Goode et al. 2002, Kiyohara and Yoshimasu 2007).  Another 
complex of proteins including ERCC1, XPF and XPG makes dual incisions around the site of the 
DNA damage and excises the damaged single-stranded nucleotide fragment, which is usually 
approximately 27-30 base pairs in length (Goode et al. 2002, Mechanic et al. 2006).  New DNA 
is synthesized by DNA polymerases, and DNA ligation completes the NER process (Braithwaite 
et al. 1998, Friedberg et al. 1995, Goode et al. 2002).  
 Certain germline mutations in NER genes lead to the recessive genetic diseases 
xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy (de Boer and 
Hoeijmakers 2000, Goode et al. 2002; Sarasin and Stary 1997).  Of particular interest with 
respect to cancer susceptibility is xeroderma pigmentosum.  This is a genetic syndrome 
associated with a greatly elevated risk of skin cancer, including basal cell carcinoma and 
malignant melanoma, due to an inability to repair ultraviolet-induced DNA damage (Cleaver 
2005, Goode et al. 2002, Kiyohara and Yoshimasu 2007, Lambert et al. 1995, Norgauer et al. 
2003, Sarasin and Stary 1997, van Steeg and Kraemer 1999).   
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Selected NER Genes and DNA Repair Phenotype 
Selected NER polymorphisms of interest are those genotyped in the LIBCSP: XPA (-
4A/G), ERCC1 (8092C/A), XPD (Lys751Gln, Asp312Asn), XPF (Arg415Gln) and XPG 
(Asp1104His).  Some of these polymorphisms alter the resulting protein's amino acid sequence 
(XPD Lys751Gln and Asp312Asn, XPF Arg415Gln, and XPG His1104Asp).  Others are located 
outside of coding regions (XPA -4A/G and ERCC1 8092C/A).  A recent report stated that "based 
upon the degree of conservation across species and the change in polarity, charge and protein 
structure caused by the substituted amino acid, the XPD codon 312, XPD codon 751, [and] XPG 
codon 1104...polymorphisms are predicted to have significant functional impact" (Mechanic et 
al. 2006) (Shen et al. 1998a).   
 Experimental studies report associations between the XPA 23A/G variant polymorphism 
and (1) reduced DNA repair capacity in "cells transfected with benzo[a]pyrene diolepoxide 
(BPDE)-treated plasmid" (Wu et al. 2003) as well as (2) an increased number of BPDE-induced 
chromatid breaks in human lymphocytes (Lin et al. 2007).  Another experimental study reported 
null results for the association between the XPA 62T/C polymorphism and DNA repair capacity 
measured by removal of induced BPDE-DNA adducts, though a weak positive association was 
observed with a multivariable model including variants in XPA, XPC, and XPG (Shen et al. 
2006).  An epidemiologic investigation reported a null association between XPA (23A/G) and 
PAH-DNA adducts among lung cancer cases (Zienolddiny et al. 2006).  The XPA 23A/G 
polymorphism was reported to modify PAH-induced DNA damage in coke oven workers 
(Pavanello et al. 2005, Wang et al. 2010).   
 A polymorphism in ERCC1 (8092C/A) was associated with BPDE-induced DNA adducts 
in one experimental study (Zhao et al. 2008).  Other laboratory investigations reported null 
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results for the 8092C/A polymorphism with respect to number of BPDE-induced chromatid 
breaks (Lin et al. 2007) and DNA repair capacity measured by removal of induced BPDE-DNA 
adducts (Shen et al. 2006).  Epidemiological studies have reported associations between variants 
in ERCC1 and chromosomal DNA damage in coke-oven workers (Cheng et al. 2007; 19007 T/C) 
as well as reduced PAH-DNA adduct levels among lung cancer cases (Zienolddiny et al. 2006; 
8092C/A).  A study conducted among coke-oven workers reported null associations between any 
of 4 polymorphisms in ERCC1 (including 19007 T/C, but not 8092C/A) and DNA damage 
measured by the Comet assay (Wang et al. 2010).     
 Epidemiological studies report null associations between variants in XPF and 
chromosomal damage measured by cytokinesis-block micronucleus frequency (Cheng et al. 
2007; Ser835Ser) and PAH-DNA adducts among lung cancer cases (Zienolddiny et al. 2006; 
Pro379Ser, Arg415Gln).  No in vitro studies examining variants in XPF and DNA repair capacity 
in human cells were identified.   
 One experimental study reported a positive association between the XPG Asp1104His 
variant polymorphism and DNA single strand breaks (Vodicka et al. 2004).  Another laboratory 
investigation found that a multivariable model accounting for polymorphisms in XPA, XPC, and 
XPG was weakly predictive of BPDE-DNA adduct removal in lymphoblastoid cells, though XPG 
Asp1104His was not independently associated with BPDE-DNA adduct removal (Shen et al. 
2006).  A third experimental study reported null results for Asp1104His and BPDE-induced 
chromatid breaks (Lin et al. 2007).  An epidemiological study found a negative association 
between the XPG His46His variant polymorphism and PAH-DNA adducts in the lung tissue of 
cancer patients (Zienolddiny et al. 2006).  Other epidemiologic studies report null results with 
respect to chromosomal and DNA damage levels in coke-oven workers (Cheng et al. 2007 for 
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Asp1104His, Wang et al. 2010 for seven variants including Asp1140His), as well as for bladder 
tumor p53 mutation status (Ryk et al. 2006; Asp1104His).  
 The most widely studied NER polymorphisms with respect to DNA repair function are 
the Asp312Asn and Lys751Gln SNPs in XPD (Pabalan et al. 2010).  Null associations between 
these variants and DNA repair capacity were reported in several controlled laboratory studies 
(Laine et al. 2007, Shen et al. 2006, Vodicka et al. 2004).  Other experimental investigations 
report associations between one or both variant XPD polymorphisms and reduced DNA repair 
capacity, especially with respect to damage from UV radiation or bulky chemical carcinogens 
(Affatato et al. 2004, Au et al. 2003, Qiao et al. 2002 a, b, Spitz et al. 2001, Lunn et al. 2000, 
Manuguerra et al. 2006).  An observational molecular epidemiologic study of genetic variation in 
XPD reported null associations with polyphenol-DNA adducts and sister chromatid exchange 
levels (Duell et al. 2000).  Other epidemiologic studies found positive associations with 
chromosomal aberrations, single-strand breaks (Sram et al. 2007, Vodicka et al. 2004), and 
somatic lung tumor p53 mutation status (Gao et al. 2003, Hou et al. 2003, Mechanic et al. 2005).  
A recent investigation reported positive associations between XPD polymorphisms and p53 
mutations in lung tumors only when assessed in combination with a BER polymorphism (in 
XRCC1; Gao et al. 2006).  Other epidemiological studies report null associations with somatic 
p53 mutations in bladder tumors (Gao et al. 2010, Ryk et al. 2006, Stern et al. 2006).   
 Studies report the following results with respect to XPD, PAH-related exposures, and 
DNA repair endpoints.  Experimental investigations have found associations between variant 
XPD Asp312Asn and Lys751Gln genotypes and "lower DNA repair of plasmid treated with 
benzo[a]pyrene diol epoxide" (Benhamou and Sarasin 2005) (Spitz et al. 2001) as well as with 
BPDE-induced DNA adducts in human lymphocytes (Zhao et al. 2008).  Null results in the 
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experimental literature were obtained for associations between Lys751Gln and BPDE-induced 
chromatid breaks (Lin et al. 2007) and between Asp312Asn or Lys751Gln and DNA repair 
capacity measured by removal of induced BPDE-DNA adducts (Shen et al. 2006).  An 
epidemiological study reported that variant polymorphisms for Asp312Asn and Lys751Gln 
reduced XPD mRNA levels in circulating lymphocytes; this association was stronger among 
smokers, especially for those with the greatest smoking duration and intensity (Pabalan et al. 
2010, Wolfe et al. 2007).  Another epidemiologic study found associations between variation in 
XPD and chromosomal aberrations in a population exposed to high levels of environmental air 
pollution, including carcinogenic PAHs (Sram et al. 2007).  Some epidemiologic studies have 
reported that variants in XPD modify chromosomal and DNA damage levels in coke-oven 
workers (Cheng et al. 2007, Leng et al. 2004), though another investigation among coke-oven 
workers found null associations between polymorphisms in XPD and DNA damage endpoints 
(Wang et al. 2010).  Finally, although a few studies report null associations between XPD 
polymorphisms and PAH-related adducts (Pavanello et al. 2005, Zienolddiny et al. 2006), most 
of the epidemiologic literature indicates that polymorphisms in XPD are associated with PAH-
related DNA adducts in occupational and non-occupational settings (Binkova et al. 2007, Hou et 
al. 2002, Hu et al. 2008; Matullo et al. 2001, 2003, Palli et al. 2001, Pastorelli et al. 2002, Tang et 
al. 2002), including in breast tissue (Tang et al. 2002).    
Selected NER Genes and Breast Cancer Risk 
 Individual epidemiologic investigations have reported positive associations between 
breast cancer and polymorphisms in NER genes, including XPD, XPF, ERCC1 and XPG (Crew 
et al. 2007, Han et al. 2009, Kumar et al. 2003, Lee et al. 2005, Milne et al. 2006, Smith et al. 
2003, 2008).  Of these genes, null associations have also been reported for variants in XPD, XPF 
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and XGF (Crew et al. 2007, Jorgensen et al. 2007, Mechanic et al. 2006, Pabalan et al. 2010).  A 
pooled study of 30,000 cases and 30,000 controls of primarily European descent assessed a SNP 
in XPF (rs744154, not the variant genotyped for this dissertation) and found a null association 
with invasive breast cancer (Gaudet et al. 2009).  Only one investigation examined associations 
between XPA and breast cancer, reporting a null result (Crew et al. 2007).  Two studies assessed 
relations between variants in ERCC1 and breast cancer, both finding positive associations at least 
in participant subgroups (Crew et al. 2007, Lee et al. 2005).  Several meta-analyses report that 
SNPs in XPD (Asp312Asn and/or Lys751Gln) are associated with breast cancer risk overall 
(Manuguerra et al. 2006, Qiu et al. 2010) or among certain ethnic groups (Jiang et al. 2010).   
 In summary, the literature regarding the selected NER variants and overall breast cancer 
risk is inconsistent and sparse.  Inconsistencies across investigations may be a reflection of the 
low statistical power common to many genetic epidemiology studies (Pabalan et al. 2010, Zhang 
et al. 2006).  As previously discussed, other methodological issues, study population differences 
and pathway complexity may underlie inconsistent results as well.    
 Few studies have examined associations between NER variants and breast cancer in light 
of PAH-related exposures.  The LIBCSP reported elevated ORs for breast cancer among women 
with at least one variant allele for the XPD Asp312Asn (OR = 1.25, 95% CI: 1.04-1.50) or 
Lys751Gln polymorphisms (OR = 1.21, 95% CI, 1.01-1.44) (combined effect: OR = 1.33, 95% 
CI: 1.08-1.64) (Crew et al. 2007, Terry et al. 2004).  Associations between variant allele 
homozygosity and breast cancer were limited to participants with PAH-DNA adduct levels above 
the median (OR = 1.6, 95% CI: 1.0, 2.6) and current smokers (OR = 2.0, 95% CI: 1.0, 3.8) for 
the Lys751Gln polymorphism (Terry et al. 2004), and to participants with detectable PAH-DNA 
adducts for the Asp312Asn polymorphism (OR = 1.8, 95% CI: 1.2, 2.8) (Crew et al. 2007).  These 
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results are consistent with the aforementioned recent meta-analysis which found associations 
between Lys751Gln and Asp312Asn polymorphisms and breast cancer only among women with 
higher levels of aromatic adducts (Pabalan et al. 2010).  Results are also consistent with another 
study population reporting that among participants with certain XPD polymorphisms, PAH-DNA 
adduct levels were higher in breast tumor tissue than in breast tissue from control participants 
with benign breast disease (Tang et al. 2002).   
 The LIBCSP also reported increased breast cancer odds among women with detectable 
PAH-DNA adducts who were homozygous for the variant allele at the 8092C/A polymorphism in 
ERCC1 (OR = 1.9, 95% CI: 1.1, 3.3), though no main effect of this variant on breast cancer odds 
was detected (Crew et al. 2007).  Null results were found for polymorphisms in XPA, XPF, and 
XPG, both with respect to overall breast cancer occurrence and within subgroups of PAH-related 
exposure or adduct levels (Crew et al. 2007).  A large investigation conducted among Caucasians 
and African Americans, the Carolina Breast Cancer Study, found the strongest associations 
between cigarette smoking and breast cancer among participants with "four or more 'at risk' 
genotypes in NER genes;" polymorphisms were genotyped in XPD, XPG, XPF, RAD23B, XPC, 
and ERCC6 (Mechanic et al. 2006).  These interaction results were observed in African 
Americans only (Mechanic et al. 2006).   
Base Excision Repair (BER) 
Overview of the BER Pathway 
The BER pathway repairs DNA damage that does not alter the shape of the DNA helix, 
including from ionizing radiation, deamination, alkylating and methylating agents, ‘non-bulky’ 
chemical adducts, and oxidative stress (Gammon and Santella 2008, Goode et al. 2002, 
Robertson et al. 2009, Zhang et al. 2006).  It is the main repair pathway correcting oxidative 
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damage to DNA bases, and may play an important role in the repair of PAH-induced DNA 
damage (Braithwaite et al. 1998, Gammon and Santella 2008).  BER tends to proceed more 
quickly than NER (Braithwaite et al. 1998).  This repair pathway is divided into two 
subpathways: short-patch BER and long-patch BER (Robertson et al. 2009).  The short-patch 
pathway replaces a single nucleotide, whereas the long-patch pathway replaces at least two 
nucleotides (Robertson et al. 2009).  It is not fully understood what factors lead to short-patch 
rather than long-patch BER (Robertson et al. 2009).  Possibilities include local ATP 
concentrations as well as lesion properties (Robertson et al. 2009).   
 In the first step of short-patch BER, a DNA glycosylase recognizes and removes the 
damaged base, leaving an apurinic/apyrimidnic (AP) site (Braithewaite et al. 1998, Goode et al. 
2002, Robertson et al. 2009).  DNA glycosylases are relatively specialized (Barnes and Lindahl 
2004).  For example, oxidative stress-induced 8-oxodeoxyguanosine lesions are excised 
exclusively by 8-oxoguanine DNA glycosylase, the enzyme encoded by OGG1 (Botieux and 
Radicella 1999).  After DNA glycosylases initiate DNA repair, an AP endonuclease (APEX1) or 
a bifunctional AP lyase such as OGG1 (which, as mentioned above, is also a DNA glycosylase) 
cleaves the DNA backbone and removes the damaged sugar residue (Boiteux et al. 1987, 
Braithwaite et al. 1998, Goode et al. 2002, O'Connor and Laval 1989, Robertson et al. 2009).  A 
DNA polymerase, usually DNA polymerase β, restores the abasic site by synthesizing a new 
nucleotide using the undamaged DNA strand as a template (Matsumoto and Kim 1995, 
Robertson et al. 2009).  DNA ligation with DNA ligase III completes the short-patch BER 
process (Kubota et al. 1996, Robertson et al. 2009, Wei et al. 1995).   
Although XRCC1 is not an enzyme, it plays a critical coordinating role in short-patch 
BER by functioning as a scaffolding protein for key enzymes including OGG1, DNA polymerase 
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β and DNA ligase III (Brem and Hall 2005, Caldecott 2003, Kubota et al. 1996, Marsin et al. 
2003, Robertson et al. 2009, Shen et al. 1998b, Thompson and West 2000, Vidal et al. 2001).  
Polymorphisms in XRCC1 may modify the resulting protein's affinities for these BER enzymes 
(Shen et al. 2005a).    
 The initial long-patch BER steps are similar to those described above: damage 
recognition and removal by a DNA glycosylase and cleavage of the DNA backbone by an AP 
endonuclease or an AP lyase (Robertson et al. 2009).  In long-patch BER, the latter step recruits 
DNA polymerase β, δ or ε, proliferating cell nuclear antigen (PCNA), flap structure-specific 
endonuclease 1 (FEN1) and DNA ligase I (LIG1) (Frosina et al. 1996, Matsumoto et al. 1994, 
Robertson et al. 2009).  The DNA polymerase synthesizes at least two contiguous nucleotides 
(Robertson et al. 2009).  FEN1 then processes the area to make it compatible with DNA ligation 
by LIG1 (Robertson et al. 2009).  PCNA plays a necessary coordinating role in long-patch BER 
by interacting with both DNA polymerase and FEN1 (Frosina et al. 1996, Klungland and Lindahl 
1997, Robertson et al. 2009).   
Selected BER Genes and DNA Repair Phenotype 
Selected BER polymorphisms of interest are those genotyped in the LIBCSP: XRCC1 
(Arg194Trp and Arg399Gln) and OGG1 (Ser326Cys).  All three of these polymorphisms alter 
the resulting protein's amino acid sequence.   
 The XRCC1 Arg399Gln polymorphism, one of the most common and widely studied 
polymorphisms in XRCC1, was related to PAH-related DNA adduct levels in three 
epidemiological investigations (Matullo et al. 2001, 2003, Zienolddiny et al. 2006).  In one 
epidemiologic study, the association between elevated bulky adduct levels and the variant 
Arg399Gln polymorphism, while elevated, did not rise to statistical significance (Palli et al. 
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2001).  This polymorphism is also associated with aflatoxin B1-DNA adducts and glycophorin A 
somatic mutations (Lunn et al. 1999), polyphenol-DNA adducts, sister chromatid exchanges 
(Duell et al. 2000) and oral tumor p53 mutation status (Hsieh et al. 2003) in epidemiologic 
research.  It was not associated with glycophorin A somatic mutations among newborns (Relton 
et al. 2004), chromosomal aberrations among policemen exposed to relatively high levels of air 
pollution (Sram et al. 2007), or bladder tumor p53 mutations (Gao et al. 2010, Ryk et al. 2006, 
Stern et al. 2006).  Studies of lung tumor p53 mutations obtained conflicting results (Gao et al. 
2003, 2006, Hou et al. 2003).  In addition, the Arg399Gln variant genotype was not associated 
with DNA damage measured by the Comet assay (Leng et al. 2004) or with chromosomal 
damage measured by micronucleus or micronucleated cell frequency (Leng et al. 2005) among 
coke-oven workers. 
 Among in vitro experimental investigations using human lymphocytes, the XRCC1 
Arg399Gln variant polymorphism was inversely related to capacity to repair bleomycin-induced 
DNA damage (Cheng et al. 2009) and was positively associated with sister chromatid exchanges 
following DNA damage induction by a "tobacco-specific nitrosamine" (Abdel-Rahman and El-
Zein 2000).  The variant polymorphism was also positively related to etheno-DNA adducts (Li et 
al. 2006), X-ray induced chromosome aberrations (Au et al. 2003), mutagen (bleomycin and 
BPDE) sensitivity measured by chromosomal breaks per cell (Wang et al. 2003), and mitotic 
delay among women with a family history of breast cancer (Hu et al. 2001).  DNA repair 
capacity and chromosome aberrations following UV-induced DNA damage were not related to 
the Arg399Gln polymorphism in two investigations (Au et al. 2003, Qiao et al. 2002b).  However, 
repair of UV-induced radiation is more relevant to the NER pathway (Braithwaite et al. 1998, 
Goode et al. 2002).   
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 The XRCC1 Trp194Arg polymorphism was not associated with aflatoxin B1-DNA adducts 
or glycophorin A somatic mutations in an epidemiologic investigation (Lunn et al. 1999).  
Likewise, in experimental studies, the Trp194Arg polymorphism was not associated with sister 
chromatid exchanges (Abdel-Rahman and El-Zein 2000), chromosome aberrations (Au et al. 
2003) or mitotic delay (Hu et al. 2001).  Another investigation reported that the variant Trp194Arg 
allele was inversely associated with mutagen sensitivity measured by chromosomal breaks per 
cell (Wang et al. 2003).  Among coke-oven workers, the SNP was not related to olive tail 
moment (Leng et al. 2004) and was marginally associated with total micronucleus (P = 0.053) 
and micronucleated cell (P = 0.050) frequencies (Leng et al. 2005).   
 The most common polymorphism in OGG1, Ser326Cys, is associated with reduced DNA 
glycosylase activity in most (Bravard et al. 2009, Dherin et al. 1999, Hill and Evans 2006, 
Kohno et al. 1998) but not all (Janssen et al. 2001) relevant investigations.  In both in vitro and in 
vivo experimental studies (conducted among animals, yeast and bacteria), absence of the OGG1 
protein consistently leads to increased rates of somatic GC-TA transversions (Klungland et al. 
1999, Michaels and Miller 1992, Thomas et al. 1997, Trapp et al. 2007).  Increased tumor 
formation is observed when both OGG1 and MYH are missing (Trapp et al. 2007, Xie et al. 
2004).  An epidemiologic study reported that the variant Ser326Cys polymorphism was 
associated with increased 8-oxodeoxyguanosine DNA lesions (Tarng et al. 2001).  Another 
epidemiologic study did not detect an association between genetic variation in OGG1 and 
chromosomal aberrations among policemen exposed to high levels of air pollution (Sram et al. 
2007).  A recent in vitro laboratory investigation reported that the 326Cys polymorphism was 
associated with increased micronuclei levels and reduced repair of induced oxidative DNA 
damage (Bravard et al. 2009).  Another in vitro study also found associations between the 
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326Cys polymorphism and DNA repair phenotypes (Aka et al. 2004).   
Selected BER Genes and Breast Cancer Risk 
Reported associations between SNPs in XRCC1 and breast cancer risk are inconsistent 
across epidemiologic investigations (Huang et al. 2009, Li et al. 2009, Zhang et al. 2006).  Three 
recent meta-analyses found associations between the Arg399Gln polymorphism and breast 
cancer among Asian, but not Caucasian, participants (Li et al. 2009, Sadaat and Ansari-Lari 
2009, Zhang et al. 2006).  A 2005 meta-analysis did not find an association between breast 
cancer and the Arg194Trp polymorphism (Hung et al. 2005).  Few studies have examined genetic 
variation in OGG1 in relation to breast cancer risk, and those that have report mainly null results 
(Choi et al. 2003, Mitra et al. 2008, Romanowicz-Makowska et al. 2008, Sangrajrang et al. 2008, 
Zhang et al. 2006).  As mentioned previously, power is often limited in epidemiological 
investigations of genetic variants (Zhang et al. 2006).   
 Few studies have examined associations between BER variants and breast cancer in light 
of PAH-related exposures.  The LIBCSP reported positive associations between the XRCC1-
399Gln allele and breast cancer among women with detectable PAH-DNA adducts (OR: 1.33, 
95% CI: 0.98, 1.84; p for interaction = 0.71) and, unexpectedly, among never smokers (OR = 
1.31, 95% CI: 1.01, 1.69; p for interaction = 0.03) (Shen et al. 2005a).  The association between 
the 399Gln allele and breast cancer was strongest among never smokers with detectable PAH-
DNA adducts (OR = 1.92, 95% CI: 1.21, 3.07) (Shen et al. 2005a).  Null associations were 
observed between XRCC1 Arg399Gln or Arg194Trp polymorphisms and overall breast cancer 
risk, and the study found no evidence of interactions between Arg194Trp and either smoking or 
PAH-DNA adducts (Shen et al. 2005a).  The LIBCSP also reported null results for variants in 
OGG1 and breast cancer, which did not vary by active smoking status (Rossner et al. 2006).    
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ADDRESSING LIMITATIONS OF PREVIOUS INVESTIGATIONS 
The current investigation examines the relationship between residential exposure to 
traffic PAHs and breast cancer, and investigates the impact of genetic variation in DNA repair 
pathways on this potential association.  Previous studies that evaluated relationships between 
PAH sources and breast cancer have mainly used inconsistently defined surrogates for PAH 
exposure such as cigarette smoking or meat consumption (Gammon and Santella 2008).  These 
surrogates contain non-PAH carcinogens, are classified and measured using strategies that vary 
across investigations, and are not consistently linked to breast cancer risk (Gammon and Santella 
2008).  PAH-DNA adducts are better characterized as biomarkers of PAH exposure.  Adduct 
studies are sparse, but consistently show an association with breast cancer (Gammon et al. 
2004a, Gammon and Santella 2008, Rundle et al. 2000a).  However, PAH-DNA adducts 
represent relatively short-term exposures (Gammon et al. 2002c, Rundle et al, 2000a), whereas 
long-term dose may be more relevant to carcinogenesis (Clark et al. 1997).  No known 
biomarkers represent long-term historical PAH exposure.   
 Several studies have examined associations between individualized air pollution or traffic 
emissions exposure estimates and breast cancer, and all found evidence of positive associations 
(Bonner et al. 2005, Crouse et al. 2010, Nie et al. 2007, Raaschou-Nielsen et al. 2011).  One 
study assessed residential exposure to TSP based on data from a small number of environmental 
monitoring sites (at birth, menarche, first birth, and 10 and 20 years prior to the case-control 
interview, as well as cumulative exposure based on data from up to 5 of the aforementioned 
years) as a rough proxy for ambient PAH exposure (Bonner et al. 2005).  The TSP measure was 
heavily influenced by industrial sources, and is therefore likely to be a less relevant and 
generalizable PAH surrogate for the general population than residential traffic.  Another study 
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examined associations between residential exposure to traffic PAH emissions (at menarche, first 
birth, and 10 and 20 years prior to the case-control interview) and breast cancer, using an adapted 
version of a model developed for the LIBCSP (Beyea et al. 2006, Nie et al. 2007).  This 
geographic model was validated and calibrated against copious field data from the Long Island 
study (Beyea et al. 2006), and is thus best suited for analyses in this population.  A third 
investigation examined associations between breast cancer and traffic-related nitrogen dioxide 
emissions in the years 2006, 1996, 1985, and after averaging emissions for 1985 and 1996 
(Crouse et al. 2010).  The fourth study evaluated long-term exposure to nitrogen oxides in 
relation to breast cancer risk (Raaschou-Nielsen et al. 2011).  Nitrogen oxides are gaseous 
pollutants, and therefore do not reflect depletion and long-term transport phenomena relevant to 
carcinogenic particulate traffic air pollution (Beyea et al. 2006, IARC 2010).   
 Longer-term cumulative measures of air pollution exposure may be more relevant to 
breast carcinogenesis (Clark et al. 1997).  This is especially true because residential ambient 
PAH and other pollutant exposure levels can vary greatly for a given woman from year to year 
due to, for example, changes in emissions or moving to a different residence (Beyea et al. 2005).  
 Furthermore, most previous epidemiological studies of traffic or air pollution have 
utilized relatively crude exposure surrogates such as distance to the nearest major road, often 
based on self-reported information, or have used data from sparse environmental monitors to 
assign exposure levels (Boothe and Shendell 2008, Heinrich et al. 2005, Nie et al. 2007, Savitz 
and Feingold 1989).  Other than the historical geographic model developed for the LIBCSP and 
adapted for the Western New York Exposures and Breast Cancer study (Nie et al. 2007), no 
previously reported traffic exposure estimation methods incorporate "excess emissions at 
intersections and during engine warm-up, which may...be important sources of variation in 
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exposure" (Beyea et al. 2006) (Carr et al. 2002, Gauderman et al. 2005).  It should be noted that 
cold-engine emissions were dropped from this investigation's exposure model following 
validation exercises (Beyea et al. 2006).  Many investigations have not validated their pollutant 
exposure estimates.    
 In contrast, the current investigation examined up to 35 years of residential traffic 
benzo[a]pyrene exposure estimates.  Traffic pollution is a ubiquitous and generalizable PAH 
exposure surrogate.  The current investigation's geographic model of residential traffic PAH 
exposure was validated against residential soil PAHs and PAH-DNA adduct levels in circulating 
mononuclear cells among LIBCSP participants, and against local monitored levels of the traffic-
related pollutant carbon monoxide (Beyea et al. 2006).  The geographic model for this 
investigation takes into account historical tailpipe PAH emissions, local transportation patterns, 
meteorological conditions, pollutant dispersion and decay data, cruise and cold-engine 
emissions, and proximity to intersections (Beyea 1999, Beyea et al. 2006), and allows for 
calculation of individualized rather than aggregated exposure estimates (Beyea et al. 2006).  
Research indicates that modeled traffic exposure estimates predict pollutant concentrations more 
effectively than cruder traffic exposure proxies or ambient monitoring data (Brauer et al. 2003, 
Heinrich et al. 2005).  Thus, this traffic model likely reduces the exposure misclassification that 
commonly arises in environmental epidemiology studies (Beyea 1999).  
 Previous studies suggest that associations between PAHs and breast cancer may be 
observed only among certain genetic subgroups (Crew et al. 2007, Shen et al. 2005, Terry et al. 
2004).  However, only one study has examined interactions between a genetic polymorphism (in 
GSTM1, a metabolic gene) and traffic or air pollution with respect to breast cancer risk (Nie et al. 
2005).  The current study is thus the first to assess whether genetic variation in DNA repair 
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pathways impacts the association between traffic or air pollution and breast cancer.  In addition, 
it is the first study to examine effect modification of this potential association by fruit or 
vegetable intake, or to evaluate associations between traffic or air pollution and breast cancer 
considered as subgroups defined tumor p53 mutation status or hormone receptor status.   
SUMMARY AND CONCLUSIONS 
Breast cancer is the most common non-skin cancer malignancy among US women (ACS 
2010).  Many risk factors have been established for this disease (ACS 2010, Hankinson et al. 
2004).  However, other genetic and environmental or lifestyle factors contributing to breast 
cancer risk have yet to be elucidated.  Previous investigations suggest a role for the environment 
in general, and for traffic and PAHs specifically, in breast carcinogenesis (Beyea et al. 2006, 
Bonner et al. 2005, Crouse et al. 2010, Gammon et al. 2004a, Laden and Hunter 1998, Lewis-
Michl et al. 1996, Li et al. 1996, 2002, Nie et al. 2007, Perera et al. 1995, Rundle et al. 2000a).  
For example, PAH-DNA adducts (Gammon et al. 2004a, Li et al. 1996, 2002, Perera et al. 1995, 
Rundle et al. 2000a) and traffic or air pollution exposure variables (Bonner et al. 2005, Crouse et 
al. 2010, Lewis-Michl et al. 1996, Nie et al. 2007) are consistently associated with breast cancer 
in epidemiologic studies.  However, relevant research is sparse.  PAHs are known human 
carcinogens (for example, in the lung) (IARC 2010) and cause mammary tumors in rodents (el-
Bayoumy et al. 1995, IARC 2010).  Vehicular traffic is a major source of ambient PAH, 
especially in or near cities (Bostrom et al. 2002, IARC 1989). 
 PAH metabolites are directly genotoxic, forming PAH-DNA adducts (Harvey et al. 1996).  
PAHs can also indirectly cause DNA damage through induction of oxidative stress (IARC 2010).  
PAH-related DNA damage is corrected through nucleotide excision repair and base excision 
repair DNA repair pathways (Braithwaite et al, 1998, Goode et al. 2002).  If DNA repair 
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mechanisms fail or are insufficient, the resulting uncorrected DNA damage can contribute to 
carcinogenesis through formation of somatic mutations in tumor suppressor genes or proto-
oncogenes (Bigger et al. 1990, 1991, Braithwaite et al. 1998, Chakravarti et al. 2008, Glatt et al. 
1989, Harvey et al. 1996, Straif et al. 2005).  Therefore, genetic polymorphisms in DNA repair 
pathways are standard candidate cancer susceptibility genes (Gammon and Santella 2008) and 
are hypothesized to modify the effects of environmental exposures on cancer risk (Berwick and 
Vineis 2000).  Previous research suggests that variants in NER and BER DNA repair genes may 
modify relations between PAH-related variables and breast cancer (Crew et al. 2007, Mechanic 
et al. 2006, Shen et al. 2005a, Terry et al. 2004).  
 The current analysis evaluates the association between vehicular traffic PAHs and breast 
cancer, and assesses interactions between traffic PAHs and DNA repair polymorphisms with 
respect to breast cancer risk.  Findings of an association between traffic PAHs and breast cancer 
may have important public health implications given the frequency of breast cancer and the 
ubiquity of traffic and PAH exposure across the general population.  Currently, no governmental 
standards exist regarding ambient environmental PAH levels.  Researching the impact of genetic 
variation on the association between breast cancer and traffic PAHs has implications with respect 
to elucidating possible biological mechanisms underlying this association and distinguishing a 
subgroup of women in the general population who may be more susceptible to the carcinogenic 
effects of traffic pollution on the breast. 
 
 
 
 
81 
 
 
 
CHAPTER II: RESEARCH METHODS 
RESEARCH AIMS, HYPOTHESES, AND STUDY RATIONALE 
Breast cancer is the most common malignancy and the second-leading cancer-related 
cause of death among women in the United States (American Cancer Society 2010).  Polycyclic 
aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants (Bostrom et al. 2002, 
IARC 2010).  These chemicals have genotoxic and estrogenic properties (IARC 2010, 
Santodonato 1997), are confirmed human carcinogens (for example, in the lung) (IARC 2010) 
and cause mammary tumors in laboratory animals (el-Bayoumy et al. 1995, IARC 2010).  
However, the association between PAHs and breast cancer in humans is unclear (Gammon and 
Santella 2008).  PAH-DNA adducts, a short-term marker of genetic damage from PAHs, are 
consistently linked with breast cancer in epidemiologic studies (Gammon et al. 2004b, Li et al. 
1996, 2002, Perera et al. 1995, Rundle et al. 2000a).  Traffic is a major source of PAH exposure, 
especially in or near cities (IARC 1989, Lioy and Greenberg 1990).   
Research regarding traffic or air pollution and breast cancer risk has been sparse, but 
consistently shows evidence of a positive association (Bonner et al. 2005, Crouse et al. 2010, 
Lewis-Michel et al. 1996, Nie et al. 2007, Raaschou-Nielsen et al. 2011, Wei et al. 2012).  Most 
research has focused on relatively short-term traffic or air pollution exposure estimates, although 
breast cancer generally develops over many years (Clark et al. 1997).  Since PAHs are genotoxic 
and can also indirectly induce oxidative DNA damage (IARC 2010), polymorphisms in DNA 
repair genes may modify associations between traffic PAHs and breast cancer.    
 This dissertation analysis evaluates the association between estimates of traffic PAH 
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exposure from a historical geographic model and breast cancer, as well as interactions between 
traffic PAHs and DNA repair variants, using the resources of a large population-based case-
control study: the Long Island Breast Cancer Study Project (LIBCSP) (Gammon et al. 2002b).  
Clarifying the association between traffic PAHs and breast cancer has important public health 
implications due to the relatively high incidence of breast cancer and ubiquitous exposure to 
traffic and PAH pollution in the US general population.  No environmental standards for ambient 
PAH levels have been established in the US.   
 This dissertation analysis could also increase understanding of breast cancer etiology 
with respect to DNA repair pathways.  Findings of interactions between traffic PAHs and 
DNA repair polymorphisms would help clarify underlying mechanisms potentially linking 
PAHs and traffic pollution to breast cancer.  Identifying subgroups of women who are 
especially susceptible to carcinogenic effects of traffic PAH exposure based on genetic 
characteristics could aid in strengthening the biological plausibility of this relationship and 
informing public health recommendations for lowering breast cancer risk in vulnerable 
populations.   
Primary Aim 1:  Traffic PAHs and Breast Cancer   
Study Aim 
Examine associations between breast cancer and estimates of residential exposure to 
PAHs from vehicular traffic.   
Hypothesis 
Residential traffic PAH exposure estimates are positively associated with breast cancer.   
Rationale 
PAHs are confirmed carcinogens in humans (e.g. in the lung) (IARC 2010, Straif et al. 
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2005) and are potent mammary carcinogens in laboratory rodents (el-Bayoumy et al. 1995).  
PAHs also exhibit estrogenic, pro-oxidant and genotoxic properties (DeMarini 2004, 
Santodonato 1997, Sorensen et al. 2003).  When PAH exposure levels are high or detoxification 
is insufficient, PAHs bind to DNA forming PAH-DNA adducts, including in breast tissue 
(Gammon and Santella 2008, Santella 1999).  PAHs can also induce oxidative DNA damage 
(Farmer et al. 2003) and may act as tumor promoters via estrogenic growth stimulation of breast 
cells (Santodonato 1997).  Uncorrected PAH-induced DNA damage can lead to somatic 
mutations in cancer-related genes, which could in turn contribute to genetic instability and 
carcinogenesis (Gammon and Santella 2008).  PAH-DNA adducts are consistently associated 
with breast cancer in epidemiologic research (Gammon et al. 2004a, Li et al. 1996, 2002, Perera 
et al. 2005, Rundle et al. 2000a).   
 Traffic is an important source of PAH exposure in the general population, especially in or 
near urban areas (IARC 1989, Lioy and Greenberg 1990).  All studies that examined associations 
between breast cancer and variables related to environmental exposure to ambient PAH or traffic 
pollution found evidence of positive associations (Bonner et al. 2005, Crouse et al. 2010, Lewis-
Michel 1996, Nie et al. 2007, Raaschou-Nielsen et al. 2011, Wei et al. 2012).  Although these 
results are encouraging, each of the four studies had certain weaknesses that the current 
investigation addresses at least in part.  One of the previous investigations calculated residential 
traffic density using a geographic information system divided into 5 km2 grids as their main 
exposure of interest, and therefore did not examine truly individualized exposure estimates 
(Lewis-Michl et al. 1996).  Another study assessed residential exposure to TSP for up to five 
individual years as a rough proxy for ambient PAH exposure, using data from a small number of 
environmental monitoring sites (Bonner et al. 2005).  The TSP measure was heavily influenced 
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by industrial sources, and is therefore likely to be a less relevant and generalizable PAH 
surrogate for the general population than residential traffic.  Another study examined associations 
between one year intervals of residential exposure to traffic PAHs and breast cancer, using an 
adapted version of the model developed for the LIBCSP (Beyea et al. 2006, Nie et al. 2007).  
This geographic model was validated and calibrated against copious field data from the Long 
Island study (Beyea et al. 2006), and is thus best suited for analyses in this population.  Finally, 
two other investigations examined associations between breast cancer and traffic-related nitrogen 
oxides (Crouse et al. 2010, Raaschou-Nielsen et al. 2011).  Nitrogen oxides are gaseous 
pollutants, and do not reflect depletion and long-term transport phenomena relevant to 
carcinogenic particulate traffic air pollution (Beyea et al. 2006, IARC 2010).   In contrast to 
previous studies, this dissertation analysis aims to examine the association between breast cancer 
and traffic PAHs using exposure estimates from an individualized, long-term (up to 35 years), 
comprehensive and validated historical geographic model (Beyea et al. 2006). 
Primary Aim 2: Effect Modification by DNA Repair Polymorphisms 
Study Aim 
Examine whether the association between residential traffic PAH exposure and breast 
cancer is modified by single nucleotide polymorphisms (SNPs) in base excision repair (BER; 
XRCC1, OGG1) and nucleotide excision repair (NER; XPA, XPD, XPF, XPG, ERCC1) 
pathways. 
Hypothesis 
 Associations between breast cancer and residential exposure to traffic PAHs are 
stronger among women with genetic polymorphisms related to reduced DNA repair capacity.   
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Rationale 
 PAH exposure can lead to DNA damage through formation of PAH-DNA adducts 
(Braithwaite et al. 1998) and through induction of oxidative stress (Goode et al. 2002).  Since 
uncorrected DNA damage can lead to somatic mutations in tumor suppressor genes and 
proto-oncogenes, which could in turn contribute to genetic instability and carcinogenesis, 
polymorphisms that affect DNA repair capacity may modify associations between PAHs and 
breast cancer risk (Gammon and Santella 2008).  Several classes of biochemical pathways 
repair DNA damage.  The NER pathway generally repairs DNA damage from bulky chemical 
adducts, while the BER pathway generally repairs oxidative DNA damage (Goode et al. 
2002, Braithwaite et al. 1998, Robertson et al. 2009).  Hence, both DNA repair pathways 
could be relevant to PAH-induced carcinogenesis.  The LIBCSP investigation is the first to 
evaluate whether genetic variation in DNA repair pathways modifies the association between 
traffic or air pollution exposure and breast cancer risk.     
Secondary Aim 1: Effect Modification by Fruit and Vegetable Intake and Menopausal Status 
Study Aim 
Evaluate whether the association between traffic PAHs and breast cancer is modified by 
menopausal status and by fruit and vegetable intake.   
Hypothesis 
The association between traffic PAH exposure and breast cancer varies by menopausal 
status.  The association is stronger among women with low fruit and vegetable intake.   
Rationale 
 The risk factor profile for breast cancer differs by menopausal status (Barlow et al. 
2006).  Studies of traffic or air pollution exposures and breast cancer risk that stratified by 
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menopausal status report differences in associations for postmenopausal and premenopausal 
subgroups (Bonner et al. 2005, Nie et al. 2007).  One study found a positive association 
between TSP exposure and breast cancer among postmenopausal, but not premenopausal, 
women (Bonner et al. 2005).  Another study reported associations between traffic exposure at 
the age of first birth and postmenopausal, but not premenopausal, breast cancer (Nie et al. 
2007).  Similarly, an investigation of breast cancer and grilled and smoked meat intake, an 
important PAH source, reported that associations were limited to postmenopausal women 
(Steck et al. 2007).  However, other analyses report associations between traffic emissions or 
PAH-related occupational exposures and premenopausal breast cancer  (Nie et al. 2007, 
Petralia et al. 1999), and a population-based investigation found a slightly stronger 
relationship between PAH-DNA adducts and premenopasual versus postmenopausal breast 
cancer (Gammon et al. 2004a).  Thus, it is difficult to predict the direction of any potential 
variation in the association between traffic PAHs and breast cancer by menopausal status.  
Possible explanations for differential findings in the literature include etiologic differences 
between premenopausal and postmenopausal breast cancers, shorter induction time among 
premenopausal cases, lower traffic or air pollution exposure levels among younger women 
(for example, due to the introduction of catalytic converters or changing industrial emissions 
standards), and sample size differences between menopausal status subgroups (Bonner et al. 
2005, Nie et al. 2007).   
 Fruit and vegetables have antioxidant and other chemopreventive properties (for 
example, related to cell cycle control) that could ameliorate PAH-induced DNA damage and 
reduce the likelihood of PAH-related carcinogenesis (Amin et al. 2009).  Fruit and vegetable 
intake is linked with decreased breast cancer risk in some, but not all, investigations (Gandini 
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et al. 2000, Gaudet et al. 2004, Howe et al. 1990, Smith-Warner et al. 2000).  A LIBCSP 
study reported relations between grilled and smoked meat intake and breast cancer that were 
stronger among women with low fruit and vegetable intake (Steck et al. 2007).  Fruit and 
vegetable consumption was also associated with lower PAH-related DNA adduct levels in 
several studies, including in the LIBCSP (Palli et al. 2000, Peluso et al. 2000, Shantakumar et 
al. 2005), and fruit and vegetable components decrease carcinogenic effects of PAHs in 
animals (Conaway et al. 2005, Kocdor et al. 2005).  
Secondary Aim 2: Associations with Breast Tumor Subtypes 
Study Aim 
Evaluate associations between traffic PAHs and breast cancer subtypes classified 
according to tumor hormone receptor (ER/PR) status and tumor p53 mutation status.  
Hypothesis 
 Associations between traffic PAHs and breast cancer differ when tumors are 
subdivided according to hormone receptor status (ER/PR) and somatic p53 mutation status 
subtypes.   
Rationale 
 Breast cancer risk factor profiles differ by tumor hormone receptor status (Althuis et 
al. 2004, Colditz et al. 2004, Nasca and Pastides 2008).  For example, ER-positive tumors 
generally show stronger associations with reproductive or hormonal risk factors than ER-
negative tumors (Althuis et al. 2004, Chen and Colditz 2007, Colditz et al. 2004, Garcia-
Closas and Chanock 2008, Nasca and Pastides 2008).  Inconsistent risk factor associations in 
the breast cancer literature may be attributable to differences in hormone receptor subtype 
distribution between study populations (Chen and Colditz 2007).  PAHs have estrogenic and 
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antiestrogenic properties (Santodonato 1997).   
 Two occupational studies assessed relations between PAH exposure and breast cancer 
categorized by tumor hormone receptor status.  Upon stratifying by hormone receptor status, 
both studies found that associations with breast cancer were limited to estrogen receptor-
positive tumors (Labreche et al. 2010, Petralia et al. 1999).  In the general population, 
however, research regarding PAH-related exposures and breast tumor hormone receptor 
status has been inconsistent (Althuis et al. 2004, Gammon et al. 2002c, 2004a,b, Manjer et al. 
2001, Morabia et al. 1998, Steck et al. 2007, Terry and Rohan 2002).  A 2004 review 
concluded that, based on the published literature, associations between cigarette smoking and 
breast cancer do not differ with respect to tumor hormone receptor status (Althuis et al. 
2004), though individual investigations report evidence of differential associations (e.g. 
Britton et al. 2002, Gammon et al. 2004b).  The only study to evaluate associations between 
traffic exposure and breast cancer categorized according to tumor hormone receptor status 
did not find evidence of differing associations by tumor subtype (Nie et al. 2007).   
 Some carcinogens induce characteristic patterns of specific tumor mutations, 
including in the p53 gene (Conway et al. 2002, Greenblatt et al. 1994).  Such 'fingerprints' 
may help clarify the etiology and biological plausibility of associations between 
environmental exposures and breast cancer (Conway et al. 2002, Greenblatt et al. 1994).  
PAHs induce somatic p53 mutations and increased p53 expression in laboratory studies 
(Greenblatt et al. 1994, Hollstein et al. 1991, Ramet et al. 1995, Ruggeri et al. 1993).  PAH-
related exposures have been associated with a range of somatic mutations in the p53 gene, 
including base substitution mutations (both transversions and transitions) as well as 
insertions and deletions (Adonis and Gil 2000, Greenblatt et al. 1994, Leavitt et al. 2008, 
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Lehman and Harris 1994, Mahadevan et al. 2003).  It should be noted that p53-mutation 
positive breast tumors are more likely to be hormone-receptor negative (Olivier et al. 2006).   
 Cigarette smoking was positively associated with breast tumor p53 mutation status in 
two studies (Conway et al. 2002, Van Emburgh et al. 2008).  However, findings from a larger 
study suggest that PAH-related variables (active or passive smoking, grilled/smoked meat 
intake, PAH-DNA adducts) are not associated with p53 mutation-positive breast cancer.  In 
fact, "participants with breast tumor p53 mutations were less likely to be exposed to PAH-
related sources than were participants with p53 mutation-negative cancer" (Mordukhovich et 
al. 2009).  Two large general population studies report possible associations between PAH-
related exposures and a differing set of specific breast tumor p53 mutation types (Conway et 
al. 2002, Mordukhovich et al. 2009). 
 PAHs are an important component of traffic pollution and exhibit estrogenic, 
antiestrogenic, pro-oxidant and genotoxic properties (Farmer et al. 2003, Jeng et al. 2010, 
Santodonato 1997).  Thus, it is plausible that associations between traffic PAHs and breast 
cancer vary with respect to tumor hormone receptor status or p53 mutation status.  It is 
difficult to predict the direction of this potential variation due to opposing estrogenic and 
antiestrogenic effects (Santodonato 1997) as well as the role of genotoxic and pro-oxidant 
effects (IARC 2010) of PAHs.  However, it is likely that the genotoxic and pro-oxidant 
properties of PAHs are dominant over estrogenic or antiestrogenic properties at the 
environmental exposure levels in the current investigation (Bostrom et al. 2002).   
LONG ISLAND BREAST CANCER STUDY PROJECT (LIBCSP) 
The parent study for this dissertation analysis is the Long Island Breast Cancer Study 
Project (Gammon et al. 2002b).  This is a large population-based case-control study initiated 
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following a federal mandate to investigate environmental risk factors for the high breast cancer 
rates in Nassau and Suffolk counties on Long Island, New York.  Primary aims of this research 
effort were to evaluate associations between breast cancer and exposure to organochlorines and 
PAHs (Gammon et al. 2002b).  The parent study received IRB approval from all relevant 
institutions, and all women gave written informed consent prior to study participation (Gammon 
et al. 2002b).  Study participants were primarily White (specifically, 93% White, 5% African 
American, 2% other; 4% self-identified as Hispanic), consistent with the race distribution in 
Nassau and Suffolk counties (Gammon et al. 2002b) 
 LIBCSP study participants were adult, English-speaking women ages 20 to 98 residing in 
Nassau or Suffolk counties on Long Island, New York (Gammon et al. 2002b).  Eligible cases 
were women with no prior personal history of breast cancer who were diagnosed with primary 
invasive or in situ breast cancer between August 1, 1996 and July 31, 1997.  Cases were recruited 
using rapid case ascertainment through frequent contact (at least twice per week) with the 
pathology departments of 31 hospitals in Long Island and New York City.  The subjects' 
physicians were contacted to confirm breast cancer diagnoses and obtain permission to contact 
the cases.  Eligible controls were women with no personal history of breast cancer residing in 
Nassau or Suffolk counties.  They were randomly selected for recruitment to the LIBCSP via 
random digit dialing (using Waksberg's method; Waksberg 1978) for women under age 65 (the 
screening response rate was 78%; Gammon et al. 2002b) and via Health Care Finance 
Administration records for women 65 years or older.  Controls were frequency matched to cases 
based on the expected age distribution among cases.  Eligible cases and controls were mailed 
information about the LIBCSP.  Recruiters then contacted the eligible participants to schedule the 
interview mainly via telephone, though some control participants were contacted in person 
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(Gammon et al. 2002b).  In total, 1,508 cases (82.1% of eligible case participants) and 1,556 
controls (62.7% of eligible control participants) completed the case-control interview.  
Participation was negatively associated with age for both cases and control participants 
(Gammon et al. 2002b). 
 The main study interview was conducted by trained interviewers at the subjects' 
residences for both cases and controls.  On average, these interviews occurred 96 days after 
diagnosis for breast cancer cases and 167 days after identification for controls (Gammon et al. 
2002b).  The case-control questionnaire collected detailed information on a wide range of 
variables (such as known or suspected breast cancer risk factors, as well as potential confounders 
or effect modifiers), including lifetime residential history in Nassau and Suffolk counties, 
demographic characteristics, medical history, family history of cancer, reproductive history, 
lifetime physical activity, cigarette smoking (both active and passive), lifetime alcohol 
consumption, menopausal status, body size across the life-course, and lifetime intake of grilled 
and smoked meat (Gammon et al. 2002b).  Variables relevant to this dissertation analysis are 
discussed in more detail in Chapter II.  Following the case-control interview, 98.2% of cases and 
97.6% of controls completed a self-administered, validated Block food frequency questionnaire 
(FFQ) (Block et al. 1986, 1990, Potischman et al. 1997), which assessed usual dietary and 
supplement intake during the year preceding the reference date (date of diagnosis for cases, date 
of identification for controls) (Gammon et al. 2002b, Shen et al. 2005b).   
 At the same study visit, LIBCSP interviewers, who were either nurses or certified 
phlebotomists, collected blood samples for 73% of both case and control participants (Gammon 
et al. 2002b).  These samples were stored and processed as described in Chapter II.   Blood 
samples were collected in order to genotype common variants in candidate breast cancer 
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susceptibility genes (for example, in DNA repair and xenobiotic metabolism pathways), to 
evaluate PAH-DNA adducts in circulating mononuclear cells (Gammon et al. 2002c), and to 
assess other biomarkers of interest (Gammon et al. 2002b). 
 The interviewers also conducted residential sampling of outdoor soil and indoor carpet 
dust among a subset of participants who had lived at their current residence for at least 15 years 
(Gammon et al. 2002b).  Soil samples were collected and analyzed for benzo[a]pyrene and other 
PAH species using high-resolution gas chromatography/mass spectroscopy for 360 cases and 356 
control participants (Beyea et al. 2006, Gammon et al. 2002b).  Carpet dust samples were 
collected and analyzed for PAH content using gas chromatography/mass spectroscopy selected 
ion monitoring for 320 cases and 356 controls (Beyea et al. 2006, Gammon et al. 2002b).  This 
component of the parent study was executed primarily in order to validate the LIBCSP 
geographic model of traffic PAH exposure (Beyea et al. 2006, Gammon et al. 2002b).  
Participants who lived at their current residence for 15 or more years differed from other 
participants with respect to age, race, education, income, parity, menopausal status, age at 
menopause, lactation history, smoking status, body mass index, alcohol intake, oral contraceptive 
use, and hormone replacement therapy use (Gammon et al. 2002b).   
 Most LIBCSP cases (n = 1473, or 97.7% of case participants) signed medical release 
forms that allowed researchers abstract their medical records in order to confirm study eligibility 
and ascertain clinical characteristics of their disease, including tumor hormone receptor status 
(Gammon et al. 2002b).  Medical records were successfully abstracted for 1,402 cases (95.2% of 
case participants).  Case participants primarily presented with hormone responsive breast tumors 
(ER+/PR+: n = 583 [59%]; ER+/PR-: n = 143 [14%]; ER-/PR+: n = 52 [5%]; ER-/PR-: n = 212 
[21%]).  Archived paraffin-embedded tumor tissue, which was used to analyze tumor markers, 
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was obtained from participating hospitals for 962 cases who signed medical release forms.  For 
p53 analyses, sufficient tumor DNA was available for 859 cases (Rossner et al. 2008).  
Laboratory procedures for ascertaining somatic p53 mutations are described in more detail in 
Chapter II. 
 Data coding and data entry were completed by Westat, Inc. in Bethesda, MD (Gammon et 
al. 2002b).  Quality control measures employed by the LIBCSP include questionnaire data 
verification as well as data range and logic checks, also completed by Westat, Inc. (Bethesda, 
MD) (Gammon et al. 2002b).  In addition, a random sample of 20% of participants were 
telephoned following their study visit in order to (1) confirm that they had been interviewed for 
the LIBCSP, (2) confirm the length of their study visit, and (3) briefly re-interview the 
participant via telephone (Gammon et al. 2002b).  Identical data collection and storage strategies 
were implemented for cases and control participants in order to minimize issues of differential 
misclassification.  Quality control measures for the laboratory and geographic modeling 
components of the LIBCSP are described below.   
 The current analysis uses existing data from the LIBCSP parent investigation, and 
likewise employs a case-control design.  Eligible subjects for the proposed investigation are 
parent study participants with complete information on all variables necessary for any given 
study aim.  Appendix Table A2.1, adapted from Gammon et al. 2002b, shows the distribution 
of study participant characteristics by case-control status in the LIBCSP.     
RESULTS FROM THE LIBCSP: PAH-RELATED EXPOSURES AND BREAST CANCER  
The LIBCSP has previously evaluated associations between several PAH-related 
exposures and breast cancer risk.  Briefly, the LIBCSP reports positive associations between 
breast cancer and long-term passive smoking (but not active smoking), grilled or smoked meat 
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intake, and PAH-DNA adducts (Gammon et al. 2004a, 2004b, Steck et al. 2007).  Relevant study 
results are described in more detail below.  Findings from the LIBCSP suggest that PAH-related 
exposures (smoking, grilled and smoked meat intake, and adducts) may not be associated with 
overall breast tumor p53 mutation status, though possible associations with specific mutation 
subgroups were detected (Mordukhovich et al. 2009).   
Active and Passive Cigarette Smoking 
The LIBCSP reported a positive association between breast cancer and long-term passive 
smoking (OR = 2.10, 95% CI: 1.47, 3.02 among nonsmokers who lived with a smoking spouse 
for over 27 years; Gammon et al. 2004b), as well as between a combined measure of active and 
passive cigarette smoking and ER/PR positive breast cancer (OR = 1.42, 95% CI: 1.00, 2.00; 
Gammon et al. 2004b).  In addition, the LIBCSP reported evidence of interactions between 
smoking and SNPs in XPD and XRCC1, but not OGG1, with respect to breast cancer risk 
(Rossner et al. 2006, Shen et al. 2005a, Terry et al. 2004).  The LIBCSP found null associations 
between breast cancer and a variety of other current or former active smoking categorizations, 
including smoking only prior to first pregnancy, as well as most passive smoking measures 
(Gammon et al. 2004b).  
Grilled and Smoked Meat Intake 
The LIBCSP reported positive associations between lifetime total grilled or smoked meat 
intake and postmenopausal, but not premenopausal, breast cancer (OR = 1.47, 95% CI: 1.12, 
1.92 for the highest vs. the lowest tertile of intake; Steck et al. 2007).  This relation was stronger 
among women with low fruit and vegetable consumption (OR = 1.74, 95% CI: 1.20, 2.50 for the 
highest vs. the lowest tertile of intake of grilled or smoked meat, p-interaction > 0.05), but did 
not appear to vary with respect to ER/PR status (Steck et al. 2007).  Elevated effect estimates 
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were reported for the intake of red, but not white, grilled or smoked meat (Steck et al. 2007).  
This study failed to find associations between breast cancer and dietary intake of benzo[a]pyrene 
in the past year, "with the possible exception of benzo[a]pyrene from meat among 
postmenopausal women whose tumors were positive for both estrogen receptors and 
progesterone receptors (OR = 1.47; CI = 0.99-2.19)" (Steck et al. 2007). 
PAH-DNA Adducts 
The LIBCSP reported positive associations between breast cancer and PAH-DNA adducts 
in circulating mononuclear cells (OR = 1.41, 95% CI: 1.07, 1.86 for the highest vs. the lowest 
quantile, and OR = 1.29, 95% CI: 1.05, 1.58 for detectable vs. nondetectable adduct levels; 
Gammon et al. 2004a).  This association did not consistently vary by levels of other PAH 
exposure sources or with respect to hormone receptor status, and was slightly stronger among 
premenopasual women (OR = 1.56, 95% CI: 1.09, 2.23 for detectable adducts, p for interaction > 
0.05) (Gammon et al. 2004a).  No dose-response relationship with breast cancer was observed 
when evaluating quantiles of PAH-DNA adduct levels (Gammon et al. 2004a).  The LIBCSP 
reports evidence of interactions between PAH-DNA adducts and SNPs in XPD, XRCC1 and 
ERCC1, but not XPA, XPF or XPG, with respect to breast cancer risk (Crew et al. 2007, Shen et 
al. 2005a, Terry et al. 2004).   
The LIBCSP found positive associations between detectable PAH-DNA adducts and 
current and past smoking as well residential soil PAHs.  Null associations were reported for 
dietary PAHs and modeled ambient benzo[a]pyrene levels, and detectable adducts showed a 
negative association with PAH levels in residential dust (Shantakumar et al. 2005).  Among 
women with detectable PAH-DNA adducts, PAH-DNA adduct levels were positively associated 
with traffic benzo[a]pyrene exposure levels derived from the LIBCSP geographic model, 
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described below (Beyea et al. 2006).   
Traffic PAHs 
Preliminary analyses in the LIBCSP show a subgroup of 1% of cases with much greater 
estimated traffic PAH exposure than all control women for absolute cumulative exposure, 
relative exposure, and maximum annual exposure (years 1960-1990; Dr. Jan Beyea, personal 
communication 2009).   
PAH EXPOSURE ASSESSMENT: A HISTORICAL GEOGRAPHIC MODEL  
Brief Overview 
A historical model of residential PAH exposure from vehicular traffic (years 1960–1995) 
was developed for the LIBCSP by Dr. Jan Beyea, a consultant at CiPI (Consulting in the Public 
Interest) (Beyea et al. 2006).  As described in detail below, this geographic model incorporates 
historical US vehicular PAH emissions data, information on traffic and transportation patterns in 
the New York metropolitan area, Long Island meteorological variables, and pollutant dispersion 
factors (Beyea et al. 2006).  The model was validated and calibrated against extensive field data 
from the LIBCSP (Beyea et al. 2006).  The LIBCSP includes 2,608 participants with traffic PAH 
exposure estimates for the year 1995 and 1,719 participants with exposure estimates spanning the 
years 1980 to 1995.  
Data Collection and Geocoding  
During the case-control interview, trained interviewers collected information regarding 
participant lifetime residential history in Nassau and Suffolk counties on Long Island, NY.  
Specifically, interviewers recorded all addresses at which a participant resided for at least one 
year in these counties, including prior to 1960 (Beyea et al. 2005).  Addresses were then 
geocoded using BLR software (BLR Data, Inc. Lebanon, NH), and poorly coded addresses were 
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cleaned manually.  A total of 8,321 residential addresses were recorded at the case-control 
interview (median = 2, maximum = 17), of which 5,501 addresses geocoded successfully to the 
level of an individual residence.  Some recorded addresses were incomplete; 300 recorded 
addresses did not include a street name and 1,715 included a street name but no address number 
(Beyea et al. 2005).  Of the 6,306 complete addresses, 87% geocoded successfully.  Failure to 
geocode complete addresses is likely due to inaccurate residential address reporting as well as 
changes in the built environment over time (Dr. Jan Beyea, personal communication 2009).  The 
geocoding success rate was 65% for 1960 addresses and 85% for current addresses, and ranged 
from 60% to 85% in the period between the year 1960 and the study interview (Dr. Jan Beyea, 
personal communication 2009).  Most LIBCSP participants provided at least one address that 
geocoded to street level (for addresses between the years 1960 and 1990, n= 2,601; for 1995 
addresses, n = 2,655).   
 Historical tailpipe emission parameters were based on measurements conducted in road 
tunnels throughout the US (Boston, Baltimore, Los Angeles, Berkeley, and New York City/New 
Jersey) and checked using individual vehicles run on dynamometer test beds (Beyea et al. 2008).  
Data used to generate cold-engine (i.e. during engine warm-up) emissions estimates included the 
"number of households at the census block level and extracts from the travel-diary database of 
the National Personal Transportation Survey," which yielded information on "the number of cold 
starts per household per hour per day" (Beyea et al. 2005) (US Department of Transportation 
[USDOT] 1996).  Data on warm-engine (i.e. cruise condition) transportation patterns were 
derived from more than 13,000 measurements of annual average daily traffic recorded on lists 
and maps from state and county traffic department records (Beyea et al. 2005).   
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Model Development  
This study evaluated a road network consisting of approximately 500,000 straight-line 
street segments within the New York metropolitan area, which encompasses 22 counties in New 
York, New Jersey, and Connecticut (Beyea et al. 2005).  In the default, uncalibrated model, 
estimated benzo[a]pyrene emissions for each road segment (in µg/km per day) were calculated as 
a product of historical traffic count on the roadway (vehicles per day) and historical average US 
tailpipe emissions per vehicle under cruise conditions (µg/km).  Cruise emissions were 
calculated for 1960, 1970, 1980, and 1990.  Estimates for other years were derived via 
interpolation or extrapolation (Beyea et al. 2005).  Emission estimates were further adjusted for 
non-cruise conditions (i.e. cold-engine operation and acceleration and deceleration at 
intersections) using parameters from the literature (Beyea et al. 2006) (e.g. Ahlvik et al. 1997).  
Emissions were adjusted for intersection traffic using a simplified version of a model originally 
developed for CO (Beyea et al. 2005, Nelli et al. 1983).  Cold-engine operation emissions were 
estimated with a modeling approach developed by Dr. Beyea (Beyea et al. 2005).   
 Vehicular PAH emission estimates were converted into predicted residential ambient 
concentrations of benzo[a]pyrene for each participant (in ng/m3) using standard meteorological 
dispersion and deposition models (Beyea et al. 2006).  Up to a distance of 100 meters from a 
given road, contributions of estimated emissions from each road segment to surrounding traffic-
related benzo[a]pyrene concentrations were calculated using highway line-source models (Chock 
1978).  The Chock model was used because of its good fit "to tracer concentrations near the 
Long Island Expressway" (Beyea et al. 2005).  Benzo[a]pyrene concentrations farther than 100 
meters from a road were calculated using a standard Gaussian plume model with Briggs 
dispersion parameters (Beyea et al. 2006, Catalano et al. 1987, Viegele and Head 1978), which 
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incorporated data on variables affecting PAH dispersion such as wind speed and direction, rain 
washout, photo decay, and particle deposition (Beyea et al. 2006, Fan et al. 1995, Huang et al. 
1995, National Council on Radiation Protection and Measurement [NCRP] 1993, Ramsdell et al. 
1994).  For consistency, the same street maps used for geocoding were used to model dispersion 
of traffic pollution. 
 Meteorological data for the dispersion model were collected in Brookhaven National 
Laboratory in Suffolk County for the year 1993 (Beyea et al. 2005).  For some variables, raw 
meteorological readings were modified for model inclusion using information from the literature 
(Beyea et al. 2006, Fan et al. 1995, Huang et al. 1995, National Council on Radiation Protection 
and Measurement [NCRP] 1993, Ramsdell et al. 1994).  For example, rainfall measurements 
were converted into washout rates using a standard function (Ramsdell et al. 1994).  Sensitivity 
analyses indicate that changing the year (1990 vs. 1993) or location (MacArthur Airport vs. 
Brookhaven National Laboratory) of meteorological data collection does not appreciably alter 
residential traffic PAH exposure estimates (Beyea et al. 2005).      
 The LIBCSP model calculated traffic benzo[a]pyrene emissions on major roads within 80 
kilometers of Nassau and Suffolk counties (Beyea et al. 2006).  In addition, a background term 
was included to account for more distant roads and other ambient PAH sources (Beyea et al. 
2006).  Indoor traffic PAH estimates were derived by multiplying outdoor residential exposure 
estimates "by an average building penetration factor of 0.75" (Beyea et al. 2005), based on 
values from the literature (Long et al. 2001).  The literature informing model parameter values 
was sparse for some variables such as distance of increased intersection emissions, the ratio of 
intersection emissions to cruise emissions, and photo decay rate (Beyea et al. 2006).  However, 
all model parameters were calibrated against field data following validation exercises (see 
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below) (Beyea et al. 2006).    
PAH exposures were calculated beginning in 1960, the earliest year for which reliable 
vehicular PAH emissions and traffic data exist across the US and in the New York metropolitan 
area, respectively (Beyea et al. 2005).  The year 1995, shortly prior to the LIBCSP reference date 
(1996-1997; date of diagnosis for cases, date of recruitment for controls), was chosen as the end 
period.  PAH exposure measures of interest, including for sensitivity analyses, are discussed in 
greater detail below (Chapter II).   
Model Validation and Calibration 
The model was validated by "checking predictions of quantities closely related to PAH air 
concentration" (Beyea et al. 2005) against relevant field data from the LIBCSP (Beyea et al. 
2006).  Specifically, the LIBCSP evaluated (1) residential benzo[a]pyrene soil levels among 
women living at their current address for at least 15 years, (2) PAH-DNA adduct levels in 
circulating mononuclear cells among women with detectable adducts, (3) US EPA monitoring 
data for carbon monoxide, a traffic-related pollutant, and (4) residential carpet PAHs among a 
subset of women living in their current home for at least 15 years (Beyea et al. 2006).  Measured 
ambient PAH concentrations were not available for validation purposes in the study area.     
 The model accurately predicted both soil PAHs and PAH-DNA adduct levels (Beyea et al. 
2006).  This was accomplished by modifying the geographic model slightly in order to predict 
LIBCSP participants' residential soil PAH concentrations and PAH-DNA adduct levels in 
mononuclear cells, and running regressions of these predictions against field measurements from 
the LIBCSP (Beyea et al. 2006).  Both validation exercises indicated that intersection emissions 
were important contributors to traffic PAH levels (80% and 40% of the total estimated exposure, 
respectively) (Beyea et al. 2006).  The model also accurately predicted carbon monoxide 
101 
 
concentrations at a local EPA monitor (Beyea et al. 2006).   
 The model was not successfully validated against the carpet dust data (Beyea et al. 2006).  
This finding is consistent with research indicating that measured residential ambient PAH 
concentrations do not correlate with house dust PAH levels (Fromme et al. 2004).  Carpet dust 
PAH level is also the only PAH-related measurement from the LIBCSP that does not decline with 
decreased urbanization, although overall carpet dust levels do correspond to the urbanization 
gradient in the study area (Beyea et al. 2006).  Instead, benzo[a]pyrene levels in carpet dust peak 
at an intermediate point along this gradient (Beyea et al. 2006).  In addition, carpet 
benzo[a]pyrene showed a negative association with detectable PAH-DNA adducts in a previous 
LIBCSP report (Shantakumar et al. 2005).  These inconsistent carpet dust data may suggest, for 
example, “possible spatial confounding with PAH-containing contamination tracked in from 
outdoors or unmodeled cooking sources” (Beyea et al. 2006). 
 Default model parameters were chosen based on sometimes sparse or variable 
information from the literature (Beyea et al. 2006).  Therefore, following validation, the model 
was calibrated against relevant field data through chi-squared minimization (Press et al. 1992), 
which "was carried out while simultaneously...optimizing a range of other model parameters 
such as washout rate, particle deposition rates, photo decay rates, and intersection distance" 
(Beyea et al. 2006).  Calibrating the model based on soil concentrations emphasized the 
contribution of warm-engine emissions, whereas the adduct-calibrated model emphasized cold-
engine emissions (Beyea et al. 2006).   
 The soil-calibrated PAH prediction model provided the best fit to field data (r2 = 0.86 for 
the soil-calibrated model, r2 = 0.58 for the adduct-calibrated model) (Beyea et al. 2006).  Soil-
calibrated estimates were therefore be used for regressions against breast cancer risk.  These 
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estimates ignore the contribution of cold-engine emissions.  The soil-calibrated model also 
incorporates a spatially varying background term (as opposed to a constant background term) 
which is proportional to estimated traffic PAH emissions from counties along metropolitan New 
York roadways, excluding Nassau, Suffolk, and Queens Counties (Beyea et al. 2006).  Other 
relevant parameters in the soil-calibrated model include a deposition velocity of 0.007 m/s, 
elevated intersection emissions for a stretch of 12.5 meters, and washout and photo decay rates 
that were one-half and one-quarter, respectively, of the rates in the default model (Beyea et al. 
2006).  Intersection emissions account for 80% of average estimated PAH exposure levels in the 
soil-calibrated model (Beyea et al. 2006).  
Treatment of Missing Data 
The current investigation evaluates the following residential traffic PAH exposure 
classifications as the a priori main exposure variables of interest: (1) 1995 exposure and (2) 
1980-1995 exposure with up to 20% of residential PAH exposure imputed for a given participant.  
Sensitivity analyses evaluated additional PAH exposure variables for the years spanning 1980 to 
1995 (complete case analysis and up to 30% multiple imputation), 1960 to 1995 (complete case 
analysis, and up to 20% and 30% multiple imputation), and 1960 to 1990 (complete case 
analysis, and up to 20% and 30% multiple imputation).   
 To address missing data, the PAH exposure metric was divided into three components 
(Dr. Jan Beyea, personal communication 2011, 2012): (1) pre-1960 exposure, (2) exposure after 
1960 but before arrival into the study area, and (3) exposure after arrival into the study area, 
though sometimes exposure could not be calculated during this period because a residential 
address did not geocode to street level. 
 Residential traffic PAH exposure from birth to the year 1960 was accumulated in the 
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period prior to reliable information on traffic patterns or PAH tailpipe emissions.  Thus, for pre-
1960 exposure, age at diagnosis or identification was used as a surrogate for time since the start 
of the unmeasured traffic PAH exposure (Dr. Jan Beyea, personal communication 2009, 2012, 
Greenland 1995).   
 Another component of participants' PAH exposure spans the period between the year 
1960 or birth, whichever occurred later, and the year in which a participant moved into the study 
area.  Reliable information regarding US tailpipe PAH emissions exist for this period.  However, 
subjects' PAH exposures could not be calculated during this time because of unknown residence 
location.  For this second exposure period, the pollutant dispersion function was treated as a 
constant, and data on historical US tailpipe PAH emissions (specifically, the integral of the 
historical emission curve) were used to develop an exposure surrogate.  This exposure surrogate 
was calculated separately for cases and controls and was standardized  to the average calculated 
traffic benzo[a]pyrene concentration on Long Island during the relevant time period (Dr. Jan 
Beyea, personal communication 2012).  Variance was added during multiple imputation and 
matched to the variance in traffic PAH exposure for study participants living on Long Island 
during the same time period, based on five-year intervals; variance was not calculated separately 
by case-control status (Beyea, personal communication 2012).   
 Following a participant's arrival into the study area, the LIBCSP historical geographic 
model generates individualized PAH exposure estimates at each residence that successfully 
geocoded to street level.  A participant's cumulative post-arrival exposure was calculated by 
summing exposure estimates from all residences through the year 1995.  However, because some 
residences failed to geocode to street level, as described above, a portion of a given participant's 
post-arrival residential traffic PAH exposure may be missing.  This missing data issue can be 
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counteracted in part by using multiple imputation (Dr. Jan Beyea, personal communication 2012, 
Rubin 1996).  Specifically, the transfer function, defined as a function that converts emissions on 
roadways to exposures at individual residences (Dr. Jan Beyea, personal communication 2012), 
was imputed for each missing post-arrival address using interpolation or extrapolation from a 
woman's known residential addresses.  When prior and subsequent addresses were available, 
draws were made from the assigned log-normal variance.  When only one address was available, 
extrapolation was used and a zero variance was assigned (Dr. Jan Beyea, personal 
communication 2012).  Imputation of the transfer function by census place was conducted as 
well, for the purposes of a sensitivity analysis.   
 For regression analyses, participants' percentage of imputed exposure, including both 
prior to and following arrival into the study area, was restricted to 0%, 20% or 30%, depending 
on the specific analysis.  Participants with greater than a pre-specified percentage of their PAH 
exposure information missing for the time period of interest were dropped from relevant 
analyses.  When using partially imputed variables in regressions, odds ratios and confidence 
limits were combined over 30 imputations using Rubin's rules (Rubin et al. 1996).  
GENOTYPING ASSAYS 
Selected SNPs 
The polymorphisms evaluated in this investigation are located in genes from BER (X-ray 
repair cross complementing group 1 [XRCC1] and 8-oxoguanine DNA glycosylase [OGG1]) and 
NER (xeroderma pigmentosum groups A, D, F, and G [XPA, XPD, XPF, XPG] and excision 
repair cross-complementing group 1 [ERCC1]) pathways.  The SNPs of interest for this 
dissertation analysis were previously genotyped in the LIBCSP study population: XPA -4A/G 
(rs1800975), ERCC1 8092C/A (rs3212986), ERCC2/XPD Lys751Gln (rs3212986) and 
105 
 
Asp312Asn (rs1799793), ERCC4/XPF Arg415Gln (rs1800067), ERCC5/XPG Asp1104His 
(rs17655), XRCC1 Arg194Trp (rs1799782), Arg399Gln (rs25487), and OGG1 Ser326Cys 
(rs1052133).   
 Genotyping data availability varied by polymorphism, ranging from 2,050 to 2,177 
participants with complete information for a given genetic variant (i.e. 91-97% of women who 
donated a blood sample; Crew et al. 2007, Rossner et al. 2006, Shen et al. 2005, Terry et al. 
2004).  Missing genotype data was mainly due to insufficient DNA available for assays (Crew et 
al. 2007, Terry et al. 2004).  All relevant SNPs were previously reported to be in Hardy-Weinberg 
equilibrium (HWE) among control LIBCSP participants (Crew et al. 2007, Rossner et al. 2006, 
Shen et al. 2005, Terry et al. 2004).   
 Some of the selected NER polymorphisms alter the resulting protein's amino acid 
sequence (XPD Lys751Gln and Asp312Asn, XPF Arg415Gln, and XPG His1104Asp).  Others 
are located outside of coding regions (XPA -4A/G and ERCC1 8092C/A).  The LIBCSP has 
reported modest positive associations between breast cancer and variant alleles in XPD 
Asp312Asn and Lys751Gln (OR range: 1.21 – 1.25) (Crew et al. 2007, Terry et al. 2004).  No 
associations between polymorphisms in XPA, XPF, ERCC1 or XPG and overall breast cancer risk 
were reported for the LIBCSP (Crew et al. 2007).   
All three selected BER polymorphisms (XRCC1 Arg194Trp, Arg399Gln, OGG1 
Ser326Cys) alter the resulting proteins' amino acid sequences.  No associations were found 
between variants in XRCC1 or OGG1 and overall breast cancer risk in the LIBCSP (Rossner et 
al. 2006, Shen et al. 2005).   
Blood Sample Collection and Storage 
Study interviewers, who were either nurses or certified phlebotomists, obtained a 40 mL 
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non-fasting blood sample at the study visit from 73.1% of  cases (n = 1,102) and 73.3% of 
control participants (n = 1,141) (Gammon et al. 2002b).  Blood donation among LIBCSP 
participants was positively associated with white race, alcohol intake, hormone replacement 
therapy use, lactation history, and mammography (Gammon et al. 2002b).  Donation was 
negatively associated with former smoking and age and was unrelated to case-control status 
(Gammon et al. 2002b).   
 Blood samples were collected and stored in EDTA-treated, lavender-top tubes at room 
temperature and shipped overnight to a laboratory in Columbia University (principal 
investigator: Dr. Regina Santella) (Gammon et al. 2002b,c).  There, the blood samples were 
aliquoted into red blood cells, mononuclear cells, granulocytes, and plasma and were stored in -
80°C freezers using preprinted bar code labels with subjects’ randomly assigned study 
identification numbers.  For most participants, blood samples were processed and aliquoted 
within 24 hours of collection.  As a quality control measure, laboratory personnel were unaware 
of the case-control status of these samples.   
DNA Extraction and Genotyping 
Pelleted mononuclear cells were separated from whole blood by Ficoll (Sigma Chemical 
Co., St. Louis, MO), washed twice with phosphate-buffered saline (PBS), and frozen at -80°C 
until DNA isolation (Gammon et al. 2002c).  DNA isolation was performed by standard methods: 
extraction using phenol and chloroform isoamyl alcohol, followed by RNase and proteinase K 
treatment (Ahn et al. 2004, Gammon et al. 2002c, Shen et al. 2005a).  Several high-throughput 
genotyping methods are available for epidemiological studies.  The genotyping methods used in 
the LIBCSP have changed over time.  All methods relevant to the SNPs selected for this 
dissertation analysis are described in detail below.   
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Fluorescence Polarization (FP) 
Polymorphisms in ERCC1, XRCC1, OGG1 and XPD (Lys751Gln) were genotyped using 
FP (Crew et al. 2007, Rossner et al. 2006, Shen et al. 2005a, Terry et al. 2004).  This method 
differentiates between alleles in a polymorphic gene "by the template-directed incorporation of a 
dye-labeled dideoxynucleotide onto an oligonucleotide primer that anneals just 5’ to the 
polymorphic base" (Shen et al. 2008) (Chen et al. 1999).  FP has the advantage over alternative 
genotyping methods of not requiring specialty probes (Crew et al. 2007). 
The following forward and reverse primers were used for polymerase chain reaction 
(PCR) amplification: ERCC1 8092C/A: forward 5’-TAGTTCCTCAGTTTCCCG-3’, reverse 5’-
TGAGCCAATTCAGCCACT-3’; XRCC1 Arg194Trp: forward 5'-
ATGAGAGCGCCAACTCTCTG-3', reverse 5'-CTACCCTCCTCCCTCAGACC-3'; XRCC1 
Arg399Gln: forward 5'-CCCCAAGTACAGCCAGGTC-3', reverse 5'-
ATTGCCCAGCACAGGATAAG-3'; OGG1 Ser326Cys: forward 5'-
TTCCACCTCCCAACACTGTCA-3', reverse 5'-ATCTAGCCTTCCGGCCCTTT-3'; XPD 
Lys751Gln: forward 5'-CCCTCTCCCTTTCCTCTGTT-3', reverse 5'-
GGCAAGACTCAGGAGTCACC-3' .    
 PCR amplification of genomic DNA was completed using a solution of water, 25 mmol/L 
MgCl2, 0.1 μL of HotStar Taq polymerase at a concentration of 5 units/mL (Roche Molecular 
Biochemicals, Indianapolis, IN), 1 μL of 10× PCR buffer, 25 ng of DNA, 0.2 μL of forward and 
reverse primers (at a concentration of 8 pmol/μL) and 0.25 μL of deoxynucleotide triphosphates 
(at a concentration of 10 mmol/L) (Roche Molecular Biochemicals) (Crew et al. 2007, Rossner et 
al. 2006, Shen et al. 2005a, Terry et al. 2004).   
Forward and reverse primers as well as deoxynucleotide triphosphates were processed 
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using 1 unit of shrimp alkaline phosphatase (at a concentraiton of 1 unit/μL) (Roche Molecular 
Biochemicals), 1 unit of Escherichia coli exonuclease I (at a concentration of 10 units/μL) (US 
Biochemical, Cleveland, OH), 1 μL of 10× buffer, and 7.9 μL of water (Crew et al. 2007, 
Rossner et al. 2006, Shen et al. 2005a, Terry et al. 2004).  This step was undertaken in order to 
"[clean] the PCR products by digesting the excess primers and deoxynucleotides" (Shen et al. 
2005a).   
Reverse extension primers were 5'-CTACACAGGCTGCTGCTG CTGCT-3', 5'-
CGGGGGCTCTCTTCTTCAGC-3', 5'-GTCGGCGGCTGCCCTCCC-3', 5’-CCCTCCTAC 
AGGTGCTGTTCA and 3'-CTGAGCAATCTGCTCTATCCTCT-5' for ERCC1 8092C/A, 
XRCC1 Arg194Trp, XRCC1 Arg399Gln, OGG1 Ser326Cys and XPD Lys751Gln, respectively 
(Crew et al. 2007, Rossner et al. 2006, Shen et al. 2005a, Terry et al. 2004).  
 Genotyping (Crew et  al. 2007, Rossner et al. 2006, Shen et al. 2005a, Terry et al. 2004) 
was carried out via an AcycloPrime FP SNP detection kit, which included dideoxynucleotide 
triphosphates labeled with R110 or TAMRA (PerkinElmer Life Science, Boston, MA).  The 
reaction mixture included 1 μL of G/T Terminator mix, 0.05 μL of acycloprimer enzyme, 2 μL of 
10× reaction buffer, 0.5 μL (10 pmol/μL) of extension primer (for a total of 7 μL of reaction 
mixture), and 9.45 μL of water.  Plates were read with a Perkin-Elmer Victor instrument 
(PerkinElmer Life Science, Boston, MA).   
Taqman Assay 
Polymorphisms in XPA (-4A/G) and XPD (Asp312Asn) were genotyped using the 
Taqman assay (Taqman PCR Core Reagent kit) (Applied Biosystems, Foster City, CA), also 
known as the fluorogenic 5'-nuclease assay (Crew et al. 2007) (Lee et al. 1993).  The following 
fluorogenic oligonucleotide reverse probes were used for allele recognition: 5'-
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AAGCCCCGTCGGCCGCCGCCATCTC[C/T]GGCCCACTCCGAGGACC TAGCTCCC-3' for 
XPA and 5'-
CGGGGCTCACCCTGCAGCACTTCGT[C/T]GGCCCACTCCGAGGACCTAGCTCCC-3' for 
XPD.  PCR amplification of 15 ng of genomic DNA was completed in a thermal cycler (95°C for 
10 minutes, 40 cycles of 95°C for 25 seconds, 65°C for 1 minute) (ABI 7500, Applied 
Biosystems) . Finally, “the fluorescence profile of each well was measured in an ABI 7500HT 
Sequence Detection System and the results were analyzed with Sequence Detection Software 
(Applied Biosystems)” (Crew et al. 2007).  The Taqman assay with fluorogenic 5’-nuclease is a 
more robust genotyping method than FP “with well-established commercially available assays” 
(Crew et al. 2007) (Lee et al. 1993). 
Sequenom 
Sequenom's high-throughput matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry was used for genotyping polymorphisms in XPF (Arg415Gln) 
and XPG (His1104Asp) (BioServe Biotechnologies, Laurel, MD) (Ahn et al. 2004, Fannon et al. 
2002).  The primers used for PCR amplification of genomic DNA were 5'-
GGAAACTAGGAGGACAAGTGAG-3' and 5'-GACTTCTTCAGCTTTGCTATCC-3' for XPF, 
and 5'-CAGCTGTTCTCCTTTGTACATTC-3' and 5'-AAACCCAGAAGAGAGGCATAAC-3' 
for XPG.  PCR was conducted using Taq polymerase (0.02 μL) (Quiagen, Valencia, CA), water 
(0.73 μL), 10 x Buffer B (0.5 μL) (Solis Biodyne), MgCl2 (0.5 μL, at a concentration of 25 
mmol/L), dNTPs (2.5 mmol/L each, 0.25 μL), the forward and reverse primers described above, 
and 2 μL of DNA, which was diluted to 2.5 ng/μL (total volume =  5 μL) (Ahn et al. 2004).  The 
Sequenom method is the most recent genotyping method used in the LIBCSP and was chosen for 
its ability to multiplex (Crew et al. 2007).  
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Quality Control 
As quality control measures, "controls for genotype at each locus and two no DNA 
controls were included on each plate" and "any samples that were outside the variables defined 
by the controls were identified as non-informative and retested" (Crew et al. 2007).  The positive 
controls for genotype were obtained through direct sequencing of relevant SNPs (Shen et al. 
2005a).  In addition, duplicates for approximately 8-11% of DNA samples, depending on the 
polymorphism, were selected for re-sampling (Crew et al. 2007, Rossner et al. 2006, Shen et al. 
2005a, Terry et al. 2004).  Laboratory personnel were blinded to both case/control status and 
duplicate sample status.  Duplicate samples for all polymorphisms showed concordance of 
greater than 90% based on the κ statistic (Crew et al. 2007, Rossner et al. 2006, Shen et al. 
2005a, Terry et al. 2004).  For discordant pairs, data from the first genotyping assay were used, 
though including or excluding these pairs did not meaningfully alter overall results (Terry et al. 
2004) (Dr.Mary Beth Terry, personal communication 2012).   
COVARIATE ASSESSMENT 
As described previously (Chapter II), trained interviewers completed two-hour in home 
questionnaires with both cases and controls, which evaluated information on a wide range of 
potential confounders, effect modifiers and known or suspected breast cancer risk factors 
(Gammon et al. 2002b).  Most cases and controls also completed a self-administered validated 
Block FFQ (Block et al. 1986, 1990, Gammon et al. 2002b, Potischman et al. 1997).   Also, most 
cases signed a medical release form allowing access to information on clinical characteristics of 
their disease (Gammon et al. 2002b) 
 Potential confounders for this investigation include age in five-year groupings, 
educational attainment (less than high school, high school graduate, some college, college 
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graduate, or post college), religion (none, Protestant, Catholic, Jewish, other), pre-tax annual 
household income for the year prior to the reference date (<$15,000, $15,000-$19,999, $20,000-
$24,999, $25,000-$34.99, $35,000-$49,999, $50,000-$69,999, $70,000-$89,999, or $90,000+), 
parity (continuous), age at first birth (continuous), and race (white, African American, or other).  
Information on all of these variables was collected in the main case-control questionnaire 
(Gammon et al. 2002b).  Potential non-genetic effect modifiers are menopausal status 
(postmenopausal vs. premenopausal), and fruit or vegetable intake (high vs. low intake).   
 The fruit and vegetable consumption variable was derived from an FFQ assessing dietary 
patterns in the year prior to the reference date (Block et al. 1986, 1990, Gammon et al. 2002b, 
Potischman et al. 1997).  Menopausal status was defined using self-reported information 
regarding date of last menstrual period, smoking status, hormone replacement therapy use, and 
history of hysterectomy or oophorectomy (Gammon et al. 2002b).  A woman was considered 
postmenopausal if she reported a complete oophorectomy prior to reference date or that her last 
menstrual period preceded the reference date by at least 6 months.  More detailed information 
regarding variable definition for menopausal status can be found in Chapter II.    
 This dissertation aims to evaluate associations between traffic PAHs and breast cancer 
divided into subtypes based on tumor markers (specifically, with respect to hormone receptor 
status and p53 mutation status).  Hormone receptor (ER/PR) status was ascertained for LIBCSP 
cases by abstracting their pathology reports (Gammon et al. 2002b).  Prior publications report 
that the majority of LIBCSP cases have ER+/PR+ breast tumors (e.g. Gammon et al. 2004b, 
Steck et al. 2007).  Breast tumor p53 mutation status was analyzed using archived paraffin-
embedded tumor tissue (n = 859).  The extracted tumor DNA was analyzed for mutations in 
exons 5-8 of the p53 gene by a multistep process wherein samples were amplified using PCR and 
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screened via the Surveyor Mutation Detection Kit (Transgenomic, Omaha, NE, USA) (Rossner 
et al. 2008).  Samples screening positive for possible mutations were confirmed and identified 
through PCR amplification and direct sequencing with an ABI 3100 capillary sequencer (Applied 
Biosystems Inc, Foster City, CA, USA) (Mordukhovich et al. 2009, Rossner et al. 2008).  A total 
of 151 p53 mutations in 15% of analyzed tumors were detected (83% point mutations, 17% 
insertions/deletions) (Morduhovich et al. 2009, Rossner et al. 2008).  Case characteristics did not 
significantly vary by tumor tissue availability (Rossner et al. 2008).      
 The LIBCSP reports associations between overall breast cancer risk and parity and age at 
first birth in age-adjusted models (Gammon et al. 2002b).  Null results were found for education, 
income, and race in age-adjusted models (Gammon et al. 2002b).  More detailed analyses in the 
LIBCSP have revealed positive associations between breast cancer and reduced fruit and 
vegetable intake (Gaudet et al. 2004).  The LIBCSP also reported a strengthened negative 
association between fruit and vegetable intake and postmenopausal breast cancer among women 
with ER-positive tumors (Gaudet et al. 2004).  No other potential confounders or effect modifiers 
have been evaluated with respect to tumor p53 mutation or hormone receptor status.   
STATISTICAL APPROACH 
Descriptive Statistics  
The sample size, mean, median, range and interquartile range were calculated for traffic 
PAH variables from all analyses, including sensitivity analyses (see Chapter III).  Means and 
sample sizes for all exposure variables were also calculated according to case-control status.  
Spearman and Pearson correlations (Rothman and Greenland 1998) between selected exposure 
variables were evaluated as well (Chapter III).  All statistical analyses were conducted using SAS 
versions 9.1.3 or 9.3 (SAS Institute, Cary, NC).        
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Exposure Variable Considerations 
Two residential traffic PAH exposure variables were chosen as the main a priori 
exposures of interest: 1995 exposure (complete case analysis) and 1980-1995 exposure (with up 
to 20% multiple imputation).  These variables were selected in order to maximize study power, 
while simultaneously benefiting from the availability of long-term data in the LIBCSP.  
Associations between breast cancer and longer-term traffic PAH exposure durations were 
explored as well (1960-1990, 1960-1995).  The association between breast cancer and peak (i.e 
maximum annual) exposure between 1960 and 1990 was evaluated in order to explore the 
importance of high short-term traffic PAH exposure relative to cumulative long-term exposure 
(Dr. Jan Beyea, personal communication 2009).   
 Some researchers believe that environmental exposures may be most relevant to breast 
cancer risk during certain critical windows of exposure, such as prior to first birth or during the 
teenage years (Hiatt et al. 2009).  The LIBCSP study likely does not have sufficient power to 
effectively explore this possibility.  However, prior LIBCSP investigations report associations 
between breast cancer and long-term cumulative measures of PAH-related exposures, such as 
long-term residential passive smoking (Gammon et al. 2004b) and lifetime intake of grilled or 
smoked meat (Steck et al. 2007).  A 2006 LIBCSP study explored the possibility of critical 
windows of susceptibility with respect to average lifetime alcohol intake and reported that 
associations with breast cancer did not vary by timing of exposure (Terry et al. 2006).       
 This analysis utilized relative rather than absolute benzo[a]pyrene exposure estimates (Dr. 
Jan Beyea, personal communication 2011).  Specifically, the value for long-term PAH exposure 
variables was calculated as a function of average estimated benzo[a]pyrene exposure for the year 
1995.  An absolute benzo[a]pyrene exposure calculation may be misleading, as benzo[a]pyrene is 
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meant to be a surrogate for all traffic PAHs (Dr. Jan Beyea, personal communication 2011).     
Main Effects Regressions 
Cubic smoothing b-splines (Hastie et al. 2009, Rothman and Greenland 1998) were 
implemented in order to derive a data-driven exposure-outcome curve for the unimputed 1995, 
1980-1995, and 1960-1990 traffic exposure variables in relation to breast cancer risk.  Spline 
analyses determined that the use of a continuous exposure variable was not appropriate (see 
Chapter III), and that the use of categorical variables was more fitting.  Quantile cutpoints for the 
exposure variables (<50th (referent), 50-<75th, 75-95th, and >95th percentiles) were informed by 
the spline figures (see Chapter III for more details).   
 Associations between residential vehicular traffic exposure estimates and breast cancer 
case-control status were evaluated using multivariable unconditional logistic regression to 
estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) (Hosmer and Lemeshow 
1989).  For the years spanning 1980 and 1995, the partially imputed traffic PAH exposure 
variable included women with up to 20% of their total traffic PAH exposure originally missing 
during these years.  Exposure gaps were filled using multiple imputation (Rubin 1996), described 
in detail in Chapter II.  Participants with more than 20% missing data for this time span were 
dropped from the analysis.  For the variable representing exposure during the year 1995 only, a 
complete case analysis was employed.   
 Analyses were also conducted among the following subsets of participants: (1) a 
complete case analysis among women with no missing exposure information between the years 
1980 and 1995, (2) among women with up to 30% of their residential traffic PAH exposure 
information imputed between the years 1980 and 1995, (3) among a subset of women with PAH 
exposure data spanning the years 1960 to 1995 (up to 20% multiple imputation), and (4) among a 
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subset of women with PAH exposure data spanning the years 1960 to 1990, in order to account 
for possible latency effects (up to 20% multiple imputation).  Among women with up to 20% of 
imputed exposure information between 1960 and 1990, the association between breast cancer 
and peak annual benzo[a]pyrene exposure was explored as well (Hosmer and Lemeshow 1989, 
Rothman and Greenland 1998).  
 In addition, the following sensitivity analyses were conducted.  The association between 
breast cancer and traffic exposure in 1995 was evaluated among women residing in their current 
home for 15 or more years (Appendix Table A2.2), and participants with the highest exposure 
levels (top 2 and 5) were removed from main effects regression analyses for the following 
variables: 1995, 1980-1995, 1960-1990 (Appendix Table A2.3).  Finally, additional sensitivity 
analyses were conducted for the 1960-1990 variable (single imputation): varying the relative 
contribution of the pre-arrival surrogate to total dose (Appendix Table A2.4), removing the 
contribution of intersections from the exposure model (Appendix Table A2.5), and imputing 
according to census place (Appendix Table A2.6).   
 Associations between breast cancer and 1995 and 1960-1990 traffic PAH exposure levels 
were also explored with breast cancer cases subdivided according to tumor characteristics.  
Specifically, this study evaluated associations with breast cancer subtypes categorized according 
to tumor p53 mutation status (p53-mutation negative vs. p53-mutation positive) and hormone 
receptor status.  Tumor hormone receptor status was classified in two different ways for this 
subanalysis: (1) ER+/PR+ versus ER-/PR+, ER+/PR-, or ER-/PR-, and (2) ER-/PR- versus 
ER+/PR+, ER+/PR-, or ER-/PR+ (Potter et al. 1995, Yang et al, 2011).  The first categorization 
was chosen for public health reasons: the ER+/PR+ subtype is the most common breast cancer 
subtype among US women and may account for the higher levels of breast cancer incidence in 
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this country relative to lower-risk countries (Yasui and Potter 1995).  The second categorization 
was chosen because there is reason to believe that ER-/PR- breast tumors differ in etiology from 
luminal ER+ or PR+ cancers (Potter et al. 1995).  Effect estimates for different tumor subtypes 
were compared using ratios of the ORs (Schlesselman 1982).  The 1995 exposure variable was 
chosen in order to maximize power for tumor subgroup analyses, and the 1960-1990 variable 
was chosen because of the information it provides on long-term exposures.  The same quantile 
cutpoints used for the main effects analyses were used for the 1995 variable when evaluating 
tumor heterogeneity by hormone receptor status (see Chapter 3).  The two upper quantiles were 
collapsed due to sample size constraints within tumor subtype subgroups when evaluating this 
association for the 1960-1990 variable, and when examining tumor heterogeneity by p53 
mutation status (Appendix Table A2.7). 
Confounding 
Because cases and controls were frequency matched by five-year age group, all statistical 
models must be adjusted for age group at reference (age at date of diagnosis for cases and age at 
date of identification for controls).  Other potential confounders were identified by a thorough 
review of the relevant literature and analysis of causal diagrams (specifically, directed acyclic 
graphs) (Shrier and Platt 2008).  A priori, it was decided that a potential confounder would be 
included in regressions if it caused at least a 10% change in the main effect of the 1995 traffic 
PAH variable on breast cancer risk when added to age-adjusted models (Rothman and Greenland 
1998; see Chapter III).  Potential confounders include educational level (less than high school, 
high school graduate, some college, college graduate, post college), annual household income 
(<$15,000, $15,000-$19,999, $20,000-$24,999, $25,000-$34,999, $35,000-$49,999, $50,000-
$69,999, $70,000-$89,999, $90,000+), body mass index at reference (in kg/m2), race (White, 
117 
 
African American, other), religion (none, Prostestant, Catholic, Jewish, other), number of live 
births (continuous), and age at first birth (continuous).   
 The amount of missing data was low for most of these variables (n=10 for education, n=3 
for race, n=0 for parity, and n=1 for age at first birth, out of a total of 3,064 study participants; 
Gammon et al. 2002b).  However, 11.5% of participants were missing information on household 
income (Gammon et al. 2004a).  Therefore, income values were imputed from regression models 
for cases and controls.  These models included age, race and education (Gammon et al. 2004a, 
Rubin 1996).   
Effect Modification 
DNA Repair Variants 
This analysis examines gene-environment interactions between traffic benzo[a]pyrene 
exposure (years 1995 and 1960-1990) and genetic variants in NER and BER DNA repair 
pathways (for ERCC1, OGG1, XPA, XPD, XPF, XPG, and XRCC1) with respect to breast cancer 
risk.  The PAH exposure variable for the year 1995 was used in order to maximize statistical 
power for gene-environment interaction analyses.  However, the 1960-1990 variable may be a 
more accurate reflection of true long-term exposure opportunity, and was therefore examined as 
well.  All of the genetic variants have been previously tested for deviations from HWE within the 
LIBCSP study population, and all were found to be in HWE among controls (Crew et al. 2007, 
Rossner et al. 2006, Shen et al. 2005, Terry et al. 2004).  
  For most genetic variants of interest, gene-environment interactions were explored using 
a co-dominant genetic model in which participants with heterozygote and variant homozygote 
genotypes are assessed independently relative to a common referent group comprising women 
with dominant homozygote genotypes (Ziegler and Konig 2006).  This approach was chosen 
118 
 
because there is no a priori reason to combine women with heterozygote and variant 
homozygote genotypes into a single group, and because previous LIBCSP reports assessing 
gene-environment interactions between DNA repair polymorphisms and PAH-related exposures 
suggested differences between participants with heterozygote and variant homozygote genotypes 
that were not present when evaluating the main effects of these polymorphisms on breast cancer 
risk (Crew et al. 2007, Terry et al. 2004).   However, a dominant genetic model was implemented 
when any cell sizes comprised fewer than 10 participants.  Specifically, in these cases, women 
with heterozygote and variant homozygote genotypes were assessed relative to a referent group 
comprising women with dominant homozygote genotypes (Ziegler and Konig 2006).  Effect 
modification by genetic polymorphisms was evaluated using two methods: (1) running separate 
regression models stratified by genotype and (2) evaluating multiplicative interactions using 
likelihood ratio tests (Rothman and Greenland 1998, Ziegler and Konig 2006).     
 In addition, effect modification by total number of 'high-risk' alleles was evaluated via (1) 
analyses stratified by low, intermediate, and high-risk genotype categories (Crew et al. 2007), 
and (2) likelihood ratio tests to assess multiplicative interactions (Rothman and Greenland 1998).  
'High-risk' alleles may be variant or wild-type alleles, and were determined by examining 
associations between traffic PAHs and breast cancer within models stratified by genotype (see 
Chapter IV).  Previously reported main effects of genotypes on breast cancer odds are shown in 
Appendix Table A2.8.   
Non-Genetic Covariates 
Interactions between traffic PAH exposure variables (1995 [CCA] and 1960-1990 [20% 
MI]) and non-genetic covariates were evaluated with respect to breast cancer occurrence.  
Specifically, potential effect modification by menopausal status (postmenopausal vs. 
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premenopausal; Appendix Table A2.9) and fruit and vegetable intake (high vs. low, classified 
according to previously reported main effects on breast cancer risk, Gaudet et al. 2004) were 
examined (see Chapter III).  Interactions were evaluated by running stratified regressions as well 
as through likelihood ratio tests (Rothman and Greenland 1998).   
 Menopausal status was initially classified as unknown for the 11.8% of women who had a 
hysterectomy but not an accompanying complete oophorectomy or who were using hormone 
replacement therapy.  Information on smoking status was used to reduce this percentage such 
that "any smoker with unknown menopausal status was categorized as postmenopausal if her age 
was >54.8 years (90th percentile for natural menopause among smoking controls), and any 
nonsmoker with unknown menopausal status was categorized as postmenopausal if her age was 
<55.4 years (90% percentile for natural menopause among nonsmoking controls)" (Gammon et 
al. 2002b).  This reduced the percentage of participants with missing menopausal status to 3.04% 
(Gammon et al. 2002b).    
Interpretation of Results 
This investigation did not rely solely on significance testing for interpreting main effects 
of traffic PAHs on breast cancer risk (overall or with the breast cancer outcome categorized 
according to tumor p53 mutation status or hormone receptor status), or when evaluating effect 
modification by genes and other covariates.  The precision of confidence intervals, the sizes of 
effect estimates, and patterns of associations were also taken into account when interpreting 
results (see Chapters III and IV).  Results from this investigation, whether positive or null, were 
carefully interpreted in light of study limitations and strengths.  The role of chance findings was 
acknowledged when discussing results.   
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STRENGTHS AND LIMITATIONS 
Traffic PAH Exposure Model  
Data regarding tailpipe emissions and transportation patterns are not reliably available 
prior to the year 1960.  Therefore, residential traffic PAH exposures were not modeled prior to 
this date (Beyea et al. 2005).  In addition, the LIBCSP did not collect residential history 
information outside of Nassau and Suffolk counties or for addresses within Nassau or Suffolk 
counties at which a participant resided for less than one year.  Non-residential traffic-related PAH 
exposure estimates, such as while at work or driving, could not be modeled.  Exposures while 
driving could be especially important for women living in the lowest exposure regions in Nassau 
or Suffolk counties (Beyea et al. 2005).  Calculated "peak exposures on roads were generally ten 
times higher than average residential exposures" (Beyea et al. 2005).  These omissions inevitably 
lead to some degree of misclassification.  The effect on model accuracy of time spent away from 
home may, however, be less than expected due to the large exposure component at night arising 
from pollutant drift from rush-hour traffic (Beyea et al. 2005).  Other limitations of the exposure 
model include uncertainties in chosen model parameters, such as dispersion variables, 
meteorological variables, the relative importance of emissions at traffic intersections, or building 
penetration factors, which could result in misclassification of the traffic PAH exposure variable.   
 The exposure model does not incorporate non-traffic sources of PAHs, including ambient 
sources such as cigarette smoke, residential heating, cooking, or leaf-burning.  However, traffic 
is often the largest ambient source of PAHs in or near urban areas (Bostrom et al. 2002, 
Dubowsky et al. 1999, Dunbar et al. 2001, IARC 1989), and is usually the largest source of air 
pollution in these areas (Maitre et al. 2002, WHO 1996).  Furthermore, traffic is more likely to 
release smaller, more health-relevant particles than some of the aforementioned ambient 
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exposure sources (Kocbach et al. 2006).  The geographic model also did not incorporate 
information regarding 'canyon effects' due to row housing (Raaschou-Nielsen et al. 2000), which 
is rare in the study area, and did not account for the small number of roads that were added to the 
study area after 1960, which is likely to have a minor impact on exposure estimates based on 
sensitivity analyses (Beyea et al. 2005). 
 Only benzo[a]pyrene was modeled as a surrogate for all traffic PAHs.  Traffic pollution 
also contains a large number of non-PAH chemicals, some of which are confirmed carcinogens 
(e.g. benzene and formaldehyde; Bostrom et al. 2002, IARC 1989, 2006, 2008).  Therefore, it is 
impossible to definitively ascribe health effects to a single traffic pollutant based on an 
observational study.  However, benzo[a]pyrene is one of the most carcinogenic PAHs and is 
representative of overall PAH exposure from vehicle exhaust (Bostrom et al. 2002, Fertmann et 
al. 2002).  Furthermore, due to their "potency and high concentrations" in vehicular exhaust, 
particulate-phase PAHs are considered among the most carcinogenic components of traffic 
emissions (Boothe and Shendell 2008).  Finally, despite being correlated, traffic-related 
pollutants do not have identical distributions.  In the LIBCSP, exposure estimates were modeled 
using PAH-specific vehicle emissions data, PAH-specific dispersion parameters, and were 
validated and calibrated against residential soil PAH levels and PAH-DNA adduct levels in 
mononuclear cells (Beyea et al. 2006).  As an illustrative example, the benzo[a]pyrene 
geographic model used in the LIBCSP needed to be altered in order to predict carbon monoxide 
levels for a validation exercise.  Specifically, the carbon monoxide model excluded "all depletion 
phenomena, because deposition, washout, and photo decay are negligible in the case of CO" 
(Beyea et al. 2006). 
 The above limitations should be interpreted in light of realistic standards in the literature.  
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Specifically, the standard approach in environmental epidemiology is to assign exposure 
estimates (often short-term and/or self-reported) based on relatively crude measures such as 
readings from sparse pollutant monitors or distance from major roads, and thus even uncertain 
modeling parameters are likely to be an improvement over these approaches (Beyea 1999).  The 
state of the art exposure model used to generate LIBCSP residential traffic PAH exposure 
estimates is a vast improvement over many comparable studies.  Model parameters were 
validated and calibrated against extensive PAH-related field data from the LIBCSP, thereby 
greatly increasing confidence in their credibility (Beyea et al. 2006).  Sensitivity analyses 
suggest that modeling uncertainties are not likely to strongly impact residential traffic PAH 
exposure estimates (Beyea et al. 2005).  Most LIBCSP participants provided at least one address 
that geocoded to street level (for addresses through the year 1990, n= 2,601; for 1995 addresses, 
n = 2,655).           
 Specific strengths of the traffic-related PAH exposure model include a comprehensive 
individualized ambient benzo[a]pyrene exposure metric spanning a large geographic area, and 
accounting for participants' residential histories for up to a 35 year period.  Exposure estimates 
were derived using a sophisticated historical geographic model that incorporated information on 
a wide range of factors including changing historical vehicular emissions and transportation 
patterns, meteorologic data, pollutant dispersion and deposition variables, acceleration and 
deceleration at intersections, cruise and cold-engine emissions, building penetration factors, and 
background ambient PAH from distant traffic and other PAH sources (Beyea et al. 2006).  The 
model was validated and calibrated against field data (specifically, residential soil PAHs, PAH-
DNA adducts in mononuclear cells, and carbon monoxide concentrations at an EPA monitoring 
site; Beyea et al. 2006).  Participants were exposed to a wide range of residential traffic PAH 
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levels, due to the gradient of urbanization across the study area (Beyea et al. 2006).  Finally, 
since breast cancer develops over many years (Clark et al. 1997), a long modeled exposure 
period may be relevant to assessing relationships with breast cancer.  Residential PAH and other 
pollutant exposure levels can vary greatly from year to year for a given woman due to, for 
example, changes in emissions or moving to a new residence (Beyea et al. 2005).   
Other Considerations 
This investigation may be subject to potential limitations standard to epidemiological 
studies such as laboratory errors with respect to genotyping or tumor classification, inaccurate 
reporting or recording of confounding or modifying covariates, and differential misclassification 
with respect to case-control status (Rothman and Greenland 1998).  However, the LIBCSP 
employed extensive quality control measures, both with regard to genotyping (e.g. genotyping 
randomly distributed duplicate DNA samples, Crew et al. 2007; see Chapter II for more details) 
and other data collection and storage procedures (e.g. running data range and logic checks and 
re-interviewing a random sample of 20% of participants, Gammon et al. 2002b; see Chapter II 
for more details).  Identical data collection and storage strategies were used for case and control 
participants.  These measures likely reduce the probability and extent of potential study 
limitations (Gammon et al. 2002b).   
 Study participation rates differed between eligible cases and controls (82.1% vs. 62.7%, 
respectively) (Gammon et al. 2002b).  Reduced participation among eligible controls was driven 
by lower participation rates among elderly women (Gammon et al. 2002b).  Finally, the LIBCSP 
is a fairly homogenous study population with respect to race (primarily white), socioeconomic 
status (relatively high) and geographic area.  This is both a strength and a limitation.  Participant 
homogeneity is an advantage with respect to confounder control as it decreases the likelihood of 
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residual confounding, but participant homogeneity also reduces the generalizability of study 
findings.  
 The LIBCSP provides a large study population with high response rates for both cases 
and controls (Gammon et al. 2002b), and DNA was collected from most LIBCSP participants 
(Gammon et al. 2002b).  The higher resulting study power is important for effectively evaluating 
associations between traffic PAHs and breast cancer, and is especially important for evaluating 
statistical interactions, such as with genetic variants.  A case-control study provides the most 
efficient means of examining associations with breast cancer risk, as a prohibitively large and 
resource-intensive cohort would be needed to obtain the same number of cases due to the 
relatively low population incidence of breast cancer (ACS 2009-2010, Rothman and Greenland 
1998).  The LIBCSP utilized extensive quality control procedures for questionnaire data and for 
the laboratory component of the investigation, as described above (Crew et al. 2007, Gammon et 
al. 2002b).  The LIBCSP also recruited incident rather than prevalent cases, which increases the 
likelihood of identifying risk factors for breast cancer occurrence rather than survival (Gammon 
et al. 2004b, Rothman and Greenland 1998).   
 Additional strengths of this study include access to the resources of a large population-
based investigation with extensive information on a wide range of variables including 
demographic and lifestyle factors, active and passive cigarette smoking history, reproductive and 
medical history, dietary intake, tumor markers and subtypes, and a variety of genetic 
polymorphisms (Gammon et al. 2002b).  This facilitates effectively controlling for potential 
confounders, assessing effect modification, and evaluating tumor subtype-specific risk factor 
associations.   
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SUMMARY 
The Long Island Breast Cancer Study Project is a large, population-based case-control 
study which has developed a unique and comprehensive long-term measure of residential 
exposure to ambient PAHs from vehicular traffic (Beyea et al. 2006).  The historical exposure 
model was validated against relevant field data from the LIBCSP (specifically, soil PAHs, PAH-
DNA adduct levels in mononuclear cells, and carbon monoxide concentrations at an EPA 
monitoring location) (Beyea et al. 2006).  The LIBCSP has collected extensive information 
regarding breast tumor subtypes and a wide range of established or possible breast cancer risk 
factors, confounders, and effect modifiers, including genetic polymorphisms in relevant 
biological pathways (Gammon et al. 2002b, Gammon and Santella 2008).   
 This dissertation analysis aims to (1) evaluate associations between residential traffic-
related PAH exposure and breast cancer, and (2) assess interactions between traffic PAH 
exposure and DNA repair polymorphisms in nucleotide excision repair and base excision repair 
pathways with respect to breast cancer risk.  Secondary research goals include evaluating 
associations between traffic PAHs and breast cancer categorized according to tumor subtypes 
(based on hormone receptor status and p53 mutation status), and assessing interactions between 
traffic PAHs and fruit and vegetable intake as well as menopausal status with respect to breast 
cancer occurrence.   
  PAHs are ubiquitous environmental carcinogens which are found in high concentrations 
in traffic exhaust (Boothe and Shendell 2008, IARC 2010).  PAHs are potent mammary 
carcinogens in laboratory animals (el-Bayoumy et al. 1995), and PAH-DNA adducts, air 
pollution, and traffic exposure are consistently linked with breast cancer in epidemiological 
studies (Beyea et al. 2006, Bonner et al. 2005, Gammon and Santella 2008, Rundle et al. 2002a).  
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However, the relevant epidemiological literature to date is sparse and no previous research has 
attempted to evaluate the association between such a comprehensive and long-term air pollution 
or traffic exposure metric and breast cancer risk, or to evaluate interactions between air pollution, 
DNA repair genotypes, and fruit and vegetable intake.   
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CHAPTER III: EXPOSURE TO TRAFFIC-RELATED POLYCYCLIC AROMATIC 
HYDROCARBONS AND BREAST CANCER RISK 
INTRODUCTION 
 
Breast cancer is the most common malignancy among women in the United States (ACS 
2011-2012).  Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous pollutants formed from 
incomplete combustion (Boström et al. 2002).  PAHs are genotoxic prooxidants, confirmed 
human lung carcinogens, and potent mammary carcinogens in laboratory animals (IARC 2010).  
However, the association between PAHs and breast cancer in women is unclear (Gammon and 
Santella 2008).  Previous population studies have reported associations between PAH-related 
exposures and breast cancer.  For example, PAHs bind to DNA, including in breast tissue, and 
the resulting DNA adducts have been linked with breast cancer in epidemiological studies, 
although the research is scant (Gammon et al. 2002c, Rundle et al. 2000).  PAH-DNA adducts 
reflect short-term exposures (Gammon et al. 2002c), whereas breast cancer is thought to develop 
over many years.  Thus, it is of interest to evaluate longer-term PAH exposures in relation to 
breast cancer risk. 
 Vehicular traffic is a major source of PAH exposure, especially near urban areas (Fromme 
et al. 2004), and is a ubiqutious and generalizable air pollution exposure surrogate (Boström et 
al. 2002).  Studies consistently report positive associations between breast cancer and air 
pollution, although the exposure assessment methods in these previous reports varied (Bonner et 
al. 2005, Crouse et al. 2010, Lewis-Michel et al. 1996, Nie et al. 2007, Raaschou-Nielsen et al. 
2011).  Some investigations relied on simple traffic density data or sparse monitors, evaluated 
relatively brief periods of exposure, focused on nitrogen oxides rather than carcinogenic 
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particulate pollution, or used unvalidated exposure assessment methods.  Further progress 
requires sophisticated modeling to reconstruct long-term cumulative exposures to ambient PAHs.   
 Breast cancer risk factor profiles differ by menopausal status and tumor subtype (ACS 
2011-2012, Chen and Colditz 2007), and fruits and vegetables may modify the carcinogenic 
effects of PAHs via antioxidant and other chemopreventive properties (Hecht et al. 2000, Jin et 
al. 2006).  However, whether the association between ambient PAHs and breast cancer varies by 
fruit/vegetable intake, tumor characteristics, and menopausal status is not well understood.   
 Our population-based study aims to evalute the association between breast cancer 
incidence and traffic-related PAH exposure, overall and within subgroups of fruit/vegetable 
intake, menopausal status and tumor subtypes (Gammon et al. 2002b).  For our study reported 
here, we utilized long-term, individualized residential traffic PAH exposure estimates, which 
were reconstructed using a comprehensive, extensively validated exposure model (Beyea et al. 
2006).  It is important to clarify the association between traffic PAHs and breast cancer given the 
high incidence of breast cancer and widespread exposure to traffic pollution worldwide. 
MATERIALS AND METHODS 
 
We used data from the case-control component of the Long Island Breast Cancer Study 
Project (LIBCSP), a population-based investigation conducted among women residing in Nassau 
and Suffolk counties in Long Island, NY (Gammon et al. 2002b).  All participating institutions 
provided Institutional Review Board approval for this study. 
Study Population 
 
Eligible case participants were diagnosed with a first primary invasive or in situ breast 
cancer between August 1996 and July 1997, and identified via rapid case ascertainment through 
contact with local pathology departments (Gammon et al. 2002b).  Eligible control participants 
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were women with no history of breast cancer, and were identified using random digit dialing 
(Waksberg 1978) for women under age 65 and Health Care Finance Administration records for 
women aged 65 years or older.  Controls were frequency matched based on the expected five-
year age distribution among the case participants.   
Respondents included 1,508 cases and 1,556 controls (82.1% and 62.7% of eligible 
participants, respectively), who ranged between 20 and 98 years of age and were mostly 
postmenopausal (67.4%) and white (92.8%); the racial distribution reflects that of the study 
counties at the time of data collection (Gammon et al. 2002b).  Over 50% of participants reported 
a household income of $50,000 or greater in the year prior to the study interview (Gammon et al. 
2002b).  In previous LIBCSP reports, we found that increased breast cancer risk was associated 
with: early age at menarche, few or no births, and little or no breastfeeding (Gammon et al. 
2002b, Shantakumar 2007); increased body size (Eng et al. 2005) and little or no physical 
activity (McCullough et al. 2012) among postmenopausal women; low fruit/vegetable intake 
(Gaudet et al. 2004) and low flavonoid intake (Fink et al. 2007); and increased blood levels of 
PAH-DNA adducts (Gammon et al. 2002c), long-term residential environmental tobacco smoke 
exposure (Gammon et al. 2004b), and increased grilled/smoked food intake (Steck et al. 2007).  
Study Questionnaire 
 
Trained interviewers administered an at-home, two-hour structured questionnaire within a 
few months of diagnosis (cases) or study recruitment (controls).  Detailed questionnaire 
information includes residential history, household income, educational attainment, race, 
religion, reproductive and medical histories, smoking, exogenous hormone use, and body size 
(Gammon et al. 2002b).  A validated Block food frequency questionnaire (Block et al. 1986, 
1990) was self-completed by 98% of cases and controls, and assessed usual dietary intake during 
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the year prior to the interview, including intake of fruits, fruit juices, and vegetables (Gaudet et 
al. 2004).  
Tumor Subtypes 
 
Medical records were abstracted for 1,402 case participants to ascertain tumor estrogen 
and progesterone receptor (ER/PR) status subtypes (Gammon et al. 2002b).  Tumor p53 
mutations, which can be induced by PAHs (Greenblatt et al. 1994), were determined using 
archived, paraffin-embedded tissue (n=859) (Rossner et al. 2009).  Briefly, the extracted tumor 
DNA was amplified using PCR, screened via the Surveyor Mutation Detection Kit 
(Transgenomic, Omaha, NE, USA), and possible mutations were confirmed with an ABI 3100 
capillary sequencer (Applied Biosystems Inc, Foster City, CA, USA).   
Traffic Exposure Assessment 
 
Interviewers collected information regarding participants' lifetime residential histories in 
Nassau and Suffolk counties.  Addresses at which a woman resided for at least one year were 
recorded and geocoded using BLR software (BLR Data, Inc. Lebanon, NH).  Most participants 
(n=2,655) provided at least one address that geocoded to the street level.  The percentage of 
addresses that geocoded successfully ranged between 60% in the 1960s and 85% in 1995 (Beyea 
et al. 2005). 
 The traffic exposure model (Beyea et al. 2005, 2006, 2013) used a road network 
comprising approximately 500,000 street segments in the New York metropolitan area, which 
includes Nassau and Suffolk counties.  Emissions for each street segment were calculated as the 
product of hourly roadway-specific traffic counts and average U.S. tailpipe emissions for the 
years 1960, 1970, 1980, and 1990.  Estimates for other years between 1960 and 1995 were 
derived via interpolation or extrapolation.  Vehicular traffic estimates include adjustment for 
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acceleration/deceleration at intersections (Beyea et al. 2006).  Emissions within 80 kilometers of 
the study area were directly calculated, and the exposure model also included a background term 
(proportional to exposures from the 22 counties just outside of the two-county study area) to 
account for more distant roads (Beyea et al. 2006).  Tailpipe emission parameters were derived 
from road tunnel measurements throughout the U.S. and checked using vehicles run on 
dynamometer test beds (Beyea et al. 2008).  Roadway traffic counts were obtained from over 
13,000 “annual average daily traffic” measurements, recorded in state and county records.   
 Roadway emissions were translated into predicted residential ambient benzo[a]pyrene 
concentrations, considered a surrogate for exposure to all traffic PAHs, using standard 
meteorological dispersion and deposition models (Beyea et al. 2006, Chock 1978, Viegele and 
Head 1978).  Up to 100 meters from a road, traffic PAH levels were estimated using highway 
line-source models (Chock 1978).  Beyond 100 meters, a standard Gaussian plume model with 
Briggs dispersion parameters (Viegele and Head 1978), which incorporated data on wind speed 
and direction, rain washout, photo decay, and particle deposition, was used (Beyea et al. 2006).  
Meteorological data were collected at Brookhaven National Laboratory (year 1993).  Changing 
the year (1990) or location (MacArthur Airport) of meteorological data collection for a 
sensitivity analysis did not appreciably alter exposure estimates (Beyea et al. 2005).  Finally, 
indoor exposures were calculated using a building penetration factor of 0.75 (Long et al. 2001).   
Model Validation 
 The exposure model was modified to predict measured residential soil and carpet PAH 
levels among women living at their current address for at least 15 years, PAH-DNA adduct levels 
in circulating mononuclear cells collected at interview, and monitoring data for carbon 
monoxide, a traffic-related pollutant (Beyea et al. 2006).  The model accurately predicted soil 
132 
 
PAHs, PAH-DNA adduct levels, and carbon monoxide concentrations, but not PAH levels in 
carpet dust (Beyea et al. 2006).  The latter finding is consistent with a study showing that 
residential ambient PAH concentrations do not correlate with house dust PAH levels (Fromme et 
al. 2004).   
 The model was calibrated against soil and PAH-DNA adduct data through chi-squared 
minimization (Beyea et al. 2006).  The soil-calibrated model provided the best fit to field data 
and was therefore used for regressions against breast cancer risk.  Emissions during engine 
warm-up, which were included during model building, did not contribute to predicting soil PAH 
levels in validation exercises and were dropped from the exposure model (Beyea et al. 2006). 
Missing Exposure Data    
 Residential histories during 1960-1995 were incomplete for study participants who 
migrated to Long Island from other locations or whose recollection of prior addresses was 
incomplete (Beyea et al. 2013).  Thus, we used a surrogate for pre-arrival exposure, which was 
standardized to the average estimated traffic PAH concentrations on Long Island during the 
relevant period, based on five-year intervals; variance was added during multiple imputation 
(MI) (Beyea et al. 2013, Rubin 1996).  For missing post-arrival addresses, multiple imputation 
was used to estimate the function converting roadway emissions to exposures at individual 
residences, using interpolation or extrapolation from a woman's known addresses (Beyea et al. 
2013).  
Statistical Methods 
 
We evaluated cumulative vehicular traffic exposures for the years 1995 (the year prior to 
case ascertainment), 1980-1995, 1960-1995 and 1960-1990, along with maximum annual 
exposure during 1960-1990.  We restricted participants' percentage of imputed exposure to 20% 
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of total exposure during 1980-1995, 1960-1995, and 1960-1990 (Beyea et al. 2013).  For 1995 
exposures, we conducted a complete case analysis (CCA), in which all participants had 
complete, unimputed exposure information.  As a sensitivity analysis, we evaluated 1980-1995 
traffic exposure as a CCA and with up to 30% MI.  We selected a range of exposure durations in 
order to maximize study power, which was higher for recent exposures, while also benefiting 
from long-term cumulative exposure information. 
 We calculated descriptive statistics for the exposure variables, overall and by case-control 
status, and evaluated Spearman and Pearson correlations (Rothman and Greenland 1998) 
between selected exposure variables.  Exposure levels were normalized to the average 
benzo[a]pyrene exposure in 1995, and expressed as relative units (Beyea et al. 2013).  Statistical 
analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).      
 Prior to undertaking regression analyses, we used age-adjusted cubic smoothing splines 
with knots at each unique exposure value (Hastie and Tibshirani 1990) to evaluate the association 
between traffic exposure (1995, 1980-1995, 1960-1990) and breast cancer risk.  The spline 
figures indicated that the association was not linear and were used to generate traffic PAH 
quantile cutpoints for regression models: <50th (referent), 50-<75th, 75-95th, and ≥95th percentiles.  
We used unconditional logistic regression (Hosmer and Lemeshow 1989) to estimate 
odds ratios (ORs) and 95% confidence intervals (CIs) for associations between traffic estimates 
and breast cancer risk.  When using partially imputed exposure variables, effect estimates and 
confidence limits were combined across 30 imputations using Rubin's rules (Rubin 1996).  
 All regression models were adjusted for the case-control frequency matching factor, five-
year age group (Gammon et al. 2002b).  Other potential confounders (educational level, annual 
household income, race, religion, parity, age at first birth, body mass index (kg/m2)) were 
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identified by a thorough literature review and analysis of directed acyclic graphs (Shrier and Platt 
2008), and evaluated for model inclusion using a 10% change in estimate criterion relative to 
age-adjusted models (Rothman and Greenland 1998).  No covariates meaningfully altered age-
adjusted effect estimates (years 1995, 1960-1990), and thus all models adjust only for age group.  
 We explored effect modification by menopausal status (pre vs. postmenopausal) and fruit 
or vegetable intake in the year prior to the study interview (≤34 vs. 35+ servings/week) for 1995 
and 1960-1990 exposures using stratified analyses and likelihood ratio tests for multiplicative 
interaction (Rothman and Greenland 1998).  Menopausal status was defined using data from the 
study questionnaire (Shantakumar 2007).  Fruit/vegetable intake was dichotomized based on 
previously reported effects on breast cancer risk in the LIBCSP (Gaudet et al. 2004).   
 We evaluated associations between traffic PAHs and breast tumor subtypes categorized 
according to p53 mutation status (mutation-positive vs. mutation-negative; Mordukhovich 2010) 
and hormone receptor status (ER+PR+ vs. all other subtypes, and ER-PR- vs. all other subtypes; 
Yang et al. 2011, Yasui and Potter 1995).  Using polytomous logistic regression (Hosmer and 
Lemeshow 1989), we simultaneously compared cases with each individual subtype to the control 
participants.  The ratio of the odds ratios (Schlesselman 1982) was used to evaluate heterogeneity 
of the effect estimates across tumor types.  The upper exposure quantiles (75-95th and ≥95th 
percentiles) were collapsed when cell sizes comprised fewer than 10 participants.   
RESULTS 
 
The number of LIBCSP respondents for whom traffic estimates are available (520-1,274 
cases; 566-1,334 controls) varied according to the exposure definition and the imputed data set 
(some women exceeded the limit on imputation percentage in certain imputation draws), and 
participants showed a wide range of exposure levels (Table 1).  For example, exposures during 
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1995 ranged between 0.02 and 30.63 relative units, with an interquartile range of 0.64 to 1.24 
and, by definition, a mean of 1.00.  Mean exposure levels were consistently higher among cases 
(Table 2).  In the year 1995, mean exposures were 1.03 and 0.97 units for cases and controls, 
respectively.  The corresponding mean levels for cumulative exposure in 1960-1990 were 227.42 
and 196.71 units of average annual exposure in the year 1995.  Short-term and longer-term 
exposure estimates were highly correlated (Supplemental Material, Table S1).   
 Adjusted cubic spline figures suggested an increased breast cancer risk among women 
with the top 1% of traffic exposure levels (data not shown).  These results are based on a small 
number of women.  Hence, we used broader quantiles in regression models in order to stabilize 
the results.  ORs from logistic regression models comparing participants with the top 5% of 
exposure levels to those with exposures below the median ranged between 0.98 (95% CI: 0.62, 
1.53) for 1980-1995 exposure when we used a complete case analysis approach, and 1.44 (95% 
CI: 0.78, 2.68) for 1960-1990 exposure with up to 20% MI (Table 3).  For recent exposure in 
1995, the corresponding OR for the top 5% of exposure levels was 1.14 (95% CI: 0.80, 1.64) 
(Table 3).  Effect estimates were strongest when considering the top 5% of long-term exposure 
estimates (1960-1990, 1960-1995), rather than more recent exposures, though confidence 
intervals were wide and included the null value (Table 3).  Varying the percent of imputation 
allowed did not appreciably alter the results shown in Table 3.  Additional sensitivity analyses 
(see Supplemental Material) also indicated that our findings are robust.  
 The traffic PAH-breast cancer association was stronger among women with low 
fruit/vegetable intake (Table 4).  For example, among women with low fruit/vegetable intake, we 
observed elevated risks for the top 5% of 1995 traffic exposures compared to levels below the 
median (OR=1.46, 95% CI: 0.89, 2.40, p for trend=0.04).  Among women with high 
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fruit/vegetable intake, the corresponding OR was 0.92 (95% CI: 0.53, 1.60) (p-interaction=0.01).   
 Traffic exposure and breast cancer risk were also more strongly associated among 
premenopausal women (Table 4), though there was no clear dose-response relationship.  For 
example, the OR for the association between breast cancer and 1995 traffic exposure (75-95th 
percentile vs. below the median) was 1.64 (95% CI: 1.13, 2.38) among premenopausal women, 
but 0.80 (95% CI: 0.62, 1.02) among postmenopausal women (p-interaction=0.02).   
 Traffic exposure in 1995 (top 5% vs. below the median) was more strongly associated 
with ER-/PR-negative breast tumors (OR=1.67; 95% CI: 0.91, 3.05), rather than ER- or PR-
positive tumors (ratio of the ORs=2.09, 95% CI: 1.08, 4.06) (Table 5).  We observed no 
heterogeneity of the effect estimates for tumor p53-mutation status subtypes (data not shown). 
DISCUSSION 
We observed a modest positive association between high-level residential exposure to 
vehicular traffic PAHs and breast cancer risk in this population-based study.  The effect estimate 
for the association was increased by 14% for recent 1995 traffic exposure and by 44% for long-
term (1960-1990) exposure, although the confidence intervals were wide.  The effect estimate for 
the association between recent traffic exposure and breast cancer was increased by 46% among 
women with low fruit/vegetable intake, by 67% among those with hormone receptor-negative 
breast tumors, and by 64% among premenopausal women.  Although U.S. traffic emissions are 
greatly reduced from the high levels of the 1960s and 1970s (Beyea et al. 2008), our results may 
have public health significance given widespread exposure to traffic pollution worldwide. 
We observed stronger associations between traffic exposure and breast cancer risk among 
women with low fruit/vegetable intake, consistent with a previous LIBCSP report which found 
that associations with grilled/smoked meat intake – another major PAH source – were more 
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pronounced among participants who consumed low levels of fruits/vegetables (Steck et al. 2007).  
Similarly, fruit/vegetable intake was negatively associated with PAH-DNA adduct levels in the 
LIBCSP (Shantakumar et al. 2005) and in an epidemiologic study conducted in Europe (Palli et 
al. 2000).  Components of fruits and vegetables have antioxidant and other chemopreventive 
properties and decrease carcinogenic effects of PAHs in animals (Hecht et al. 2000, Jin et al. 
2006).  Ours is the first population-based breast cancer study to evaluate interactions between air 
pollution and nutrition, and our results require confirmation.   
 Traffic-breast cancer associations were stronger among premenopausal women in our 
study, consistent with previous LIBCSP reports regarding combined active/passive smoking 
exposure (Gammon et al. 2004b) and PAH-DNA adducts (Gammon et al. 2002c).  Similarly, a 
recent systematic review concluded that associations between environmental tobacco smoke and 
premenopausal, but not postmenopausal, breast cancer were “consistent with causality” (Johnson 
et al. 2011).  We also found stronger associations with traffic among women with ER-/PR-
negative breast tumors, which are overrepresented among premenopausal women (Chen and 
Colditz 2007).  Previous studies conducted in an area with high industrial emissions reported 
positive associations between air pollution and breast cancer that varied inconsistently by 
menopausal status, depending on the exposure definition used, and did not vary by tumor 
hormone-receptor subtype (Bonner et al. 2005, Nie et al. 2007).   
 Traffic exposure was not related to tumor p53-mutation status in our study, consistent 
with an LIBCSP report evaluating active and passive smoking, grilled/smoked meat intake, and 
PAH-DNA adducts (Mordukhovich et al. 2010).  Active, but not passive, smoking was associated 
with p53-mutation positive breast cancer in a smaller population study (Conway et al. 2002),  
 Several mechanisms potentially underlie the observed association between traffic-
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related PAHs and breast cancer risk.  PAHs are genotoxic, damaging DNA primarily through 
formation of PAH-DNA adducts; they may also induce inflammation and oxidative stress, 
resulting in oxidative DNA lesions (IARC 2010).  Uncorrected DNA damage can cause 
somatic mutations in tumor suppressor genes or proto-oncogenes, which could in turn 
contribute to carcinogenesis (Gammon and Santella 2008, IARC 2010).   
 Limitations of our study include some missing address information, which was corrected 
in part through multiple imputation.  Our results were robust to varying the percentage of 
imputation allowed (0-30%).  In addition, the exposure model did not generate non-residential 
traffic exposure estimates.  A nation-wide study reported that, on average, American men and 
women spend almost 70% of their day inside (64.97%) or just outside (2.50%) of their 
residences, both overall and in a large city (Chicago, IL) (Leech et al. 2002).  A Canadian study 
found similar results among women only (Nethery et al. 2009).   
The purpose of our exposure model was to estimate vehicular traffic exposures, thus by 
design we did not incorporate information on non-traffic sources of ambient PAHs, such as 
environmental tobacco smoke, cooking or heating (Beyea et al. 2013).  Traffic is often the largest 
source of ambient PAHs near urban areas (Fromme et al. 2004, Nielsen 1996) and generates 
smaller, more inflammatory particles than some other ambient sources (Kocbach et al. 2006).   
 Benzo[a]pyrene was modeled as a surrogate for all traffic PAHs.  Traffic pollution 
contains many chemicals, including many PAHs and other confirmed carcinogens (Boström et al. 
2002).  It is impossible to ascribe health effects to a single traffic pollutant based on an 
observational study.  However, benzo[a]pyrene is one of the most carcinogenic PAHs and is 
representative of overall PAH exposure from vehicle exhaust (Boström et al. 2002), and 
particulate PAHs are among the most carcinogenic components of traffic exhaust (Boothe and 
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Shendell 2008).  Furthermore, traffic pollutants do not have identical distributions (Beyea et al. 
2006).  In our study, exposures were modeled using PAH-specific emissions data and dispersion 
parameters, and were validated and calibrated against soil PAH levels (Beyea et al. 2006).   
 Strengths of our study include long-term, individualized traffic PAH exposure 
estimates generated from an extensively validated exposure model that incorporated 
information regarding historical tailpipe emissions, local traffic patterns, meteorological 
conditions, pollutant dispersion, deposition and decay data, building penetration, proximity to 
intersections, and background PAHs (Beyea et al. 2006).  Participants had a wide range of 
exposure levels due to the gradient of urbanization across the study area (Beyea et al. 2006).  
In addition, the LIBCSP is a large, population-based study with detailed information 
regarding many covariates, which facilitates controlling for confounders, assessing effect 
modification, and evaluating heterogeneity within breast cancer subtypes (Gammon et al. 
2002b).          
CONCLUSIONS 
We observed positive associations between breast cancer risk and comparatively high 
levels of residential traffic PAHs, particularly among women with low fruit/vegetable intake, 
hormone receptor negative tumors, and premenopausal breast cancer, although the confidence 
intervals were wide.  Future studies should examine associations between traffic exposure and 
breast cancer within larger or more highly exposed study populations, and should evaluate 
interactions with genetic variants in relevant pathways.  If confirmed, our results will contribute 
to increased understanding of breast cancer etiology, strengthen the biological plausibility of the 
relationship between vehicular traffic and breast cancer, and help identify vulnerable 
populations.  
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Table 3.1.  Distributions of cumulative residential vehicular traffic PAH exposure estimates.    
 
Traffic Exposure Yearsa N Mean Median Minimum Maximum IQR 
1995 (CCA) 2608 1.00 0.84 0.02 30.63 0.64, 1.24 
1980-1995 (CCA) 1719 22.22 18.51 1.78 389.40 13.96, 27.85 
1980-1995 (20% MI)b 1966-1983 22.21 18.41 1.78 501.81 13.80, 27.59 
1980-1995 (30% MI)b 2047-2069 22.06 18.21 1.78 501.81 13.74, 27.28 
1960-1995 (20% MI)b 1112-1152 216.64 178.92 15.84 8876.15 128.98, 256.72 
1960-1990 (20% MI)b 1095-1147 211.47 175.20 15.66 5469.61 127.77, 251.03 
1960-1990 (20% MI, peak)b,c 1095-1147 13.38 10.77 0.88 333.70 7.52, 16.34 
 
CCA: complete case analysis; IQR: interquartile range; MI: multiple imputation; PAH: polycyclic 
aromatic hydrocarbon 
a) Exposures are normalized to the mean exposure level for 1995. 
b) Combined over m=30 imputations.  Sample size varies across imputed data sets.   
c) Maximum annual exposure. 
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Table 3.2. Residential traffic polycyclic aromatic hydrocarbon exposure estimates by case-
control status. 
 
Traffic Exposure Yearsa 
Cases (n = 1,508) 
 
Controls (n = 1,556) 
 
N Mean (IQR) N Mean (IQR) 
1995 (CCA) 1274 1.03 (0.62) 1334 0.97 (0.55) 
1980-1995 (CCA) 846 22.78 (14.66) 873 21.68 (13.42) 
1980-1995 (20% MI)b 961-973 22.97 (14.12) 1004-1016 21.48 (13.39) 
1980-1995 (30% MI)b 995-1009 22.83 (14.10) 1048-1062 21.32 (13.16) 
1960-1995 (20% MI)b 528-561 232.65 (125.03) 577-608 201.94 (122.12) 
1960-1990 (20% MI)b 520-551 227.42 (125.31) 566-597 196.71 (122.06) 
1960-1990 (20% MI, peak)b,c 520-551 14.45 (9.21) 566-597 12.39 (7.96) 
 
CCA: complete case analysis; IQR: interquartile range; MI: multiple imputation                   
a) Exposures are normalized to the mean exposure level for 1995.                                                                            
b) Combined over m=30 imputations.  Sample size varies across imputed data sets.   
c) Maximum annual exposure. 
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Table 3.3.  Associations between varying time ranges of exposure to PAHs from residential 
traffic and breast cancer risk. 
  
Traffic Exposure Years Cases Controls Percentiles of 
Exposure 
Age-adjusted  
OR (95% CI)  
1995 (CCA) 645 659 <50th  1.00 (referent) 
 299 353 50-<75th  0.87 (0.72, 1.04) 
 260 261 75-<95th  1.01 (0.82, 1.23) 
 70 61 ≥95th  1.14 (0.80, 1.64) 
1980-1995 (CCA) 431 428 <50th  1.00 (referent) 
 201 230 50-<75th  0.86 (0.68, 1.08) 
 171 173 75-<95th  0.95 (0.74, 1.22) 
 43 42 ≥95th  0.98 (0.62, 1.53) 
1980-1995 (20% MI)a 491-502 498-510 <50th  1.00 (referent) 
 225-231 256-264 50-<75th  0.87 (0.70, 1.09) 
 192-195 202-205 75-<95th  0.93 (0.74, 1.18) 
 48-49 43-45 ≥95th  1.04 (0.68, 1.61) 
1980-1995 (30% MI)a 514-526 526-539 <50th  1.00 (referent) 
 230-238 266-274 50-<75th  0.87 (0.70, 1.08) 
 195-201 205-209 75-<95th  0.95 (0.75, 1.20) 
 49-50 45-46 ≥95th  1.05 (0.69, 1.61) 
1960-1995 (20% MI)a 267-301 299-327 <50th  1.00 (referent) 
 123-137 134-158 50-<75th  0.99 (0.72, 1.35) 
 97-110 110-120 75-<95th  0.92 (0.66, 1.29) 
 24-29 19-22 ≥95th  1.38 (0.74, 2.55) 
1960-1990 (20% MI)a 262-287 289-320 <50th  1.00 (referent) 
 122-139 136-155 50-<75th  0.99 (0.73, 1.36) 
 96-111 111-121 75-<95th  0.95 (0.68, 1.32) 
 24-29 19-21 ≥95th  1.44 (0.78, 2.68) 
1960-1990 (20% MI, peak)b 249-271 269-291 <50th  1.00 (referent) 
 118-126 135-151 50-<75th  0.91 (0.67, 1.25) 
 112-126 121-134 75-<95th  1.02 (0.74, 1.40)  
 32-39 27-33 ≥95th  1.29 (0.75, 2.24) 
 
CCA: complete case analysis; CI: confidence interval; MI: multiple imputation; OR: odds ratio; PAH: 
polycyclic aromatic hydrocarbon 
a) Combined over m=30 imputations.  Sample size varies across imputed data sets.    
b) Maximum annual exposure. 
143 
 
Table 3.4. Associations between residential vehicular traffic exposure and breast cancer risk, 
within strata of fruit/vegetable intake and menopausal status.  
 
Traffic Exposure 
Classifications 
Cases Controls Age-adjusted 
OR (95% CI) 
Cases Controls Age-adjusted 
OR (95% CI) 
p for 
interaction 
Fruit/vegetable Intakea  
 Low High 
1995 (CCA)  0.01 
<50th percentile 404 431 1.00 (referent) 228 215 1.00 (referent)  
50-75th percentile 193 188 1.10 (0.86, 1.41) 98 159 0.58 (0.43, 0.80)  
75-95th percentile 156 132 1.24 (0.94, 1.62) 99 120 0.78 (0.56, 1.08)  
≥95th percentile 42 30 1.46 (0.89, 2.40) 28 29 0.92 (0.53, 1.60)  
p for trend   0.04   0.14  
1960-1990 (20% MI)b,,c 0.04 
<50th percentile 169-182 174-200 1.00 (referent) 89-105 100-113 1.00 (referent)  
50-75th percentile 79-92 73-84 1.19 (0.80, 1.77) 35-45 59-70 0.67 (0.39, 1.13)  
≥75th percentile 79-89 56-64 1.43 (0.94, 2.16) 42-49 66-72 0.71 (0.43, 1.15)  
p for trend   0.09   0.12  
Menopausal Status 
Premenopausal Postmenopausal 
1995 (CCA)  0.02 
<50th percentile 190 229 1.00 (referent) 439 397 1.00 (referent)  
50-75th percentile 101 122 0.95 (0.68, 1.32) 193 222 0.79 (0.62, 1.00)  
75-95th percentile 91 67 1.64 (1.13, 2.38) 166 186 0.80 (0.62, 1.02)  
≥95th percentile 16 16 1.20 (0.58, 2.47) 51 43 1.06 (0.69, 1.63)  
p for trend   0.04   0.21  
1960-1990 (20% MI)b,c 0.50 
<50th percentile 49-66 56-73 1.00 (referent) 209-228 210-240 1.00 (referent)  
50-75th percentile 23-29 29-38 0.84 (0.42, 1.66) 95-108 101-114 1.00 (0.70, 1.42)  
≥75th percentile 23-29 19-26 1.31 (0.63, 2.71) 97-109 109-115 0.91 (0.64, 1.29)  
p for trend   0.60   0.60  
 
CCA: complete case analysis; CI: confidence interval; MI: multiple imputation; OR: odds ratio 
a) 35+ vs. 0-34 servings/week (Gaudet et al. 2004).                                                                          
b) Combined over m=30 imputations.  Sample size varies across imputed data sets.            
c) The upper quantiles were combined to avoid cell sizes of <10.  The overall OR for the association 
between traffic exposure (≥75th vs. <50th percentile) and breast cancer is 1.02 (95% CI: 0.75, 1.39). 
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Table 3.5.  Associations between residential vehicular traffic PAH exposure and the risk of breast 
cancer categorized by tumor hormone receptor status.   
 
Tumor Categories Percentiles of 
Exposure 
Cases Controls Age-adjusted  
OR (95% CI) 
ER+/PR+ vs. other subtypes (ER-/PR+, ER+/PR-, or ER-/PR-) 
ER+ and PR+ breast cancer <50th  281 659 1 
 50-<75th  105 353 0.69 (0.53, 0.90) 
 75-<95th  94 261 0.82 (0.62, 1.08) 
 ≥95th  23 61 0.86 (0.52, 1.41) 
ER- or PR- breast cancer <50th  192 659 1 
 50-<75th  70 353 0.68 (0.50, 0.91) 
 75-<95th  61 261 0.78 (0.57, 1.08) 
 ≥95th  21 61 1.15 (0.68, 1.94) 
Ratio of ORs (top quantiles: 0.86/1.15): 0.74 (0.40, 1.38) 
ER-/PR- vs. other subtypes (ER+/PR-, ER-/PR+, or ER+/PR+) 
ER- and PR- breast cancer <50th  97 659 1 
 50-<75th  41 353 0.79 (0.54, 1.16) 
 75-<95th  31 261 0.81 (0.52, 1.24) 
 ≥95th  15 61 1.67 (0.91, 3.05) 
ER+ or PR+ breast cancer <50th  376 659 1 
 50-<75th  134 353 0.66 (0.52, 0.83) 
 75-<95th  124 261 0.81 (0.63, 1.03) 
 ≥95th  29 61 0.80 (0.50, 1.27) 
Ratio of ORs (top quantiles: 1.67/0.80): 2.09 (1.08, 4.06) 
 
CI: confidence interval; ER: estrogen receptor; OR: odds ratio from polytomous logistic regression; 
PAH: polycyclic aromatic hydrocarbon; PR: progesterone receptor                             
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SUPPLEMENTAL MATERIAL 
Spearman correlation coefficients for the associations between the traffic exposure 
estimates were stronger than Pearson correlations, likely because Pearson correlation is more 
sensitive to outliers.  For example, the Pearson and Spearman coefficients comparing 1995 and 
1960-1990 (20% MI) exposures were 0.41 and 0.76, respectively.  Outlier exposure estimates in 
our study reflect truly increased exposures for these individuals due to proximity to heavily 
trafficked intersections (Beyea et al. 2006, 2013).  Thus, Pearson coefficients may be informative 
when considering women with the highest exposure levels, but Spearman coefficients are 
probably more representative of the overall ranking for most participants.   
 We also examined the association between traffic exposure during 1995 and breast cancer 
risk among women residing in their current home for 15 or more years, and found that the 
association was similar among these long-term residents (as compared to among all participants).   
 In addition, we conducted a sensitivity analysis removing the top 2 and top 5 participants 
with the highest exposure levels from regression models (1995, 1980-1995, 1960-1990) in order 
to assess the influence of outliers on the reported effect estimates. For 1960-1990 exposure (20% 
single imputation), we varied the relative contribution of the pre-arrival surrogate to total 
exposure (Beyea et al. 2013), removed the contribution of intersections from the exposure model, 
and imputed missing exposures according to census place (i.e. city, town, or village; Beyea et al. 
2013).  Emissions at intersections contribute strongly to total traffic PAH exposure because of 
the increased acceleration/deceleration that takes place there (Beyea et al. 2006). 
  Removing participants with the highest exposures attenuated effect estimates to a small 
extent (data not shown).  Halving or doubling the contribution of the pre-arrival surrogate to 
cumulative exposure or imputing according to census division did not appreciably alter our 
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results (data not shown).  After removing the contribution of intersections from the exposure 
model, we observed null associations between traffic PAH exposure and breast cancer risk (even 
among women with the highest exposures) which is consistent with a previous LIBCSP report 
indicating the importance of intersection emissions to total exposure (Beyea et al. 2006); 
however, interactions with fruit/vegetable intake were still evident (data not shown).   
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Table 3.6. Correlations between selected residential vehicular traffic PAH exposure variables.  
 
Traffic Exposure 
Years 
1995 1980-1995 
CCA 
1960-1995 
CCA 
1960-1990 
CCA 
1960-1990  
20% MIa 
Spearman correlations 
1995 1 0.95 0.85 0.84 0.76 
1980-1995 CCA  1 0.92 0.92 0.88 
1960-1995 CCA   1 1.00 1.00 
1960-1990, CCA    1 1.00 
1960-1990 20% MIa     1 
Pearson correlations 
1995 1 0.91 0.59 0.58 0.41 
1980-1995 CCA  1 0.71 0.69 0.70 
1960-1995 CCA    1 1.00 1.00 
1960-1990 CCA    1 1.00 
1960-1990 20% MIa     1 
 
CCA: complete case analysis; MI: multiple imputation; PAH: polycyclic aromatic hydrocarbon 
a) Combined over m=30 imputations; sample size varies across imputed data sets (see text for methods).   
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CHAPTER IV: POLYMORPHISMS IN DNA REPAIR GENES, TRAFFIC-RELATED 
POLYCYCLIC AROMATIC HYDROCARBON EXPOSURE, AND BREAST CANCER RISK 
 
INTRODUCTION 
Breast cancer is the most common malignancy among women in the United States (ACS 
2011-2012).  Polycyclic aromatic hydrocarbons (PAHs) are incomplete combustion by-products 
found in air pollution (Bostrom et al. 2002,  IARC 2010).  In particular, vehicular traffic is a 
major contributor to ambient PAH levels, especially near cities (Harrison et al. 1996, Nielsen 
1996).   
 PAHs are confirmed human lung carcinogens and potent mammary carcinogens in 
animal models (IARC 2010).  However, the association between PAH exposure and breast 
cancer in women is still under investigation (Gammon and Santella 2008).  PAH-DNA adducts 
(Gammon et al. 2002c, Rundle et al. 2000) and air pollution exposure (Bonner et al. 2005, 
Mordukhovich et al. 2013 [submitted], Nie et al. 2007) have been associated with breast cancer 
in prior epidemiological studies, including in our study population (Gammon et al. 2002c, 
Mordukhovich et al. 2013 [submitted]).    
 PAHs damage DNA by forming bulky adducts (Braithwaite et al. 1998) and by inducing 
oxidative stress (IARC 2010).  If unrepaired, PAH-induced DNA damage can lead to somatic 
mutations in tumor suppressor genes or proto-oncogenes, thereby contributing to carcinogenesis 
(Gammon and Santella 2008).  Hence, genetic polymorphisms that alter DNA repair capacity 
may modify associations between PAH-related exposures and breast cancer risk (Berwick and 
Vineis 2000).  Of the four major DNA repair pathways (Christmann et al. 2003), nucleotide 
excision repair (NER) and base excision repair (BER) are most likely to mend PAH-induced 
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DNA damage, since the NER pathway repairs bulky DNA adducts and the BER pathway repairs 
oxidative DNA damage (Goode et al. 2002, Braithwaite et al. 1998, Robertson et al. 2009).   
 The few studies conducted to date suggest that polymorphisms in NER and BER genes 
may interact with PAH-related exposures, such as cigarette smoke or PAH-DNA adducts, with 
respect to breast cancer risk (Crew et al. 2007, Mechanic et al. 2006, Shen et al. 2005, Terry et 
al. 2004).  However, the impact of DNA repair polymorphisms on the relationship between air 
pollution and breast cancer has not been evaluated previously.  Our study examines the 
association between residential vehicular traffic exposure and breast cancer risk within strata of 
NER and BER genotypes, using the resources of a population-based investigation (Gammon et 
al. 2002b).  Findings of this first study to examine these associations, if confirmed, will increase 
understanding of breast cancer etiology, clarify mechanisms linking traffic PAHs to breast cancer 
risk, and identify women who may be particularly susceptible to the carcinogenic effects of 
traffic pollution on the breast.   
MATERIALS AND METHODS 
Our study used data from the case-control component of the Long Island Breast Cancer 
Study Project (LIBCSP), a population-based investigation conducted among adult women (ages 
20-98) residing in Nassau and Suffolk counties in Long Island, NY (Gammon et al. 2002b).  This 
study was approved by the institutional review boards of all participating institutions.  
Study Population 
 
Case participants were diagnosed with a first primary invasive or in situ breast cancer 
between July 1996 and August 1997, and were recruited via rapid case ascertainment through 
contact with the pathology departments of local hospitals.  Control participants were women with 
no personal history of breast cancer.  Controls under age 65 were identified using random digit 
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dialing (Waksberg 1978), and those aged 65 years or older were identified via Health Care 
Finance Administration rosters.  Control participants were frequency matched based on the 
expected age distribution among the cases.  In total, 1,508 cases and 1,556 controls (82.1% and 
62.7% of eligible participants, respectively) completed the case-control study interview.  Most 
participants were post-menopausal and white, which is consistent with the underlying racial 
distribution of the study counties at the time of data collection (Gammon et al. 2002b).   
 Previous studies using LIBCSP resources reported positive associations between several 
PAH-related exposures and overall breast cancer risk: elevated PAH-DNA adducts in 
mononuclear cells (Gammon et al. 2002c), long-term residential exposure to environmental 
tobacco smoke (Gammon et al. 2004b), increased consumption of grilled/smoked meat (Steck et 
al. 2007), and the top 5% of long-term residential vehicular traffic exposures, compared with 
exposures below the median (Mordukhovich et al. 2013 [submitted]).    
Study Questionnaire 
Trained interviewers administered a two-hour structured questionnaire in participants' 
homes (Gammon et al. 2002b).  The questionnaire evaluated detailed information regarding a 
wide range of factors used in our analyses, including lifetime residential history, demographic 
characteristics, reproductive and medical history, and body size (Gammon et al. 2002b).  
Traffic Exposure Assessment 
 
Participants' historical residential traffic-related PAH exposures were reconstructed using 
a model which incorporated lifetime residential history in the study counties, historical U.S. 
vehicular PAH emissions and roadway-specific traffic patterns, local meteorological data, 
pollutant dispersion factors, and excess emissions at intersections (Beyea et al. 2005, 2006, 2008, 
2013).  In a validation study, the model accurately predicted residential soil PAH measurements 
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as well as participants' levels of PAH-DNA adducts in mononuclear cells (Beyea et al. 2006).   
 Exposure estimates were reconstructed for the years 1960-1990 and 1995.  Some 
participants moved to the study area after 1960, and others had periods of incomplete address 
data while residing in the study counties.  Hence, an exposure surrogate was developed to 
estimate pre-arrival exposures, with variance added during multiple imputation (MI), and 
missing post-arrival exposures were calculated via MI based on participants' known residential 
addresses (Beyea et al. 2013, Rubin 1996).  The percentage of imputation was restricted to ≤20% 
of total 1960-1990 exposure (Mordukhovich et al. 2013 [submitted]).  For 1995 exposure, only 
women with complete, unimputed exposure information were included in regressions (denoted as 
a complete case analysis (CCA)).  
 Because our exposure model predicted benzo[a]pyrene levels as a surrogate for all traffic 
PAHs, exposure estimates were normalized to the mean exposure level for the year 1995 and 
presented as relative units of average annual exposure during 1995 (Beyea et al. 2006, 2013).  
Exposures in the year 1995 ranged between 0.02 and 31 relative units (mean=1.0), and 
cumulative exposures during the years 1960-1990 (20% MI) ranged between 16 and 5467 
relative units of average annual exposure in 1995 (mean=212) (Mordukhovich et al. 2013 
[submitted]).  Most LIBCSP participants had lived in their current home for at least 15 years 
(Gammon et al. 2002b), and previously reported correlations between exposures in 1995 and 
1960-1990 were strong (Mordukhovich et al. 2013 [submitted]). 
Blood Sample Collection and DNA Extraction 
 
Study interviewers, who were either nurses or certified phlebotomists, obtained a 40 mL 
non-fasting blood sample at the study visit from 73% of both cases and control participants 
(Gammon et al. 2002b).  Blood samples were collected in EDTA-treated tubes and shipped 
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overnight to a laboratory in Columbia University, where they were aliquoted and stored in -80°C 
freezers using participants’ randomly assigned study identification numbers (Gammon et al. 
2002b).   
Mononuclear cells were separated from whole blood using Ficoll (Sigma Chemical Co., 
St. Louis, MO), washed twice with phosphate-buffered saline, and frozen until DNA isolation 
(Gammon et al. 2002b).  DNA was extracted using phenol and chloroform isoamyl alcohol, 
followed by RNase and proteinase K treatment (Gammon et al. 2002b, Shen et al. 2005).   
Genotyping 
 
Our study evaluated single nucleotide polymorphisms (SNPs) in the following genes: 
excision repair cross-complementing group 1 (ERCC1, 8092C/A), 8-oxoguanine DNA 
glycosylase 1 (OGG1, Ser326Cys), x-ray repair cross complementing group 1 (XRCC1, 
Arg399Gln and Arg194Trp), and xeroderma pigmentosum groups A (XPA, -4A/G), D (XPD, 
Lys751Gln and Asp312Asn), F (XPF, Arg415Gln), and G (XPG, Asp1104His).  These SNPs 
were previously found to be in Hardy-Weinberg equilibrium among LIBCSP controls (Crew et 
al. 2007, Rossner et al. 2006, Shen et al. 2005, Terry et al. 2004).  Genotyping was completed for 
91-97% of women who donated a blood sample, depending on the polymorphism (n=2,050-
2,177); missing genotype data was mainly due to insufficient DNA available for assays (Crew et 
al. 2007, Rossner et al. 2006, Shen et al. 2005, Terry et al. 2004).    
Several high-throughput genotyping methods are available for use in epidemiological 
studies, and the methods used in the LIBCSP have changed over time.  SNPs in ERCC1, XRCC1, 
OGG1 and XPD (Lys751Gln) were genotyped using fluorescence polarization (FP) (Crew et al. 
2007, Rossner et al. 2006, Shen et al. 2005, Terry et al. 2004), which identifies the polymorphic 
base using a template-directed, dye-labeled dideoxynucleotide (Shen et al. 2008).  SNPs in XPA 
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and XPD (Asp312Asn) were genotyped using the Taqman assay (Applied Biosystems, Foster 
City, CA) (Crew et al. 2007), which uses fluorogenic oligonucleotide reverse probes for allele 
recognition.  SNPs in XPF and XPG were genotyped using Sequenom's high-throughput matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry, chosen for its ability to 
multiplex (BioServe Biotechnologies, Laurel, MD) (Crew et al. 2007).  
Quality control measures included negative and positive controls for genotype on each 
plate (Crew et al. 2007).  In addition, duplicates for approximately 10% of DNA samples were 
selected for re-sampling.  As previously reported, concordance between duplicate samples was 
high for all SNPs (κ>90%; Crew et al. 2007, Rossner et al. 2006, Shen et al. 2005, Terry et al. 
2004).   Laboratory personnel were blinded to case-control status and duplicate sample status.   
Statistical Methods 
 
Our study examined associations between tertiles of traffic-related PAH exposure (years 
1995 and 1960-1990) and breast cancer risk within strata of NER and BER polymorphisms.  We 
evaluated PAH exposures for the year 1995 in order to maximize statistical power for gene-
environment interaction analyses.  We also evaluated 1960-1990 exposure estimates, as these 
may be a more accurate reflection of long-term exposure opportunity.  We chose a categorical 
exposure variable because of the previously reported non-linear relationship between traffic 
PAHs and breast cancer risk in the LIBCSP (Mordukhovich et al. 2013 [submitted]).   
 We used unconditional logistic regression to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs) (Hosmer and Lemeshow 1989).  Trend tests (n=45) were conducted 
within stratified models, and likelihood ratio tests (n=18) were used to assess multiplicative 
interactions between traffic PAHs and SNPs (Rothman and Greenland 1998).  When evaluating 
1960-1990 exposures, effect estimates and confidence limits were combined across 30 imputed 
154 
 
data sets using Rubin's rules (Rubin 1996).  Statistical analyses were conducted using SAS 
version 9.3 (SAS Institute, Cary, NC).  No adjustment for multiple comparisons was made.   
 Potential confounders (educational attainment, household income, race, religion, parity, 
age at first birth, body mass index (kg/m2)) were identified by a thorough literature review and 
analysis of causal diagrams (Mordukhovich et al. 2013 [submitted], Shrier and Platt 2008).  No 
covariates were retained using the 10% change in estimate criterion (Rothman and Greenland 
1998) relative to age-adjusted models (Mordukhovich et al. 2013 [submitted]).  Hence, 
regression models are adjusted only for the frequency matching factor, five-year age group.  
 Participants with heterozygote, variant homozygote, and homozygous major genotypes 
were considered separately in our study.  We chose this approach because there was no a priori 
reason to combine women with heterozygote and variant homozygote genotypes into a single 
group, and because previous LIBCSP reports evaluating interactions between DNA repair 
polymorphisms and PAH-related exposures suggested differences between participants with 
heterozygote and variant homozygote genotypes that were not present when evaluating the main 
effects of these SNPs on breast cancer risk (Crew et al. 2007, Terry et al. 2004).  However, 
participants with heterozygote and variant homozygote genotypes were combined when tertile-
specific cell sizes comprised fewer than 10 cases and 10 controls (Peduzzi et al. 1996).   
 Finally, in a post-hoc analysis, we combined individual SNPs showing evidence of 
interactions with traffic PAHs.  Using a previously reported method (Crew et al. 2007, Mechanic 
et al. 2006), we examined traffic-breast cancer associations stratified according to the number of 
'high-risk' alleles (0-2, 3-4, ≥5) from the following SNPs: XPD Lys751Gln (Gln), XRCC1 
Arg194Trp (Trp), XRCC1 Arg399Gln (Arg), and OGG1 Ser326Cys (Ser).   
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RESULTS 
 The number of LIBCSP participants with available exposure estimates varied according 
to the traffic PAH exposure definition (1995 vs. 1960-1990 estimates) and the imputed data set 
(some women were not included in all 30 imputed data sets because they exceeded the 20% limit 
on imputation percentage for certain imputation draws; Beyea et al. 2013, Mordukhovich et al. 
2013 [submitted], Rubin 1996).  Sample size also varied by the polymorphisms considered 
(XPD, XPF, XPG, ERCC1, OGG1, and XRCC1). Specifically, the study population size with 
SNP assays completed varied as follows: 1995 traffic estimates, 848-915 cases and 913-964 
controls; 1960-1990 traffic estimates, 332-429 cases and 368-474 controls (Tables 1 and 2). 
 Among women with available genotyping data, ORs for the association between traffic 
exposure (highest vs. lowest tertile) and breast cancer risk were 1.01 (95% CI: 0.80, 1.26) and 
1.04 (95% CI: 0.81, 1.33) for 1995 and 1960-1990 exposures, respectively.  We present 
associations between traffic PAHs and breast cancer risk within strata of DNA repair SNPs in 
Tables 1 and 2.   
 We found no evidence of interactions between traffic PAHs and the following SNPs: XPA 
-4A/G, XPF Arg415Gln, XPG Asp1104His, ERCC1 8092C/A, and XPD Asp312Asn. This lack 
of heterogeneity within genotype strata was evident regardless of whether we considered traffic 
PAHs estimated for 1995 (Table 1) or 1960-1990 (Table 2).   
 The association between vehicular traffic exposure in 1995 and breast cancer risk was of 
larger magnitude and greater precision among women with the homozygous variant genotype for 
the XPD Lys751Gln polymorphism: OR (highest vs. lowest tertile) = 2.27 (95% CI: 1.22, 4.23; p 
for trend=0.01) (Table 1).  Among women with the homozygous major or heterozygous 
genotypes, the corresponding ORs were 0.88 (95% CI: 0.61, 1.26) and 0.91 (95% CI: 0.65, 1.26), 
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respectively (p-interaction=0.03).  Results for this SNP were similar, though less precise, when 
evaluating cumulative exposure for the years 1960-1990 (Table 2).   
 The relationship between 1960-1990 traffic exposure and breast cancer risk was also 
stronger among women with at least one variant allele for the XRCC1 Arg194Trp polymorphism 
(OR=3.04, 95% CI:0.97, 9.51; p for trend=0.049, p-interaction=0.30), among women with the 
homozygous major genotype for XRCC1 Arg399Gln (OR=1.88, 95% CI: 1.04, 3.41; p for 
trend=0.04, p-interaction=0.59), and among women with the homozygous major genotype for 
OGG1 Ser326Cys (OR=1.77, 95% CI: 1.09, 2.88; p for trend=0.02, p-interaction=0.52) (Table 
2).  The results were similar, but less precise and of smaller magnitude, when evaluating 1995 
exposures (Table 1).   
 We examined the associations between traffic PAHs (highest vs. lowest tertile) and breast 
cancer risk stratified by the number of high-risk alleles in XPD (Lys751Gln), XRCC1 
(Arg194Trp), XRCC1 (Arg399Gln), and OGG1 (Ser326Cys).  These SNPs were selected based 
on results presented in Tables 1 and 2.  The ORs were strongest among women with 5 or more 
'high-risk' variants (1995: OR = 3.22, 95% CI: 1.56, 6.66, p for trend = 0.002; 1960-1990: OR = 
3.95, 95% CI: 1.24, 12.58, p for trend = 0.02), with no clear evidence of a positive association 
among those with fewer (0-2 or 3-4) high-risk variants (Table 3). 
DISCUSSION 
 
In the first breast cancer study to evaluate interactions between vehicular traffic and DNA 
repair polymorphisms, the estimated association between traffic exposure (upper vs. lower 
tertiles) and breast cancer risk was of two-fold greater magnitude among women with the 
homozygous variant genotype for the XPD Lys751Gln polymorphism.  This finding is consistent 
with the existing literature regarding XPD, PAH exposures, and breast cancer risk (Crew et al. 
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2007, Tang et al. 2002, Terry et al. 2004).  In addition, the association between long-term traffic 
exposure and breast cancer was of three-fold greater magnitude among those with the 
homozygous major genotype for XRCC1 Arg399Gln, and of nearly two-fold greatter magnitude 
among women with the homozygous major genotype for OGG1 Ser326Cys or with at least one 
variant allele for XRCC1 Arg194Trp. However, the associated confidence intervals were wide.  If 
replicated, our findings may have public health significance due to widespread exposure to 
traffic emissions worldwide.   
 Air pollution, an important PAH source (Bonner et al. 2002, Harrison et al. 1996, Nielsen 
1996), has been associated with breast cancer risk in other population studies (Bonner et al. 
2005, Nie et al. 2007).  The LIBCSP previously reported positive associations between trafic 
PAHs and breast cancer risk among biologically plausible subgroups of women, including those 
with very high long-term exposures, premenopausal breast cancer, hormone-receptor negative 
breast tumors, or low intake of fruits/vegetables (Mordukhovich et al. 2013 [submitted]).   
 PAHs damage DNA by causing bulky adducts (Braithwaite et al. 1998) and oxidative 
lesions (Goode et al. 2002), and the resulting damage can be repaired through NER and BER 
pathways (Braithwaite et al. 1998, Goode et al. 2002, Robertson et al. 2009,  Wood 1997). NER 
is a complex process involving many proteins, including XPA, which recognizes DNA damage, 
and XPD, which unwinds DNA at the lesion site; ERCC1, XPF and XPG excise the damaged 
nucleotide fragment (Wood 1997).  Proteins involved in BER include OGG1, which recognizes 
DNA damage and removes the damaged nucleotide, and XRCC1, a scaffolding protein 
(Robertson et al. 2009).  Functional variants in the DNA repair genes encoding these proteins 
may modify associations between traffic PAHs and breast cancer risk (Berwick and Vineis 2000).    
 Studies evaluating the main effects of DNA repair genotypes on breast cancer risk report 
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inconsistent associations for most NER and BER polymorphisms (Choi et al. 2003, Crew et al. 
2007, Mechanic et al. 2006).  Variants in XPD are more consistently related to breast cancer, 
including in several meta-analyses (Manuguerra et al. 2006, Qiu et al. 2010).  The LIBCSP 
likewise reports modest positive associations between breast cancer risk and polymorphisms in 
XPD (Crew et al. 2007, Terry et al. 2004), but not other NER or BER genes (Crew et al. 2007, 
Rossner et al. 2006, Shen et al. 2005).   
 Our study found that the association between vehicular traffic exposure and breast cancer 
risk was of two times greater magnitude among women with the homozygous variant genotype 
for the XPD Lys751Gln polymorphism.  This is consistent with a previous report from our study 
population, which observed that the association between breast cancer and variant allele 
homozygosity for this SNP was limited to those with PAH-DNA adduct levels above the median 
and to current smokers (Terry et al. 2004).  The Lys751Gln polymorphism is also linked to PAH-
related DNA damage in epidemiological studies (Matullo et al. 2003, Palli et al. 2001), including 
increased levels of PAH-DNA adducts in breast tissue (Tang et al. 2002).  Hence, the literature 
regarding PAH-related exposures, the XPD Lys751Gln polymorphism, and breast cancer risk has 
been consistent to date (Gammon and Santella 2008).   
In contrast, associations with other NER and BER variants have been inconsistently 
reported.  For example, we observed that effect estimates for the relationship between traffic 
PAHs and breast cancer were 3-fold higher among women with the homozygous major genotype 
for the XRCC1 Arg399Gln polymorphism, consistent with a study which reported an inverse 
association between the variant allele for this SNP and PAH-DNA adducts in lung tissue 
(Zienolddiny et al. 2006).  However, the LIBCSP investigators have previously reported positive 
associations between the variant XRCC1-399Gln allele and breast cancer among women with 
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detectable PAH-DNA adducts and among never smokers (Shen et al. 2005).            
 We also report associations of nearly two-fold greater magnitude between traffic exposure 
and breast cancer risk among women with at least one variant allele for the XRCC1 Arg194Trp 
polymorphism and among those with the homozygous major genotype for the OGG1 Ser326Cys 
polymorphism.  Previous studies found no evidence of interactions between these 
polymorphisms and active smoking (OGG1, XRCC1) or PAH-DNA adducts (XRCC1) (Shen et 
al. 2005, Rossner et al. 2006).  Consistent with our results, epidemiologic studies reported 
positive associations between the variant XRCC1 Trp194Arg SNP and micronucleus frequencies 
among coke oven workers, who are exposed to high levels of PAHs (Leng et al. 2005), as well as 
PAH-DNA adducts in lung tissue (Zienolddiny et al. 2006).  However, only the variant OGG1 
Ser326Cys polymorphism has been linked to DNA damage endpoints, such as oxidative DNA 
lesions (Tarng et al. 2001), in several investigations (Aka et al. 2004, Bravard et al. 2009).   
 Finally, we report no evidence of interactions between traffic PAHs and SNPs in XPA, 
XPF, XPG, ERCC1, and XPD (Asp312Asn only).  These findings are consistent with a previous 
LIBCSP report evaluating interactions between PAH-DNA adducts, smoking, and 
polymorphisms in XPA, XPF, and XPG with respect to breast cancer risk (Crew et al. 2007).  
This same study reported evidence of interactions between PAH-DNA adducts, but not active or 
passive smoking, and the ERCC1 8092C/A and XPD Asp312Asn SNPs (Crew et al. 2007).   
  These inconsistencies in the literature could be due in part to the use of different PAH 
exposure surrogates across studies: we evaluated air pollution, while other investigations focused 
on cigarette smoking and PAH-DNA adducts.  This complicates interpretation of study results, as 
PAH sources vary with regard to a range of properties, including exposure levels and pathways, 
particle size, and co-pollutants (IARC 2010).  Differing results across sources of PAH exposure 
160 
 
may also suggest a more complicated role for certain polymorphisms.  For example, DNA repair 
polymorphisms could interact differently with lower- and higher-level PAH exposures.  Also, 
variations in study methodology, exposure and outcome definitions, and participant 
characteristics, as well as possible chance findings, may underlie inconsistent findings.    
 Interpretation of our study results requires careful consideration of our study limitations 
as well as our strengths. Our study had limited power for evaluating lower level interactions, 
particularly when examining long-term traffic exposures, which increases the likelihood of both 
false positive and false negative findings (Rothman and Greenland 1998).  We also did not have 
sufficient statistical power to evaluate interactions between DNA repair polymorphisms and 
high-level residential traffic exposures among the most highly exposed 1-5% of study subjects 
(Mordukhovich et al. 2013 [submitted]), due to sample size constraints within genetic subgroups.  
This may have attenuated or obscured some associations.  In addition, our results were not 
adjusted for multiple comparisons.  However, we used a targeted pathway approach in carefully 
selecting NER and BER polymorphisms that were likely to interact with traffic PAH exposures 
(Braithwaite et al. 1998, Goode et al. 2002).    
 Ours is the first study to evaluate the impact of variation in DNA repair genes on the 
association between breast cancer risk and air pollution, a ubiqutious and generalizable exposure 
source (Bostrom et al. 2002).  It is one of only a small number of breast cancer studies to 
examine interactions between DNA repair variants and any PAH-related exposure (Crew et al. 
2007, Mechanic et al. 2006, Shen et al. 2005, Terry et al. 2004).  Thus, we believe our 
investigation is an important addition to the sparse literature for this topic.  Furthermore, our 
results for the XPD Lys751Gln SNP are consistent with the growing literature regarding this 
DNA repair gene, PAH exposures, and breast cancer risk, which increases confidence in our 
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findings (Crew et al. 2007, Tang et al. 2002, Terry et al. 2004).  Other strengths of our study 
include the use of a sophisticated, validated model to reconstruct historical traffic exposures 
(Beyea et al. 2006, 2013), and extensive quality control procedures which were implemented for 
genotyping assays and questionnaire data (Crew et al. 2007, Gammon et al. 2002b).   
CONCLUSIONS 
 
Associations between vehicular traffic and breast cancer were 2- to 3-fold greater among 
women with polymorphisms in certain nucleotide excision repair and base excision repair genes, 
although confidence intervals were wide.  This is the first breast cancer study to examine 
interactions between air pollution and DNA repair polymorphisms, and our findings require 
confirmation in larger studies.  Future breast cancer studies should also evaluate interactions 
between traffic exposures and genetic variants in oxidative stress and carcinogen metabolizing 
pathways.  Our findings, if confirmed, may help identify women who are particularly susceptible 
to the carcinogenic effects of traffic pollution on the breast, and may help clarify mechanisms 
linking traffic PAHs to breast cancer risk. 
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Table 4.1. Associations between traffic polycyclic aromatic hydrocarbon (PAH) exposure in 
1995 and breast cancer, stratified by DNA repair genotype.   
 
DNA Repair 
Polymorphisms 
Associations between Tertiles of Traffic Exposure and Breast Cancer 
within Genotype Strata 
 
Genotypea Cases (n)  
Controls 
(n) 
Tertile of 
exposureb 
Age-adjusted  
OR (95% CI) 
p for 
trend   p
c 
XPA -4A/G GG 128 132 1 1.0 0.81 0.62 
  134 141 2 0.96 (0.68, 1.35)   
  146 153 3 0.96 (0.69, 1.34)   
 GA 153 140 1 1.0 0.83  
  114 157 2 0.65 (0.46, 0.91)   
  142 120 3 1.06 (0.75, 1.48)   
 AA 31 35 1 1.0 0.88  
  29 50 2 0.66 (0.34, 1.28)   
  32 30 3 1.08 (0.53, 2.19)   
ERCC1 8092C/A CC 154 164 1 1.0 0.49 0.47 
  139 204 2 0.69 (0.51, 0.95)   
  165 150 3 1.12 (0.81, 1.53)   
 CA 140 127 1 1.0 0.47  
  116 126 2 0.83 (0.59, 1.18)   
  127 129 3 0.88 (0.62, 1.24)   
 AA 17 18 1 1.0 0.84  
  24 18 2 1.40 (0.57, 3.46)   
  24 22 3 1.12 (0.46, 2.74)   
XPF Arg415Gln GG 250 250 1 1.0 0.86 0.47 
  225 280 2 0.78 (0.61, 1.01)   
  248 244 3 0.98 (0.76, 1.26)   
 GA or AA 48 51 1 1.0 0.49  
  43 60 2 0.75 (0.43, 1.31)   
  52 44 3 1.23 (0.69, 2.16)   
XPG Asp1104His GG 189 167 1 1.0 0.46 0.17 
  133 186 2 0.62 (0.46, 0.84)   
  155 147 3 0.91 (0.67, 1.24)   
 GC 92 111 1 1.0 0.97  
  113 118 2 1.10 (0.75, 1.62)   
  109 120 3 1.01 (0.69, 1.49)   
 CC 17 20 1 1.0 0.34  
  17 26 2 0.77 (0.32, 1.89)   
  23 18 3 1.52 (0.62, 3.71)   
XPD Lys751Gln AA 123 124 1 1.0 0.47 0.033 
  97 140 2 0.68 (0.47, 0.97)   
  112 124 3 0.88 (0.61, 1.26)   
 AC 148 131 1 1.0 0.58  
  141 157 2 0.77 (0.56, 1.08)   
  155 146 3 0.91 (0.65, 1.26)   
 CC 36 53 1 1.0 0.011  
  40 51 2 1.15 (0.64, 2.08)   
  49 31 3 2.27 (1.22, 4.23)   
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XPD Asp312Asn GG 123 141 1 1.0 0.55 0.98 
  109 152 2 0.80 (0.56, 1.13)   
  133 131 3 1.11 (0.79, 1.57)   
 GA 147 120 1 1.0 0.29  
  128 147 2 0.69 (0.49, 0.96)   
  145 138 3 0.83 (0.59, 1.16)   
 AA 41 46 1 1.0 0.29  
  38 50 2 0.88 (0.48, 1.59)   
  42 33 3 1.42 (0.76, 2.65)   
XRCC1 Arg399Gln GG 124 137 1 1.0 0.91 0.98 
  108 123 2 0.95 (0.66, 1.35)   
  121 133 3 0.98 (0.69, 1.39)   
 GA 157 141 1 1.0 0.73  
  139 183 2 0.66 (0.48, 0.91)   
  166 135 3 1.06 (0.76, 1.46)   
 AA 31 31 1 1.0 0.83  
  35 45 2 0.79 (0.40, 1.53)   
  34 36 3 0.92 (0.46, 1.83)   
XRCC1 Arg194Trp CC 277 266 1 1.0  0.70  0.20 
  250 308 2 0.76 (0.60, 0.96)   
  277 267 3 0.95 (0.75, 1.21)   
 CT or TT 35 42 1 1.0 0.22  
  32 43 2 0.89 (0.47, 1.71)   
  43 36 3 1.49 (0.79, 2.81)   
OGG1 Ser326Cys CC 191 197 1 1.0 0.75 0.62 
  149 202 2 0.75 (0.56, 1.00)   
  183 173 3 1.06 (0.79, 1.42)   
 GC 101 97 1 1.0 0.80  
  111 123 2 0.84 (0.58, 1.24)   
  115 113 3 0.94 (0.64, 1.39)   
 GG 14 12 1 1.0 0.89  
  16 19 2 0.72 (0.26, 2.01)   
  15 14 3 0.92 (0.32, 2.66)   
 
a) Women with heterozygote and homozygote variant genotypes were combined to avoid cell sizes of <10  
b) Traffic PAH exposures were calculated as units of average annual exposure in 1995.  Tertiles: 0-0.70, 
0.71-1.04, and ≥1.05 relative units. Tertile-specific exposure values are not presented because only 
relative rather than absolute traffic PAH exposures were estimated (see text for methods).     
c) p for interaction. 
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Table 4.2.  Associations between traffic polycyclic aromatic hydrocarbon (PAH) exposure in 
1960-1990 and breast cancer, stratified by DNA repair genotype.     
DNA Repair 
Polymorphisms 
Associations between Tertiles of Traffic Exposure and Breast Cancer 
within Genotype Strata 
Genotypea Cases (n)  
Controls 
(n) 
Tertile of 
exposureb 
Age-adjusted  
OR (95% CI) 
p for 
trend   p
c  
XPA -4A/G GG 51-63d 63-74 1 1.0 0.74 0.41 
  67-67 53-62 2 1.32 (0.78, 2.24)   
  49-58 54-59 3 1.08 (0.63, 1.87)   
 GA or AA 60-75 76-92 1 1.0 0.11  
  57-67 84-97 2 0.87 (0.52, 1.43)   
  78-90 60-76 3 1.50 (0.91, 2.47)   
ERCC1 8092C/A CC 57-68 75-88 1 1.0 0.47 0.63 
  63-72 72-86 2 1.11 (0.68, 1.82)   
  60-72 64-73 3 1.21 (0.73, 2.01)   
 CA or AA 56-71 64-78 1 1.0 0.24  
  56-66 66-76 2 0.89 (0.53, 1.51)   
  68-75 50-61 3 1.39 (0.82, 2.36)   
XPF Arg415Gln GG 93-109 109-130 1 1.0 0.15 0.57 
  100-112 121-135 2 0.98 (0.66, 1.45)   
  105-118 85-101 3 1.37 (0.91, 2.06)   
 GA or AA 17-25 24-31 1 1.0 0.91  
  13-19 17-23 2 1.04 (0.41, 2.66)   
  17-21 19-24 3 1.03 (0.42, 2.53)   
XPG Asp1104His GG 64-78 68-82 1 1.0 0.34 0.55 
  57-68 79-92 2 0.81 (0.49, 1.34)   
  67-78 53-67 3 1.31 (0.78, 2.18)   
 GC or CC 43-56 60-74 1 1.0 0.51  
  52-59 55-64 2 1.22 (0.69, 2.16)   
  49-58 53-61 3 1.22 (0.69, 2.14)   
XPD Lys751Gln AA 38-49 52-65 1 1.0 0.57 0.50 
  51-58 55-64 2 1.24 (0.71, 2.18)   
  47-53 51-59 3 1.19 (0.66, 2.12)   
 AC 59-70 61-73 1 1.0 0.42  
  50-58 63-74 2 0.79 (0.46, 1.35)   
  60-69 48-56 3 1.27 (0.74, 2.16)   
 CC 10-16 23-29 1 1.0 0.10  
  17-21 18-23 2 1.77 (0.66, 4.74)   
  19-24 16-21 3 2.24 (0.80, 6.25)   
XPD Asp312Asn GG 47-57 58-74 1 1.0 0.61 0.57 
  51-61 63-73 2 1.07 (0.62, 1.83)   
  49-57 52-62 3 1.16 (0.66, 2.05)   
 GA or AA 64-81 79-94 1 1.0 0.18  
  65-77 75-88 2 1.02 (0.63, 1.66)   
  77-87 63-74 3 1.40 (0.87, 2.26)   
XRCC1 Arg399Gln GG 36-45 56-69 1 1.0 0.039 0.59 
  49-60 50-59 2 1.51 (0.85, 2.68)   
  55-65 41-51 3 1.88 (1.04, 3.41)   
 GA 60-74 62-79 1 1.0 0.93  
  55-64 70-88 2 0.83 (0.50, 1.40)   
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  62-69 59-68 3 1.02 (0.61, 1.72)   
 AA 12-19 16-21 1 1.0 0.98  
  11-16 17-22 2 0.74 (0.25, 2.18)   
  11-17 13-17 3 1.07 (0.36, 3.18)   
XRCC1 Arg194Trp CC 102-121 122-144 1 1.0  0.44 0.30 
  104-116 122-137 2 0.99 (0.68, 1.46)   
  110-121 104-117 3 1.17 (0.79, 1.73)   
 CT or TT 10-14 17-24 1 1.0 0.049  
  16-20 20-24 2 1.61 (0.54, 4.76)   
  19-23 13-18 3 3.04 (0.97, 9.51)   
OGG1 Ser326Cys CC 65-78 88-106 1 1.0 0.022 0.52 
  64-75 78-90 2 1.14 (0.71, 1.84)   
  77-90 58-69 3 1.77 (1.09, 2.88)   
 GC or GG 46-57 48-56 1 1.0 0.52  
  50-60 57-70 2 0.87 (0.49, 1.54)   
  49-56 57-68 3 0.84 (0.48, 1.47)   
 
a) Women with heterozygote and homozygote variant genotypes were combined to avoid cell sizes of <10 
b) Traffic PAH exposures were calculated as units of average annual exposure in 1995.  Tertiles: 0-144.50, 
144.51-220.35, and ≥220.36 relative units. 
c) p for interaction. 
d) Effect estimates and their associated confidence intervals were combined across 30 imputed data sets; 
sample sizes vary across data sets because some women exceeded the 20% limit on imputation percentage 
for certain imputation draws. 
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Table 4.3.  Associations between traffic PAH exposure and breast cancer, stratified by combined 
DNA repair genotypes in XPD, XRCC1, and OGG1.    
 
 
Number of 
High-Risk  
Allelesa 
 
 
Associations between Tertiles of Traffic PAHs and Breast Cancer 
within Genotype Strata 
 
1995 (CCA) 1960-1990 (≤20% MI) 
Cases (n) Controls (n) Age-adjusted  
OR (95% CI)b 
Cases (n) Controls (n) Age-adjusted  
OR (95% CI)b,c 
0-2 28 35 1.0 13-17 16-23 1.0 
 27 46 0.73 (0.37, 1.46) 8-14 10-15 1.17 (0.38, 3.61) 
 30 35 1.06 (0.52, 2.14) 8-12 18-22 0.57 (0.18, 1.76) 
p for trend   0.87   0.42 
3-4 106 96 1.0 28-41 38-45 1.0 
 84 104 0.69 (0.46, 1.04) 45-53 50-59 1.09 (0.57, 2.06) 
 92 96 0.83 (0.55, 1.24) 39-45 34-41 1.26 (0.63, 2.53) 
p for trend   0.35   0.52 
5-8 24 44 1.0 5-10 21-29 1.0 
 24 38 1.15 (0.56, 2.35) 9-12 9-14 3.05 (0.83, 11.26) 
 38 22 3.22 (1.56, 6.66) 17-21 13-17 3.95 (1.24, 12.58) 
p for trend   0.0019   0.016 
 
CCA: complete case analysis; MI: multiple imputation; PAH: polycyclic aromatic hydrocarbon (see text 
for methods). 
a) Alleles were combined from the following genes: XPD Lys751Gln (Gln), XRCC1 Arg194Trp (Arg), 
XRCC1 Arg399Gln (Arg), and OGG1 Ser326Cys (Ser). 
b) Traffic PAH exposures were calculated as units of average annual exposure in 1995.  Tertiles (1995): 0-
0.70, 0.71-1.04, and ≥1.05 relative units.  Tertiles (1960-1990): 0-144.50, 144.51-220.35, and ≥220.36 
relative units. 
c)  Effect estimates and their associated confidence intervals were combined across 30 imputed data sets; 
sample sizes vary across data sets because some women exceeded the 20% limit on imputation percentage 
for certain imputation draws.  
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CHAPTER V: DISCUSSION 
REVIEW OF STUDY AIMS 
The primary aims of this dissertation were to evaluate associations between historical 
residential exposure to vehicular traffic-related polycyclic aromatic hydrocarbons (PAHs) and 
breast cancer risk, overall and within strata of nucleotide excision repair (NER) and base 
excision repair (BER) polymorphisms, using the resources of a population-based case-control 
study (the Long Island Breast Cancer Study Project (LIBCSP); Gammon et al. 2002b).  
Secondary aims of this study were to assess interactions between traffic PAHs and fruit and 
vegetable intake, as well as menopausal status, with respect to breast cancer risk, and to evaluate 
associations between traffic PAH exposure and breast cancer considered as subtypes of tumor 
hormone receptor status and somatic p53 mutation status.   
SUMMARY OF RESULTS 
Positive associations were observed between higher-level residential exposure to 
vehicular traffic PAHs and breast cancer risk.  In adjusted cubic spline figures, an increased 
breast cancer risk among women with the top 1% of vehicular traffic exposure levels was 
evident, and in logistic regression models that compared participants with the top 5% of traffic 
PAH exposures to those with exposures below the median, effect estimates for breast cancer 
were increased by 14% for recent 1995 traffic exposures and by 44% for cumulative exposures 
during 1960-1990.  Associations between traffic exposure in 1995 and breast cancer risk were 
increased by 46% among women with low fruit/vegetable intake, and by 67% and 64% among 
those with hormone receptor-negative breast tumors or premenopausal breast cancer, 
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respectively.  However, confidence intervals for all of these estimates were wide. 
 The association between traffic PAH exposure (upper vs. lower tertiles) and breast cancer 
risk was also increased more than two-fold among women with the XPD Lys751Gln 
homozygous variant genotype.  The association between cumulative 1960-1990 traffic exposure 
and breast cancer risk was three times higher for those with homozygous wild-type genotypes for 
XRCC1 Arg399Gln, and nearly two times higher for women with homozygous wild-type 
genotypes for the OGG1 Ser326Cys polymorphism or with at least one variant allele for the 
XRCC1 Arg194Trp polymorphism.  No interactions were observed between recent or long-term 
traffic PAH exposure and the following DNA repair polymorphisms: XPA -4A/G, XPF 
Arg415Gln, XPG Asp1104His, ERCC1 8092C/A, and XPD Asp312Asn. 
COMPARISON TO PREVIOUS INVESTIGATIONS 
Previous studies have reported positive associations between residential air pollution 
exposure and breast cancer (Bonner et al. 2005, Crouse et al. 2010, Lewis-Michl et al. 1996, Nie 
et al. 2007, Raaschou-Nielsen et al. 2011).  In a breast cancer study conducted in Buffalo NY, 
effect estimates were increased over two-fold when comparing the highest and lowest quartiles 
of overall and traffic-related particulate pollution exposure in an area with high industrial 
emissions (Bonner et al. 2005, Nie et al. 2007).  More modestly elevated estimates (<50%) were 
observed by other investigators when examining continuous traffic-related nitrogen oxide levels 
(Crouse et al. 2010, Raaschou-Nielsen et al. 2011) or high residential traffic density (Lewis-
Michl et al. 1996). 
 Some of these previous studies relied on simple traffic density data (Lewis-Michl et al. 
1996) or sparse monitors (Bonner et al. 2005) to generate exposure estimates, or lacked data on 
the carcinogenic particulate portion of air pollution (Crouse et al. 2010, Raaschou-Nielsen et al. 
169 
 
2011).  Only two studies used validated exposure assessment methods (Nie et al. 2007, 
Raaschou-Nielsen et al. 2011), and most studies focused on short-term exposure surrogates.  For 
the study reported here, up to 35 years of individualized traffic-related particulate PAH exposure 
estimates were generated using a comprehensive exposure model, which was validated against 
extensive LIBCSP field data (Beyea et al. 2006).  The consistency of positive associations across 
studies is encouraging given differences in air pollution exposure assessment, exposure levels 
and timing, and participant characteristics between study populations.   
 In our study, the association between residential traffic exposure and breast cancer risk 
was stronger among women who consumed low levels of fruits and vegetables.  This is 
consistent with a previous LIBCSP report regarding breast cancer and grilled/smoked meat 
intake – another major PAH source (Steck et al. 2007).  Fruit and vegetable intake has also been 
negatively associated with PAH-DNA adduct levels in the LIBCSP (Shantakumar et al. 2005) 
and in an epidemiologic study conducted in Europe (Palli et al. 2000).  This is the first 
population-based breast cancer study to evaluate interactions between air pollution and dietary 
intake, and these findings require confirmation.   
 Traffic-breast cancer associations were also stronger among premenopausal women in the 
study reported here, consistent with previous LIBCSP reports regarding active and passive 
smoking (Gammon et al. 2004b) and PAH-DNA adduct levels (Gammon et al. 2002c).  
Similarly, a recent systematic review concluded that associations between environmental tobacco 
smoke and premenopausal, but not postmenopausal, breast cancer were “consistent with 
causality” (Johnson et al. 2011).  Stronger associations were also noted between traffic PAH 
exposure and ER/PR-negative breast tumors, which are overrepresented among premenopausal 
women (Chen and Colditz 2007).  Previous studies conducted in an area with high industrial 
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emissions reported positive associations between air pollution and breast cancer risk that varied 
inconsistently by menopausal status, depending on the exposure definition used, and did not vary 
by tumor hormone-receptor subtype (Bonner et al. 2005, Nie et al. 2007).   
 In this LIBCSP study, the association between traffic exposure and breast cancer risk was 
twice as strong among women with the homozygous variant genotype for the XPD Lys751Gln 
polymorphism.  This is consistent with a previous LIBCSP report, which observed that the 
association between breast cancer and variant allele homozygosity for this SNP was limited to 
those with PAH-DNA adduct levels above the median and to current smokers (Terry et al. 2004).  
The Lys751Gln polymorphism is also linked to PAH-related DNA damage in epidemiological 
studies (Matullo et al. 2003, Palli et al. 2001), including increased levels of PAH-DNA adducts in 
breast tissue (Tang et al. 2002).  Hence, the literature regarding PAH-related exposures, the XPD, 
Lys751Gln polymorphism and breast cancer risk has been consistent to date.   
The literature regarding breast cancer risk, PAH exposures, and the other variants 
examined in this study has been less consistent.  For example, we observed a 3-fold higher effect 
estimate for the association between long-term traffic exposure and breast cancer risk among 
women with the homozygous wild-type genotype for XRCC1 Arg399Gln, consistent with a study 
which reported an inverse association between the variant allele for this SNP and PAH-DNA 
adducts in lung tissue (Zienolddiny et al. 2006).  However, the LIBCSP investigators previously 
reported positive associations between the variant XRCC1-399Gln allele and breast cancer risk 
among women with detectable PAH-DNA adducts and among never smokers (Shen et al. 2005).           
 Associations between long-term traffic exposure and breast cancer risk were nearly two-
fold higher among women with at least one variant allele for the XRCC1 Arg194Trp 
polymorphism and among those with the homozygous wild-type genotype for the OGG1 
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Ser326Cys polymorphism.  Previous studies found no evidence of interactions between these 
polymorphisms and active smoking (OGG1, XRCC1) or PAH-DNA adducts (XRCC1) (Shen et 
al. 2005, Rossner et al. 2006).  Consistent with our results, studies have reported positive 
associations between the variant XRCC1 Trp194Arg SNP and micronucleus frequencies among 
coke oven workers, who are exposed to high levels of PAHs (Leng et al. 2005), as well as PAH-
DNA adducts in lung tissue (Zienolddiny et al. 2006).  However, only the variant OGG1 
Ser326Cys polymorphism has been linked to DNA damage, such as oxidative DNA lesions 
(Tarng et al. 2001), in several investigations (Aka et al. 2004, Bravard et al. 2009).   
 Finally, this study reported no evidence of interactions between traffic PAHs and SNPs in 
the following DNA repair genes: XPA, XPF, XPG, ERCC1, and XPD (Asp312Asn only).  This is 
consistent with a previous LIBCSP report evaluating interactions between PAH-DNA adducts, 
smoking, and polymorphisms in XPA, XPF, and XPG (Crew et al. 2007).  This latter study 
reported evidence of interactions between PAH-DNA adducts, but not active or passive smoking, 
and the ERCC1 8092C/A and XPD Asp312Asn polymorphisms (Crew et al. 2007). 
Inconsistencies in the literature regarding PAH-related exposures, most DNA repair 
genes, and breast cancer risk could be due in part to the use of different PAH exposure surrogates 
across investigations.  The current study evaluated air pollution, while other investigations 
focused on cigarette smoking and PAH-DNA adducts.  This complicates interpretation of study 
results, as PAH sources vary with regard to a range of properties, including co-pollutants and 
typical exposure levels (IARC 2010).  Differing results across sources of PAH exposure may also 
suggest a more complicated role for certain polymorphisms.  For example, DNA repair 
polymorphisms could interact differently with lower- and higher-level PAH exposures (Dr. 
Regina Santella, personal communication 2013.  In addition, variations in study methodology, 
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exposure and outcome definitions, and participant characteristics, as well as possible chance 
findings, may underlie inconsistent findings.    
BIOLOGICAL PLAUSIBILITY AND MECHANISMS 
 Several mechanisms may underlie the potential association between traffic-related 
PAH exposure and breast cancer risk.  PAHs are lipophilic and are stored in adipose tissue, 
including in the breast (Morris and Seifter 1992).  When exposure levels are high or 
detoxification is insufficient, PAHs bind to DNA, forming PAH-DNA adducts, including in 
breast tissue (Gammon and Santella 2008, Santella 1999).  PAHs have inflammatory (Jeng et 
al. 2010), pro-oxidant, and genotoxic (Farmer et al. 2003) properties, and induce oxidative 
DNA damage (Farmer et al. 2003).  If uncorrected, PAH-induced DNA damage can cause 
somatic mutations in tumor suppressor genes or proto-oncogenes, which could in turn 
contribute to carcinogenesis (Gammon and Santella 2008).  Several classes of biochemical 
pathways repair DNA damage.  The NER pathway generally repairs DNA damage from 
bulky adducts, while the BER pathway generally repairs oxidative DNA damage (Goode et 
al. 2002, Braithwaite et al. 1998, Robertson et al. 2009).  Hence, both DNA repair pathways 
could modify the effects of PAH exposures on breast cancer risk (Berwick and Vineis 2000).   
 In the study reported here, associations between traffic PAHs and breast cancer were 
stronger among women with low fruit/vegetable intake.  This is consistent with the 
experimental evidence demonstrating that fruit and vegetable components have antioxidant 
and chemopreventive properties and are known to decrease the carcinogenic effects of PAH 
exposure in animals (Jin et al. 2006, Wattenberg and Loub 1978).     
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STUDY LIMITATIONS 
Exposure Model 
Traffic exposures were reconstructed for the years spanning 1960 and 1995.  However, 
some participants moved to the study area after 1960, and others provided an incomplete address 
history while residing in the study area.  Hence, limitations of our study include some missing 
address information, which was corrected in part through the use of multiple imputation (Beyea 
et al. 2013, Rubin 1996).  Results for traffic-breast cancer associations were robust to varying the 
percentage of imputation (0-30%; see Chapter III).   
 Our model did not generate non-residential traffic exposure estimates, such as at work or 
while driving.  A nation-wide study reported that, on average, American men and women spend 
almost 70% of their day inside (64.97%) or just outside (2.50%) of their residences, both overall 
and in a large city (Chicago, IL) (Leech et al. 2002).  A Canadian study found similar results 
among women only (Nethery et al. 2009).  In addition, the effect of time spent away from home 
may also be less than expected due to the large exposure component at night arising from 
pollutant drift from rush-hour traffic (Beyea et al. 2005).   
The purpose of the exposure model was to estimate vehicular traffic exposures.  
Therefore, the model did not incorporate information on non-traffic sources of ambient PAHs, 
such as cooking, heating, leaf burning, or tobacco smoke (Beyea et al. 2005, 2006, 2013).  
Traffic is often the largest ambient source of PAHs near urban areas (Fromme et al. 2004, 
Nielsen 1996) and is more likely to release smaller and more inflammatory particles than some 
of the other ambient sources (Kocbach et al. 2006).   
 Benzo[a]pyrene was modeled as a surrogate for all traffic PAHs.  Traffic pollution 
contains many chemicals, including many PAHs and other confirmed carcinogens (e.g. 
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benzene; Boström et al. 2002).  It is impossible to ascribe health effects to a single traffic 
pollutant based on an observational study.  Nevertheless, benzo[a]pyrene is one of the most 
carcinogenic PAHs and is representative of overall PAH exposure from vehicle exhaust (Boström 
et al. 2002).  Particulate PAHs are among the most carcinogenic components of traffic exhaust, 
where they are found in high concentrations (Boothe and Shendell 2008).  Furthermore, traffic 
pollutants do not have identical distributions (Beyea et al. 2006).  In the LIBCSP, exposures were 
modeled using PAH-specific emissions data and dispersion parameters, and were validated and 
calibrated against soil PAH levels (Beyea et al. 2006).  As an illustrative example, the LIBCSP 
traffic exposure model was altered (i.e. all depletion parameters were removed from the model) 
in order to predict carbon monoxide levels for a validation exercise.     
Other Considerations 
The study reported here had limited power for evaluating lower level interactions, 
particularly when examining long-term traffic exposures, where data was sparse.  A smaller 
sample size increases the likelihood of both false positive and false negative findings (Rothman 
and Greenland 1998).  This study also lacked sufficient statistical power to evaluate interactions 
between DNA repair polymorphisms and high-level residential traffic exposures among the most 
highly exposed 1-5% of study subjects (Chapter III), due to sample size constraints within 
genetic subgroups.  This may have attenuated or obscured some associations.  Interaction results 
were not adjusted for multiple comparisons.  However, this study took a targeted pathway 
approach in selecting polymorphisms and dietary intake variables that were likely to interact 
with traffic PAHs, and is therefore much less likely to generate false-positive findings than if 
using an exploratory approach (Thompson 1994).  
 This study may be subject to potential limitations standard to epidemiological 
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investigations, such as laboratory errors with respect to genotyping or tumor classification, 
inaccurate reporting or recording of potentially confounding or modifying factors, and 
differential misclassification with respect to case-control status (Rothman and Greenland 1998).  
However, the LIBCSP  has employed extensive quality control measures with regard to 
genotyping, tumor assays, and questionnaire data collection and storage procedures (described in 
the following section; Crew et al. 2007, Gammon et al. 2002b).  These measures greatly reduce 
the probability of these potential study limitations (Gammon et al. 2002b).   
 Finally, the LIBCSP study population is fairly homogenous with respect to both 
socioeconomic status and race (Gammon et al. 2002b).  This is both a limitation and a strength: 
participant homogeneity decreases the likelihood of residual confounding (Rothman and 
Greenland 1998), but reduces the generalizability of study findings. 
STUDY STRENGTHS 
Exposure Model 
The study reported here used a comprehensive, individualized traffic exposure metric 
spanning a large geographic area and accounting for participants' residential histories for up to a 
35 year period (Beyea et al. 2005, 2006).  Vehicular traffic exposure estimates were derived 
using a sophisticated model that incorporated information on a wide range of factors including 
historical vehicular emissions and local transportation patterns, local meteorologic data, pollutant 
dispersion, deposition and decay factors, excess emissions from acceleration and deceleration at 
intersections, cruise and cold-engine emissions, building penetration factors, and background 
ambient PAHs from distant traffic sources (Beyea et al. 2006).  The model was validated against 
extensive field data, (Beyea et al. 2006).  Specifically, it was shown to accurately predict 
residential soil PAH levels, PAH-DNA adducts in mononuclear cells, and carbon monoxide 
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concentrations at an EPA monitoring site (Beyea et al. 2006).  Participants were exposed to a 
wide range of residential traffic-related PAH levels, due to the gradient of urbanization across the 
study area (Beyea et al. 2006).  Finally, breast cancer develops over many years (Clark et al. 
1997), so a long modeled exposure period may be ideal for assessing relationships with breast 
cancer.  A woman's traffic exposure level can vary greatly from year to year due to changes in 
emissions standards or moving to a new residence (Beyea et al. 2005, 2013). 
Other Considerations 
The LIBCSP utilized extensive quality control procedures for both questionnaire data and 
the laboratory component of the investigation.  Specifically, approximately 10% of DNA samples 
were duplicated, distributed randomly on genoyping plates, and re-genotyped, and positive and 
negative controls were also included on each genotyping plate (Crew et al. 2007, Rossner et al. 
2006, Shen et al. 2005, Terry et al. 2004).  Responses from the case-control interview were 
checked using data range and logic checks, and a random sample of 20% of participants were 
briefly re-interviewed (Gammon et al. 2002b).  Identical data collection and storage strategies 
were used for cases and controls, and laboratory personnel were blinded to both case-control 
status and duplicate status of participants' blood samples.   
 Additional strengths of this study include access to the resources of a large population-
based investigation with extensive information regarding a wide range of factors, including 
demographic and lifestyle factors, active and passive cigarette smoking history, reproductive 
history, dietary intake, tumor markers and subtypes, and genetic polymorphisms in several PAH-
related pathways (Gammon et al. 2002b).  This facilitates effectively controlling for potential 
confounders, assessing effect modification, and evaluating tumor subtype-specific risk factor 
associations.  The LIBCSP recruited incident rather than prevalent cases, which increases the 
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likelihood of identifying risk factors for breast cancer occurrence rather than survival (Gammon 
et al. 2002b, Rothman and Greenland 1998).   
 This is the first study to evaluate the impact of DNA repair polymorphisms or dietary 
intake on the association between air pollution exposure and breast cancer risk, and one of a 
small number of studies to examine interactions between DNA repair variants and any PAH-
related exposure with respect to breast cancer risk (Crew et al. 2007, Mechanic et al. 2006, Shen 
et al. 2005, Terry et al. 2004).  Hence, this analysis is an important addition to the sparse 
literature on this subject.  Our results for XPD are consistent with the growing literature 
regarding this DNA repair gene, PAH exposures, and breast cancer risk (Crew et al. 2007, 
Pabalan et al. 2010, Tang et al. 2002, Terry et al. 2004).   
FUTURE DIRECTIONS, PUBLIC HEALTH IMPLICATIONS, AND CONCLUSIONS 
This study reports a positive association between breast cancer and high-level residential 
exposure to vehicular traffic PAHs reconstructed using a comprehensive, validated historical 
model.  The association was most pronounced among women with low fruit/vegetable intake, 
hormone receptor negative tumors, premenopausal breast cancer, or certain NER or BER 
polymorphisms, though the associated confidence intervals were wide.  Although U.S. traffic 
emissions are greatly reduced from the high levels of the 1960s and 1970s (Beyea et al. 2008), 
these findings may have public health significance given the relatively high incidence of breast 
cancer and ubiquitous exposure to traffic pollution worldwide, particularly in countries where 
vehicular traffic PAH emissions remain high (Han and Naeher 2006).   
 Future studies should examine associations between traffic exposure and breast cancer 
risk within larger or more highly exposed study populations, and in combination with other PAH 
sources (such as smoking or grilled/smoked foods).  In addition to replicating the associations 
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evaluated in the current study, future investigations could examine interactions between traffic-
related PAHs and intake of specific fruit/vegetable types or components, such as cruciferous 
vegetables, dietary antioxidants or phytonutrients, in order to evaluate whether particular fruits or 
vegetables are particularly beneficial for potential amelioration of breast cancer risk.  Future 
studies could also evaluate interactions between air pollution and polymorphisms in biologically 
relevant genes, including in DNA repair, oxidative stress and carcinogen metabolizing pathways.   
 If confirmed, our results will contribute to increased understanding of breast cancer 
etiology, clarify mechanisms linking traffic to breast cancer and strengthen the biological 
plausibility of this relationship, and help identify identify women who may be especially 
susceptible to the carcinogenic effects of traffic pollution on the breast. 
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APPENDIX: ADDITIONAL TABLES AND FIGURES 
Figure A1.1 : Metabolism of Polycyclic Aromatic Hydrocarbons in Relation to Breast Cancer 
Risk. 
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Table A2.1 Previously reported participant characteristics by case-control status 
.  
 
Variables 
Cases (n = 1,508) 
 
Controls (n =  1,556) 
 
P valuea 
Mean (SD) N (%) Mean (SD) N (%) 
Age group at reference b     0.0064 
< 35 years  39 (2.6)  45 (2.9)  
35-44 years  181 (12.0)  245 (15.8)  
45-54 years  397 (26.3)  423 (27.2)  
55-64 years  372 (24.7)  403 (25.9)  
65-74 years  365 (24.2)  310 (19.9)  
75-84 years  134 (8.9)  112 (7.2)  
85+ years  20 (1.3)  18 (1.2)  
Educational level b     0.024 
< High school  183 (12.2)  150 (9.7)  
High school graduate  538 (35.8)  526 (33.9)  
Some college  360 (24.0)  415 (26.7)  
College graduate  191 (12.7)  236 (15.2)  
Post college  230 (15.3)  225 (14.5)  
Income c      
<$15,000  115 (7.7)  84 (5.4) 0.033 
$15,000-$19,999  73 (4.9)  85 (5.5)  
$20,000-$24,999  98 (6.5)  126 (8.1)  
$25,000-$34,999  245 (16.3)  211 (13.6)  
$35,000-$49,999  243 (16.2)  264 (17.0)  
$50,000-$69,999  252 (16.8)  288 (18.5)  
$70,000-$89,999  190 (12.6)  210 (13.5)  
$90,000+  288 (19.2)  286 (18.4)  
Race c     0.073 
White  1411 (93.8)  1429 (91.8)  
African American  69 (4.6)  85 (5.5)  
Other  25 (1.7)  42 (2.7)  
Menopausal status d     0.29 
Premenopausal  468 (31.7)  500 (33.5)  
Postmenopausal  1010 (68.3)  993 (66.5)  
Fruit/vegetable intake d     0.046 
0-34 servings/week  945 (63.9)  918 (60.4)  
35+ servings/week  533 (36.1)  602 (39.6)  
BMI at reference (kg/m2)  26.61 (5.7)  26.36 (5.8)  0.24  
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Parity  2.37 (1.6)  2.55 (1.7)  0.0021  
Age at first birth d 25.50 (4.7)  25.03 (4.6)  0.0093 
 
BMI: body mass index; SD: Standard Deviation                                       
a) Cases and control participants were compared using Student's t test and chi-square analyisis.        
b) Gammon et al. 2002b.                                                                                                                                           
c) Income was imputed for 11.5% of participants based on age, race, and education.                           
d) Gaudet et al. 2004.    
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Table A2.2. Associations between traffic exposure in the year 1995 and breast cancer, overall and 
among long-term residents a.  
 
 
Exposure Years 
 
Variable Classifications 
 
Cases Controls Quantiles OR (95% CI)  
1995 (overall) 645 659 <50th percentile 1 
 299 353 50-<75th percentile 0.87 (0.72, 1.04) 
 260 261 75-<95th percentile 1.01 (0.82, 1.23) 
 70 61 ≥95th percentile 1.14 (0.80, 1.64) 
1995 (15+ year residents) 326 303 <50th percentile 1 
 167 204 50-<75th percentile 0.76 (0.59, 0.98) 
 128 146 75-<95th percentile 0.80 (0.60, 1.06) 
 33 33 ≥95th percentile 0.89 (0.53, 1.48) 
1995 (overall) 645 659 <50th percentile 1.00 (referent) 
 299 353 50-<75th percentile 0.87 (0.72, 1.04) 
 312 313 75-<99th percentile 1.00 (0.83, 1.22) 
 18 9 ≥99th percentile 2.02 (0.90, 4.53) 
1995 (15+ year residents) 326 303 <50th percentile 1 
 167 204 50-<75th percentile 0.76 (0.59, 0.98) 
 151 177 75-<99th percentile 0.78 (0.59, 1.02) 
 10 2 ≥99th percentile 4.39 (0.95, 20.30) 
 
CI: confidence interval; OR: odds ratio 
a) Defined as women residing in their current home for 15 or more years.          
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Table A2.3.  Associations between selected residential traffic exposure variables and breast 
cancer, removing participants with the highest exposure levels.     
        
Exposure Years Cases Controls Quantiles OR (95% CI)a  
top 2 removed 
OR (95% CI)a 
top 5 removed 
1995 (CCA) 645 659 <50th  1 1 
 299 353 50-<75th  0.87 (0.72, 1.04) 0.87 (0.72, 1.04) 
 260 261 75-<95th  1.01 (0.82, 1.23) 1.01 (0.82, 1.23) 
 68, 66 61, 60 ≥95th (vs 1.14) 1.11 (0.77, 1.60) 1.10 (0.76, 1.59) 
1980-1995 (CCA) 431 428 <50th  1 1 
 201 230 50-<75th  0.86 (0.68, 1.08) 0.86 (0.68, 1.08) 
 171 173 75-<95th  0.95 (0.74, 1.22) 0.95 (0.74, 1.22) 
 41, 38 42 ≥95th (vs. 0.98) 0.93 (0.59, 1.46) 0.86 (0.54, 1.37) 
1960-1990 (20% MI)b 262-287 289-320 <50th  1 1 
 122-139 136-155 50-<75th  0.99 (0.73, 1.36) 0.99 (0.73, 1.36) 
 96-111 111-121 75-<95th  0.95 (0.68, 1.32) 0.95 (0.68, 1.32) 
 22-27, 19-24 19-21, 19-21 ≥95th (vs.1.44) 1.32 (0.70, 2.48) 1.20 (0.63, 2.28) 
 
CCA: complete case analysis; CI: confidence interval; MI: multiple imputation; OR: odds ratio 
a) Models are age-adjusted, as cases and control participants were frequency matched by age group.     
b) Partially imputed datasets are combined over m = 30 imputations using Rubin's rules.  Sample size 
varies by the imputed data set (see text for methods).   
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 Table A2.4.  Associations between traffic polycyclic aromatic hydrocarbon exposure and breast 
cancer, varying the relative contribution of the pre-arrival surrogate.  
 
 
Exposure Years a 
 
Variable Classifications 
 
Cases Controls Quantiles Age-adjusted  
OR (95% CI)  
1960-1990 (doubled) 254-279 279-305 <50th percentile 1.00 (referent) 
 124-141 141-160 50-<75th percentile 0.95 (0.69, 1.30) 
 96-121 112-126 75-<95th percentile 0.95 (0.68, 1.33) 
 25-32 21-25 ≥95th percentile 1.37 (0.75, 2.50) 
1960-1990 (halved) 264-290 295-324 <50th percentile 1.00 (referent) 
 120-139 132-148 50-<75th percentile 1.02 (0.75, 1.40) 
 93-107 108-117 75-<95th percentile 0.94 (0.67, 1.30) 
 24-28 19-21 ≥95th percentile 1.46 (0.78, 2.71) 
 
CI: confidence interval; MI: multiple imputation; OR: odds ratio 
a) Up to 20% of dose was imputed for each exposure variable (single imputation; see text for methods). 
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Table A2.5.  Associations between traffic PAH exposure and breast cancer, turning off the 
intersection component of the exposure model.  
 
 
Exposure Years a 
 
Variable Classifications 
 
Cases Controls Quantiles Age-adjusted OR 
(95% CI)  
1960-1990 283 320 <50th percentile 1.00 (referent) 
 133 122 50-<75th percentile 1.22 (0.91, 1.64) 
 105 114 75-<95th percentile 1.02 (0.75, 1.40) 
 19 23 ≥95th percentile 0.90 (0.48, 1.70) 
1960-1990 283 320 <50th percentile 1.00 (referent) 
 133 122 50-<75th percentile 1.22 (0.91, 1.64) 
 119 130 75-<99th percentile 1.02 (0.75, 1.37) 
 5 7 ≥99th percentile 0.75 (0.23, 2.40) 
 
CCA: complete case analysis; CI: confidence interval; MI: multiple imputation; OR: odds ratio; PAH: 
polycyclic aromatic hydrocarbon 
a) Up to 20% of dose was imputed for each exposure variable (single imputation; see text for methods). 
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Table A2.6.  Associations between traffic PAH exposure and breast cancer, with partial 
imputation conducted using imputation by census place.  
 
 
Exposure Years a 
 
Variable Classifications 
 
Cases Controls Quantiles Age-adjusted OR (95% 
CI)  
1960-1990  262 301 <50th percentile 1.00 (referent) 
 133 139 50-<75th percentile 1.09 (0.81, 1.45) 
 110 115 75-<95th percentile 1.07 (0.78, 1.46) 
 25 22 ≥95th percentile 1.27 (0.70, 2.31) 
1960-1990  262 301 <50th percentile 1.00 (referent) 
 133 139 50-<75th percentile 1.09 (0.81, 1.45) 
 125 135 75-<99th percentile 1.03 (0.77, 1.39) 
 10 2 ≥99th percentile 5.85 (1.26, 27.13) 
 
CCA: complete case analysis; CI: confidence interval; MI: multiple imputation; OR: odds ratio; PAH: 
polycyclic aromatic hydrocarbon 
a) Up to 20% of dose was imputed for each exposure variable (single imputation).   
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Table A2.7.  Associations between selected residential traffic exposure variables and breast 
cancer categorized by tumor characteristics.   
 
Tumor 
Characteristics 
1995 (CCA) 1960-1990 (20% MI)a 
Cases Controls Age-adjusted  
OR (95% CI) 
Cases Controls Age-adjusted 
OR (95% CI) 
ER+/PR+ breast cancer 
<50th percentile 659 281 1 289-320 125-144 1 
50-<75th percentile 353 105 0.69 (0.53, 0.90) 136-155 35-44 0.61 (0.39, 0.95) 
≥75th percentile 322 117 0.83 (0.64, 1.07) 132-140 46-62 0.80 (0.54, 1.20) 
ER+/PR- or ER-/PR+  or ER-/PR- breast cancer  
<50th percentile 659 192 1 289-320 73-82 1 
50-<75th percentile 353 70 0.68 (0.50, 0.91) 136-155 27-34 0.82 (0.50, 1.35) 
≥75th percentile 322 82 0.85 (0.64, 1.14) 132-140 30-36 0.86 (0.53, 1.39) 
ER-/PR- breast cancer  
<50th percentile 659 97 1 289-320 36-44 1 
50-<75th percentile 353 41 0.79 (0.54, 1.16) 136-155 12-16 0.75 (0.38, 1.48) 
≥75th percentile 322 46 0.97 (0.67, 1.41) 132-140 13-18 0.86 (0.45, 1.64) 
ER+/PR- or ER-/PR+  or ER+/PR+ breast cancer 
<50th percentile 659 376 1 289-320 163-182 1 
50-<75th percentile 353 134 0.66 (0.52, 0.83) 136-155 49-62 0.67 (0.45, 0.99) 
≥75th percentile 322 153 0.80 (0.64, 1.01) 132-140 62-70 0.82 (0.57, 1.18) 
p53 mutation-positive breast cancer  
<50th percentile 659 58 1 289-320 18-23 1 
50-<75th percentile 353 29 0.93 (0.58, 1.48) 136-155 6-13 0.89 (0.36, 2.21) 
≥75th percentile 322 23 0.79 (0.48, 1.31) 132-140 10-13 1.14 (0.52, 2.49) 
p53 mutation-negative breast cancer 
<50th percentile 659 293 1 289-320 137-154 1 
50-<75th percentile 353 142 0.90 (0.71, 1.14) 136-155 63-72 0.99 (0.68, 1.44) 
≥75th percentile 322 172 1.16 (0.92, 1.47) 132-140 65-73 1.00 (0.69, 1.44) 
 
CCA: complete case analysis; CI: confidence interval; ER: estrogen receptor; MI: multiple imputation; 
OR: odds ratio; PR: progesterone receptor                             
a) All partially imputed datasets are combined over m=30 imputations using Rubin's rules (see text for 
methods); sample size varies by imputation draw.  
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Table A2.8. Previously reported main effects of DNA repair polymorphisms on breast cancer 
risk.       
Polymorphisms Genotypes Cases, n (%) Controls, n (%) Age-adjusted OR (95% CI) 
XPA -4A/G (rs1800975) a GG 488 (46.1) 488 (44.3) 1.00 
 GA 466 (44.0) 477 (43.3) 0.97 (0.81, 1.17) 
 AA 105 (9.9) 137 (12.4) 0.77 (0.58, 1.02) 
ERCC1 8092C/A (rs3212986) a CC 551 (52.1) 606 (54.9) 1.00 
 CA 434 (41.1) 436 (39.5) 1.09 (0.92, 1.30) 
 AA 72 (6.8) 62 (5.6) 1.29 (0.90, 1.85) 
XPD Lys751Gln (rs13181) b AA (Lys/Lys) 387 (36.8) 453 (41.1) 1.00 
 AC (Lys/Gln) 513 (48.7) 498 (45.2) 1.22 (1.01, 1.46) 
 CC (Gln/Gln) 153 (14.5) 151 (13.7) 1.18 (0.91, 1.53) 
XPD Asp312Asn (rs1799793) a GG (Asp/Asp) 415 (40.2) 490 (45.2) 1.00 
 GA (Asp/Asn) 478 (46.4) 454 (41.9) 1.25 (1.04, 1.50) 
 AA (Asn/Asn) 138 (13.4) 139 (12.8) 1.16 (0.89, 1.52) 
XPF Arg415Gln (rs1800067) a GG (Arg/Arg) 859 (84.4) 888 (83.4) 1.00 
 GA (Arg/Gln) 156 (15.3) 167 (15.7) 0.99 (0.78, 1.26) 
 AA (Gln/Gln) 3 (0.3) 10 (0.9) 0.27 (0.07, 1.00) 
XPG Asp1104His (rs17655) a GG (Asp/Asp) 562 (56.3) 571 (54.3) 1.00 
 GC (Asp/His) 371 (37.1) 409 (38.9) 0.94 (0.78, 1.13) 
 CC (His/His) 66 (6.6) 71 (6.8) 0.98 (0.69, 1.41) 
XRCC1 Arg194Trp (rs1799782) CC (Arg/Arg) 948 (88.0) 974 (87.3) 1.00 
 CT (Arg/Trp) 125 (11.6) 134 (12.0) 0.96 (0.74, 1.24) 
 TT (Trp/Trp) 4 (0.4) 8 (0.7) 0.50 (0.15, 1.66) 
XRCC1 Arg399Gln (rs25487) c GG (Arg/Arg) 412 (38.6) 444 (40.0) 1.00 
 GA (Arg/Gln) 539 (50.5) 536 (48.3) 1.08 (0.90, 1.29) 
 AA (Gln/Gln) 116 (10.9) 130 (11.7) 0.97 (0.73, 1.29) 
OGG1 Ser326Cys (rs1052133)d CC (Ser/Ser) 615 (59.1) 653 (59.7) 1.00 
 GC (Ser/Cys) 375 (36.0) 385 (35.2) 1.04 (0.87, 1.24) 
 CC (Cys/Cys) 51 (4.9) 55 (5.0) 0.99 (0.66, 1.47) 
 
OR: odds ratio; CI: confidence interval 
a) Crew et al. 2007 
b) Terry et al. 2004 
c) Shen et al. 2005 
d) Rossner et al. 2006 
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